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Colorectal Cancer
Colorectal cancer epidemiology
Colorectal cancer (CRC) is a significant public health problem. It is the third most
commonly diagnosed malignancy and the fourth leading cause of cancer-re-
lated deaths in the world.1 In the Western-world it even ranks third or second
as cancer-related death in both men and women. 2 3 Worldwide, approximately
1.4 million new colorectal cancer cases were diagnosed and almost 700,000
 related deaths occurred in 2012. 4 The burden of CRC is expected to increase
to more than 2.2 million new cases and 1.1 million cancer deaths by 2030. 1 The
increase is linked to ongoing societal and economic developments in many low-
and middle-income countries. Highly developed countries where rates remain
among the highest in the world, show stabilizing or decreasing trends. In the
Netherlands, 13,043 people were diagnosed with CRC in 2013 increasing to
15,192 in 2014 with introduction of population screening, and almost 5,000 peo-
ple die per year from this disease. 5 The incidence of CRC increases with age
and is higher in men compared to women. 5 6
Natural history
Most colorectal cancers develop from benign precursor colonic lesions or polyps.
The majority of cancers (65-95%) are believed to develop through the so-called
adenoma-carcinoma sequence: from adenomatous polyps (adenomas) to cancer
(Figure 1, 7). Estimated progression time from adenoma onset to cancer is approx-
imately 20 years. 8 9 A minority of cancers develops through alternative pathways,
in particular through the serrated neoplasia pathway (5-33%). 10
Chapter 1
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Figure 1. Schematic
overview of the 
adenoma-carcinoma
sequence. For the 
National Cancer 
Institute © 2018 
Terese Winslow LLC,
U.S. Govt. has certain
rights. 7 
With permission.
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The shape of adenomas can vary from pedunculated (stalked) to broad-
based, flat or depressed. Adenomas can have tubular (<25% villous compo-
nent), tubulovillous (25-75% villous component), or villous (>75% villous
component) histology, and vary in size. Adenomas are generally classified as
having low-grade or high-grade dysplasia. 11-13 Images of adenoma histology
and dysplasia are presented in Figure 2. 14 15 An adenoma large in size (≥10 mm),
with (tubulo)villous histology, or high-grade dysplasia (HGD) is assumed to have
elevated risk to develop into CRC. An adenoma with at least one of these char-
acteristics is therefore called an advanced adenoma. An adenoma without these
characteristics is called a non-advanced adenoma. Approximately 30-50% of
people will develop one or more adenomas throughout their life, however only
about 3-5% of people develop CRC. 6 16
Serrated lesions include sessile serrated adenoma or polyps (SSA/P), tradi-
tional serrated adenomas (TSA) and hyperplastic polyps, 17 and are morpholog-
ically characterized by a serrated (“saw-tooth”) architecture (Figure 3, 15).
Hyperplastic polyps were originally believed to be benign, however over the
past years this opinion has changed. Now some pathologists believe that a sub-
set of hyperplastic polyps can develop into SSA/P that are considered to have
malignant potential. 10 18 The serrated neoplasia pathway was first described in
1996, 19 and only found traction over the last 15 years. SSA/P have only recently
accurately been captured and reported in community practice. The study on
which this thesis is based was initiated prior to that time and captures data start-
ing in 1990 – 2002. Therefore serrated lesions are not specifically discussed in
this thesis.
CRC staging 
The progression from adenoma to carcinoma includes invasion through layers
of the colon wall. The stage of cancer depends on the depth of invasion (and
spread of malignant tissue). From the inside colon (lumen) to the pericolorectal
tissue, the layers of the colonic wall are: mucosa, lamina propria, muscularis mu-
cosae (thin muscle layer), submuscosa, muscularis propria (thick muscle layer),
subserosa, and serosa. Cancers are classified on the basis of 1) the depth of in-
vasion of the primary tumour, 2) presence of metastases in lymph nodes, and 3)
presence of metastases in distant organs (TNM-classification). Based on this
classification cancer stages are defined by the American Joint Committee on
Cancer (AJCC). Adenomas or polyps are lesions that do not invade further than
the lamina propria or muscularis mucosae, including carcinoma in situ. Stage I
cancers are local tumours that invade into the submucosa or muscularis propria
General introduction
9
hoofdst 1_Opmaak 1  25-11-18  17:55  Pagina 9
(muscle layer). Stage II cancers invade the (sub)serosa or pericolorectal tissues
and potentially penetrate the outer layer of the colorectum. Stage III cancers
affect one or more lymph nodes. Stage IV cancers have metastases in distant
organs 13. Images of cancer stages I-IV are given in Figure 4. 7 In the Netherlands,
the 5-year survival ranges from 94% in patients with stage I cancer to
 approximately 12% in those with stage IV cancer. 5
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Figure 2. Microscopic images of (A) histological types of adenomatous polyps:
tubular adenoma (left) 14 and villous adenoma (right) 15; and (B) adenomatous
tissue with low-grade dysplasia (left) and high-grade dysplasia (right) 15. With
kind permission.
Figure 3. Microscopic images of serrated polyps: hyperplastic polyp, sessile
serrated lesion, and traditional serrated adenoma 15. With kind permission.
A
B
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Stage I. Cancer has spread from the mucosa
to the muscle layer. 
Stage II. Cancer has spread through: the
 muscle layer to the serosa (IIA); the serosa but
has not spread to nearby organs (IIB); the
serosa to nearby organs (IIC).
Stage IIIA. Cancer has spread: through the
mucosa to the submucosa and may have
spread to the muscle layer, and to 1-3  nearby
lymph nodes or tissues near the lymph nodes.
OR, through the mucosa to the submucosa
and 4-6 nearby lymph nodes.  
Stage IIIB. Cancer has spread: through the
muscle layer to the serosa or through the
serosa but not to nearby organs; and to 1-3
nearby lymph nodes or to tissues near the
lymph nodes. OR, to the muscle layer or to
the serosa, and to 4-6 nearby lymph nodes.
OR, through the mucosa to the submucosa
and may have spread to the muscle layer; and
to ≥7 nearby lymph nodes. 
Stage IIIC. Cancer has spread through the
serosa but not to nearby organs; cancer has
spread to 4-6 nearby lymph nodes. OR, can-
cer has spread through the muscle layer to
the serosa or has spread through the serosa
but not to nearby organs; cancer has spread
to ≥7 nearby lymph nodes. OR, cancer has
spread through the serosa to nearby organs
and to one or more nearby lymph nodes or to
tissues near the lymph nodes.
Stage IV. The cancer has spread to other parts
of the body, such as the lymph nodes, lung,
liver, abdominal wall, or ovary.
Figure 4. Colorectal cancer stages I-IV.
For stages I-III, showing the layers of the
colon/rectal wall. For stage IV, the inset
shows cancer cell spreading. For the
 National Cancer Institute © 2018 Terese
Winslow LLC, U.S. Govt. has certain
rights. 7 With permission.
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In the Netherlands, the stage distribution before the introduction of a national
CRC screening program was 18%, 31%, 29%, and 23%, for stages I, II, II and IV
respectively. 5 After the introduction of the screening program, a shift in stage
distribution is expected towards more early stage cancers. In 2015, after the in-
troduction of screening more lower stage cancers were diagnosed for screen-
detected CRCs compared to symptom-detected CRCs, the distribution of
cancers in stages I, II, III and IV were 48%, 19%, 27%, and 6% versus 17%, 23%,
35%, and 26%, respectively. 20
Prevention of colorectal cancer
There are three forms of prevention: primary, secondary and tertiary. Below,
these three types of prevention are described. In this thesis the emphasis is on
secondary prevention of CRC. 
Primary prevention
Lifestyle and nutritional factors influence CRC risk. It is assumed that 18-32% of CRC
cases can be prevented through modification of dietary and lifestyle factors. 21 22
Meta-analyses of observational studies have been performed, but large random-
ized trials are lacking. Factors associated with higher risk of CRC include obesity
(especially abdominal fatness), tobacco smoking, alcohol consumption and con-
sumption of red or processed meat. 22 23 The pooled relative risk (RR) for obese vs.
normal BMI (body mass index) is 1.33 (95%CI, 1.25 – 1.42) and for waist circumfer-
ence (highest vs. lowest category) 1.46 (95%CI, 1.33 – 1.60). 24 25 Smoking (ever
smokers  vs. never smokers) increased CRC incidence and mortality, pooled RR =
1.18 (95%CI, 1.11- 1.25) and RR = 1.25 (95%CI, 1.14- 1.37),  respectively. 26 Also, for-
mer smokers are at increased risk compared to never smokers and the association
with smoking is higher for rectal cancer than for colon cancer. 27 Compared to non-
drinkers, the pooled RR for alcohol consumption was 1.16 (95% CI, 0.99 to 1.36) for
persons who consumed 30 to less than 45 g/d, and 1.41 (95%CI, 1.16 – 1.72) for
those who consumed 45 g/d or more. 28 Red meat consumption increased the CRC
incidence by 17-28% per 100-120 g/day (pooled RR, 1.17; 95% CI 1.05–1.31 and
pooled RR, 1.28; 95% CI 1.18–1.39) and processed meat per 30-50 g/day by 9-18%
(pooled RR, 1.09; 95% CI 1.05–1.13 and pooled RR, 1.18; 95% CI 1.10–1.28). 29 30
Factors that may decrease CRC risk include physical activity, chemoprevention
by means of NSAIDs (use of aspirin), and possibly high intake of fruits and veg-
etables. Physical activity may decrease CRC incidence by 24% (pooled RR, 0.76;
95% CI, 0.72–0.81) 31 and (daily) aspirin use may reduce long-term CRC risk after
10-20 years by 40% (pooled RR, 0.60; 95% CI, 0.52 – 0.86). 32
Chapter 1
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Secondary prevention
The CRC incidence and mortality can be reduced by secondary prevention
through screening and surveillance. Since progression time from adenoma to
carcinoma is substantial, it leaves considerable room for early detection and re-
moval of (early stage) cancers and precursor lesions (adenomas). Therefore CRC
is well suited for screening. 
Screening
Screening aims to detect the disease at an earlier stage with a more favourable
prognosis (preventing the number of deaths due to the disease or leading to
prolonged survival time), before onset of clinical signs or symptoms. Unfortu-
nately, screening also has disadvantages. It can lead to over-diagnosis and
overtreatment (detection and treatment of cancers or adenomas that would
have never been found without screening). Also, serious complications of
screening have been reported, like colonic perforation after colonoscopy and
even death.
Various screening methods for CRC are available. They can be classified into
stool tests, endoscopic or imaging tests and other tests. Stool tests are self-
tests requiring participants to collect one or more samples of their stool and
send it to a laboratory for analysis. There are three types of stool tests currently
on the market: guaiac faecal occult blood tests (gFOBT), faecal immunochem-
ical tests (FIT), and stool-DNA tests (sDNA). In the laboratory, the stool samples
are investigated for the presence of haem (gFOBT), globin (FIT) or DNA muta-
tions (sDNA). A positive stool test requires follow-up with colonoscopy to eval-
uate the presence of polyps or cancer.
Colonoscopy (Figure 5) and sigmoidoscopy are both endoscopic tests, during
which a flexible tube with a videochip digital camera is inserted via the anus to
visualize the colorectum. During the procedure cancers can be biopsied and
polyps or adenomas can be removed. Both invasive procedures require bowel
preparation, but the preparation for colonoscopy is considerably more burden-
some. Sigmoidoscopy only visualizes the distal part of the colon (rectum, sig-
moid and descending colon), while colonoscopy visualizes the full colon. As a
consequence sigmoidoscopy cannot detect proximal lesions. 
Computed tomography colonography (CTC) is a non-invasive imaging tech-
nique of the colorectum. Scans are made to construct two- or three dimensional
images that are used to search for presence of neoplastic lesions. CTC requires
a burdensome bowel cleansing as preparation, like colonoscopy. When tested
positive, it requires follow-up with colonoscopy.
General introduction
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Two other tests, not yet standard use in current practice, are colon capsule
endoscopy (CCE) and blood tests. With CCE the colon is visualized though an
ingestible capsule with a video camera at both ends for imaging as it progresses
through the gastrointestinal tract. CCE requires good or excellent bowel prepa-
ration similar to colonoscopy. 33 34 With blood tests a routine sample of blood
is collected and analysed for tumour markers (circulating protein biomarkers
and tumour-specific mutations in circulating DNA). 35 Also these tests require
follow-up after a positive screen test with colonoscopy. 
So far, the only evidence for effectiveness of screening from randomized con-
trolled trials is available for gFOBT and sigmoidoscopy, showing a CRC mortality
reduction of 11-33% with repeated biennial gFOBT 36-40 and 22-33% after single
sigmoidoscopy. 41-45 However, given similarities between FIT and gFOBT (speci-
ficity) and better performance characteristics of FIT (sensitivity), FIT is considered
superior to gFOBT. 46-50 Observational studies suggested that the mortality re-
duction after FIT was at least as of the same magnitude as with gFOBT, ranging
from 32-80%. 51-53 Similarly, colonoscopy is expected to be more effective than
sigmoidoscopy because these are both endoscopic examinations with a further
reach for colonoscopy. However, colonoscopy is also more burdensome. Over-
all, there is no consensus on which screening test is best. Currently, several RCT’s
are underway comparing colonoscopy and FIT. 54 55
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Figure 5. Colonoscopy. 
A thin, lighted tube is
 inserted through the anus
and rectum and into the
colon to look for abnormal
areas. For the National
 Cancer Institute © 2018
Terese Winslow LLC, U.S.
Govt. has certain rights. 7
With permission.
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As a consequence of differences in CRC incidence, the impact of the disease
relative to other health problems, the capacity to treat the disease, economic
resources, healthcare structure and infrastructure to support screening (e.g. abil-
ity to identify the target population at risk and the availability of a cancer reg-
istry), there are widely different CRC screening practices across the world, see
Figure 6 56. The national CRC screening program in the Netherlands uses bien-
nial FIT screening. More information on the Dutch screening program can be
found below under ‘CRC screening in the Netherlands’. (page 18)
General introduction
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Figure 6. Overview of various screening practices across the world in 2014.
 Regional differences with in one country are, except for North-America, not
taken into account in these figures. (A) Overview of screening programmes in
European region. (B) Overview of screening programmes in regions of the
Americas. (C) Overview of screening programmes in Western Pacific, South-East
Asia and Eastern Mediterranean region. FIT, Faecal immunochemical test for
haemoglobin; gFOBT, Guaiac faecal occult blood test. 56 With permission.
A B
C
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Surveillance colonoscopy
Individuals in whom adenomas have been detected and removed (as a result of
colonoscopy screening, colonoscopy follow-up after a positive screen test or
during colonoscopy indicated for symptoms) have an increased risk for CRC
compared with the general population, even after adenomas have been re-
moved. 57 58 Patients with adenoma are therefore recommended to undergo reg-
ular surveillance colonoscopy. 59-63 In this thesis we focused on risk stratification of
adenoma patients and intervals for surveillance colonoscopy for further guideline
development. For more information on surveillance colonoscopy: effectiveness,
burden, (international) guidelines, its shortcomings and adherence to guidelines,
see below under heading ‘Surveillance in adenoma patients’. (page 18)
Tertiary prevention: CRC treatment
Over the last two decades CRC treatment has improved disease outcome and
extended a patients’ survival time. 6 Depending on cancer stage and location,
treatment of CRC include local treatment (surgery and/or radiotherapy) and/or
systemic treatment (chemotherapy, targeted therapy and immunotherapy). 64
Treatment of rectal cancer varies somewhat from colon cancer, differences in-
clude surgical technique, the use of radiation therapy, and the method of
chemotherapy administration. 65 
Usually stage I-II colon cancers and stage I rectal cancers are treated locally with
surgery. More advanced cancers require combinations of treatments, for stage II-
III rectal cancers preoperative chemo radiation therapy is the preferred treatment
(combination of chemo- and radiation therapy). Neoadjuvant chemotherapy and
radiation therapy aim to shrink tumours and kill cancer cells. 64 65 Treatment for
stage III colon cancers involves surgery with adjuvant chemotherapy. Adjuvant
chemotherapy is used to kill any cancer cells that might have been left behind as
well as cancer cells that might have escaped from the main tumour and settled in
other parts of the body. Commonly used drugs for chemotherapy are 5-Fluo-
rouracil (5-FU), capecitabine (Xeloda), irinotecan (Camptosar), oxaliplatin (Eloxatin),
and trifluridine and tipiracil (Lonsurf). 64 For stage IV colon and rectal cancers treat-
ment involves a combination of surgery, chemotherapy and targeted therapy. 65
Targeted therapy include drugs that either target blood vessel formation to stop
tumours to form new blood vessels (examples are bevacizumab (Avastin), ramu-
cirumab (Cyramza), and ziv-aflibercept (Zaltrap)), or target cancer cell growth (ex-
amples are cetuximab (Erbitux) and panitumumab (Vectibix)). A drug that targets
both is regorafenib (Stivarga). 64 In addition, immunotherapy can be used to stim-
ulate or suppress the immune system to help the body fight cancer. 65 It can
Chapter 1
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shrink tumours or slow down their growth. Examples are pembrolizumab
(Keytruda) and nivolumab (Opdivo). 64
Colonoscopy 
Colonoscopy is key in the prevention and management of CRC. Colonoscopy is
either used as primary screening test or for diagnostic follow-up for all other CRC
screening tests, for surveillance after polyp or adenoma removal (polypectomy),
and is also the gold standard for detection of lesions in people with abdominal
symptoms. In patients over 50 years old, about 50-60% of all colonoscopies are
performed for screening and surveillance purposes. 66 67 Colonoscopy is the most
sensitive method for the detection of CRC and its precursor lesions. The estimated
sensitivity of colonoscopy is 95% for CRC and 85% for medium sized (6-9 mm) ade-
nomas, the specificity is assumed to be 86%. 68 69 However, the effectiveness of
colonoscopy depends strongly on its quality. The introduction of colorectal can-
cer screening programs has led to a growing interest in quality assurance for
colonoscopy practices. High-quality colonoscopies are complete procedures
with cecal intubation, having a withdrawal time of at least 6 minutes and a good
bowel preparation (Boston Bowel Preparation Score ≥6), at which all relevant
lesions/polyps are detected and radically (completely) removed. 70-72 Missed or
incompletely removed lesions may result in interval cancers after colonoscopy
(post-colonoscopy colorectal cancers). These cancers are detected after
colonoscopy and before the date of the next recommended colonoscopy or
screening. 73 Interval cancer reduces the effectiveness of a screening or surveil-
lance program and is an indicator of sensitivity. 
Complications of colonoscopy
Although colonoscopy is the most accurate test of the available screening tests
for CRC, the procedure is not without risk of complications. Major reported com-
plications are bleeding, colonic perforation and even death. Widely differing
complication rates have been reported 74 75, e.g. perforation rates ranging from
2.2 to 11.4 per 10,000 colonoscopies. Since the colonoscopy is one of the most
commonly performed examinations, several gastrointestinal societies adopted
safety standards to control the quality of the colonoscopy. The latest recom-
mendation of the American Society for Gastrointestinal Endoscopy (ASGE) and
the American College of Gastroenterology (ACG) aims for a maximum of 20
perforations in 10,000 colonoscopies. 76 For screening colonoscopies, no more
than 10 perforations in 10,000 colonoscopies is acceptable. 76 77
General introduction
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The demand for colonoscopy is increasing, mainly due to the implementation
of colorectal screening programs. 78 The absolute number of individuals ex-
posed to colonoscopy is dependent on the chosen screening and surveillance
programme. In order to make an optimal choice which stategy is prefered sev-
eral characteristics should be taken into account like participation rates, costs,
harms and benefits. Especially in screening programs, it is important that the
participants are aware of both benefits and risks of the procedures, so that an
informed decision can be made whether or not to undergo colonoscopy. For
quality control purposes, a regular review of complication rates of colonoscopy
in the screening and clinical settings is essential.
CRC screening in the Netherlands
In the Netherlands, biennial FIT screening was introduced nationally in 2014 for
men and women aged 55-75 years. The program is implemented gradually by
age group over a period of 5 years, allowing for timely increase in colonoscopy
capacity. In 2019 the program covers the full age range (55-75), targeting a pop-
ulation of 2.2 million annually. 79 80
In the first 3 years of the Dutch program almost 3.4 million individuals were
invited (for first and/or second round), over 2.4 million participated by returning
a FIT test which led to 151,411 positive test results and to at least 121,481 indi-
viduals undergoing colonoscopy. Of individuals undergoing colonoscopy, about
9,900 individuals were diagnosed with CRC and almost 79,000 (approximately
65%) with adenoma, of whom two-third with advanced adenoma. 81-83 The pro-
portion of patients with advanced adenoma was 44% in the first screening round
and 36% in the second screening round. A large proportion of patients with
adenoma is recommended a surveillance colonoscopy and will return for
colonoscopy within the next 5 years. 
Surveillance of adenoma patients
Adenoma patients in whom adenomas have been removed are believed to be still
at elevated risk of CRC compared to the general population. 57 84 Within 3-5 years
of follow-up, 20-50% of adenoma patients will have adenoma recurrence. 84-87 Due
to the presumed elevated CRC risk adenoma patients are generally advised to
undergo regular surveillance colonoscopy. 61 62 Compared to the general popula-
tion, CRC mortality was reduced by 53% in patients with colonoscopy with
polypectomy after a follow-up period of up to 23 years (median follow-up was 16
years). 88 However, other studies found a smaller effect on CRC incidence and mor-
tality reduction in adenoma patients undergoing surveillance colonoscopy. 58 89 92
Chapter 1
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Surveillance colonoscopy should be targeted at adenoma patients most likely
to benefit and should be minimized to the lowest frequency needed to protect
against CRC. According to two meta-analyses, risk of advanced neoplasia re-
currence is higher when adenomas at index colonoscopy had the following char-
acteristics: large size (>=10 mm), villous histology and proximal location. 90 91
Patients with these characteristics warrant more intense surveillance. This is con-
firmed by a study of Løberg and Kalager et al. showing a higher risk of CRC
mortality in high-risk adenoma patients within a median follow-up period of 7.7
years (standardized incidence-based mortality ratio = 1.16 (95% CI 1.02 – 1.31)
compared to the general population. 92
Surveillance colonoscopies are estimated to constitute 13%–40% of all
colonoscopies performed. 66 93-95 This proportion may increase in the near future
due to the adoption of population screening, unless the introduction of screen-
ing is accompanied by introduction of more selective surveillance guidelines. 
Guidelines for surveillance of adenoma patients
Internationally, risk stratification of adenoma patients in guidelines for surveillance
colonoscopy is predominately based on adenoma multiplicity and categorization
of an adenoma as advanced or non-advanced (Table 1). 61 62 96 Similar to the 2012
US guideline, the 2013 European (European Society of Gastrointestinal Endoscopy,
ESGE) guideline classifies patients as high-risk if either 3 or more adenomas or at
least one high-risk adenoma is removed (i.e., a large adenoma or an adenoma
with (tubulo)villous histology or high grade dysplasia). 61 62 Three-year surveillance
intervals are recommended for high-risk patients and five to ten year intervals for
low-risk patients. 61 62 The UK, Scottish, Australian, and other European Union
guidelines distinguish 3 categories, with the distinction of recommending a 1-
year surveillance interval for patients with 5 adenomas, 59 60 96 97 very large (20
mm) adenomas 59 or in case of 3 or more adenomas with at least one large (≥10
mm). 60 97 Patients with 10 or more adenomas should be referred for genetic
counselling. 61 96
In the Netherlands, the first guideline for surveillance of adenoma patients was is-
sued in 1988. This guideline recommended a repeat colonoscopy within 1 year to
check for complete removal of polyps in all patients, and subsequently a 3 year or
5 year interval for patients with multiple or a single adenoma, respectively. 99 In
1998 the guideline-workinggroup concluded that a repeat colonoscopy one year
after removal of an initial single adenoma was no longer indicated, and could
safely be perfomed after 2-3 years. 100 In 2002, the surveillance guideline recom-
General introduction
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mended patients with three or more adenomas to have surveillance
colonoscopy after three years, and patients with less than three adenomas after
six years. 63 At the time the 2002 guidelines were set, a more specific guideline
was not possible, because of lack of sufficient data. At the initiation of this thesis,
Chapter 1
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ESGE 2013 61
US 2012 62
European Union 2012 59
UK 2010 60
Scottish 2011 97
Australian 2011 96
Dutch 2002 63
Dutch 2013 98
Number or advanced 
(Size/ HGD/ Villous)
Number or advanced 
(Size/ HGD/ Villous)
Number & size
Number & size
Number & size
Number or advanced
(Size/ HGD/ Villous)
Number 
Number, size, location & villous
• >101
• ≥5, <10 mm
• ≥20 mm
• ≥5 
• ≥3 & ≥1 ≥10 mm
• SP, ≥10 mm 
• ≥5 
• ≥3 & ≥1 ≥10 mm
• ≥5
• SP, ≥10 mm 
• ≥3 
• ≥10 mm
• HGD
• Villous 
• SP, HGD
• SP, ≥10 mm 
• ≥3 – 10
• ≥10 mm
• HGD
• Villous 
• SP, HGD
• SP, ≥10 mm
• TSA
• 3-4, <10 mm
• 10-<20 mm
• Villous3
• HGD3
• 3-4, <10 mm
• 1-2, ≥10 mm
• 3-4, <10 mm
• 1-2, ≥10 mm
• ≥3
• ≥10 mm
• TV/ Villous
• HGD
• ≥3
• Risk score 3-5
• 1-2, <10mm, Tub, LGD
• <10 mm SP, LGD
• 1-2, <10mm, Tub, LGD
• SP, <10 mm, no dysplasia2
• HP, <10 mm2
• 1-2, <10mm
• Tubular & LGD3
• 1-2, <10mm
• 1-2, <10mm, LGD
• 1-2, <10 mm, Tub, LGD
• 1-2
• Risk score 1-2
Guideline Interval based on adenoma
characteristic 
1 year 3 years 5-10 years *
Surveillance interval
HGD = high-grade dysplasia, LGD = low-grade dysplasia, Tub = tubular, TV = tubulovillous,
TSA = traditional serrated adenoma, SP = serrated polyp, HP=hyperplastic polyp
* ESGE 2013 61: Return to screening or colonoscopy in 10 years; US 2012 62: 5-10 years;
 European Union 2012 59: Routine screening; UK 2010 60: 5 years or no screening; Scottish
2011 97: 5 years: Australian 2011 96: 5 years: Dutch 2002 63: 6 years; Dutch 2013 98: 5 years for
patients with risk score 1-2, FIT screening after10 years for patients with risk score 0.
1 surveillance interval < 3 years
2 Surveillance interval 5 years for SP, 10 years for HP
3 Optional additional criteria.
Table 1. Risk stratification and interval recommendations for surveillance after
polypectomy according to various guidelines
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a survey had indicated discomfort of gastroenterologists with the existing guide-
lines. Their recommended surveillance intervals differed from the guideline, be-
cause they felt that important risk factors for adenoma recurrence were not
considered. They assumed a higher perceived risk for adenoma patients with
presence of other risk factors than solely adenoma number. This discomfort and
lack of adherence formed the basis for our study, called Surveillance After
Polypectomy – Towards Efficient Guidelines (SAP-study), and the resulting
change in guideline in 2013 (see Chapter 8, Figure 1 for more detail). 
Shortcomings in guidelines for surveillance in adenoma patients
In general, all international surveillance guidelines are based on very little em-
pirical evidence. No randomized controlled trials have evaluated the benefit of
surveillance compared to no surveillance or have evaluated effectiveness of sur-
veillance in a setting with screening and only two studies compared CRC risk at
different surveillance intervals. 84 101 The largest, the National Polyp Study, com-
pared two surveillance schemes for patients with newly diagnosed adenomas,
surveillance at 1 year plus at 3 years versus surveillance at 3 years only, and con-
cluded that the interval for colonoscopy surveillance can be extended to 3 years
after complete removal of initial polyps for most patients. 84
There are more observational studies concerning surveillance of adenoma
patients. Some have assessed independent predictors of advanced neoplasia
at surveillance. Predictors of advanced neoplasia are studied, as a proxy for CRC
risk, to better target colonoscopies to those patients who benefit most from the
procedure. These studies consistently showed that adenoma multiplicity, size
and villous histology are each independent predictors of advanced adenoma
recurrence. 90 91 Despite these findings, guidelines do not incorporate a higher
risk level for patients in whom multiple risk factors are present. Furthermore,
several additional predictors for recurrent advanced colorectal neoplasia, such
as older age, male sex, and proximal location of the adenoma(s) are generally
not considered at all. 91 Additionally, most recommended intervals for surveil-
lance in guidelines are based on expert opinion, not on formal decision analysis
(cost-effectiveness). Formal decision analysis is needed to take into account
costs and harms, besides effectiveness. 
Adherence to surveillance guidelines
For optimal effectiveness of CRC prevention and limitation of resource deple-
tion, adherence to surveillance guidelines is required. Surveys show that gas-
troenterologists often advise shorter surveillance intervals than recommended
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21
hoofdst 1_Opmaak 1  25-11-18  17:55  Pagina 21
by guidelines. 102-105 However, results from surveys are indicators of adherence,
but may be too optimistic. These results reflect gastroenterologists’ intention im-
mediately after the colonoscopy, which is only one factor on whether or when sur-
veillance colonoscopy will take place. Also, they may be prone to bias because of
desirable answers. Few studies have assessed actual adherence to surveillance
guidelines in clinical practice. 106-108 Most were either relatively small single-centre
studies or based on self-reported patient survey. The proportion of patients not
having surveillance was often not assessed. Adherence to surveillance guidelines
is generally poor, with mainly too frequent surveillance in low-risk adenoma pa-
tients and too little surveillance in high-risk patients. 104 106 107 109
Aim and research questions (outline of this thesis)
The aim of this thesis is to propose more efficient guidelines for surveillance of
adenoma patients in the Netherlands. This thesis is divided into three parts an-
swering the following research questions:
Part I: Complications of colonoscopy
1. What are perforation and mortality rates of colonoscopy according to liter-
ature over the past 30 years? (Chapter 2)
Part II: Predictors of (advanced) neoplasia recurrence and more efficient
 surveillance of adenoma patients
2. What are adenoma and colonoscopy-related predictors of (advanced) col-
orectal neoplasia recurrence at surveillance examinations? (Chapter 3)
3. How can we improve risk stratification of adenoma patients? (Chapter 4)
4. What are cost-effective strategies for surveillance of adenoma patients with
different risk profiles? (Chapter 5)
Part III: Adherence to and acceptance of guidelines for surveillance of
 adenoma patients
5. What are actual adherence rates to recommended surveillance intervals in
clinical practice? What is the influence of a recent change in the guideline?
(Chapter 6)
6. Is the new risk-stratified surveillance guideline feasible for gastroenterolo-
gists? What difficulties do gastroenterologists have regarding guideline in-
terpretation or compliance? (Chapter 7)
Chapter 1
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Chapter 8, the general discussion, concludes this thesis with the answers to and
discussion of the above mentioned research questions. 
Support 
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Abstract
Background & Aims: We investigated adenoma and colonoscopy characteris-
tics that are associated with recurrent colorectal neoplasia based on data from
community-based surveillance practice.
Methods: We analyzed data on 2990 consecutive patients (55% male; mean age
61 years) newly diagnosed with adenomas from 1988 to 2002 at 10 hospitals
throughout the Netherlands. Medical records were reviewed until December 1,
2008. We excluded patients with hereditary colorectal cancer (CRC) syndromes,
a history of CRC, inflammatory bowel disease, or without surveillance data. We
analyzed associations among adenoma number, size, grade of dysplasia, villous
histology, and location with recurrence of advanced adenoma (AA) and non-ad-
vanced adenoma (NAA). We performed a multivariable multinomial logistic re-
gression analysis to estimate odds ratios (ORs) and 95% confidence intervals
(CIs).
Results: During the surveillance period, 203 (7%) patients were diagnosed with
AA and 954 (32%) patients with NAA. The remaining 1833 (61%) patients had
no adenomas during a median follow-up of 48 months. Factors associated with
AA during the surveillance period included baseline number of adenomas (ORs
ranging from 1.6 for 2 adenomas; 95% CI: 1.1–2.4 to 3.3 for ≥5 adenomas;95%
CI: 1.7–6.6), adenoma size ≥10 mm (OR = 1.7; 95% CI: 1.2–2.3), villous histology
(OR = 2.0; 95% CI: 1.2–3.2), proximal location (OR = 1.6; 95% CI: 1.2−2.3), insuf-
ficient bowel preparation (OR = 3.4; 95% CI: 1.6-7.4), and only distal
colonoscopy reach (OR = 3.2; 95% CI: 1.2-8.5). Adenoma number had the great-
est association with NAA. High-grade dysplasia was not associated with AA or
NAA. 
Conclusions: Large size and number, villous histology, proximal location of ade-
nomas, insufficient bowel preparation, and poor colonoscopy reach were asso-
ciated with detection of AA during surveillance based on data from
community-based practice. These characteristics should be used jointly to de-
velop surveillance policies for adenoma patients.
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Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer-related death in
the Western world.1, 2 Detecting and removing (early-stage) cancers and pre-
cursor lesions (adenomas) can reduce CRC incidence and mortality.3-5 Individu-
als in whom adenomas are detected have an increased risk of CRC developing
compared with the average population, even after the adenoma has been re-
moved.4, 6-9 Therefore it is recommended that adenoma patients undergo reg-
ular surveillance colonoscopy.10-14 Surveillance colonoscopy currently presents
a considerable burden for individuals and demand on endoscopy units. To in-
crease the efficacy of surveillance, risk stratification based on advanced ade-
noma (AA) recurrence rates with well-allocated surveillance intervals is needed.
Patients with high-risk adenomas, so called “advanced adenomas”, or with >2
adenomas are especially known for higher advanced adenoma recurrence
rates.4, 9, 15, 16 Advanced adenomas are usually defined as adenoma(s) with at
least one of the following characteristics size ≥10mm, high-grade dysplasia
(HGD), and (tubulo)villous histology.
Currently recommended surveillance intervals differ between countries and
institutions, and are predominantly based on adenoma multiplicity and catego-
rization of an adenoma as advanced or nonadvanced.11-13 None of the surveil-
lance guidelines have incorporated recommendations when specific
combinations of the various aspects (ie, size ≥10mm, villousness, HGD) of ad-
vanced adenomas are present. Previous studies suggested that these adenoma
characteristics are independent predictors of adenoma recurrence, but these
studies were often small or assessed the adenoma predictors one at a time.17-
19 Two meta-analyses explored the predictive effect of individual adenoma char-
acteristics on AA recurrence.9, 19 These studies included data from clinical trials
performed in the United States, often with high quality examinations and per-
protocol surveillance intervals. Most studies included patients with prior ade-
nomas and without certain medical conditions, and approximately half of the
population included also underwent a dietary or chemopreventive intervention.
The aim of the present study was to determine independent adenoma-related
and colonoscopy-related predictors and their associated odds ratios for (ad-
vanced) colorectal adenomas during clinical surveillance practice in a large com-
munity-based study.
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Methods
Data collection
We used the nationwide registry of histopathology and cytopathology (PALGA)
to select patients with newly diagnosed adenoma between 1988 and 2002 from
10 hospitals (3 academic and 7 nonacademic) in The Netherlands. Participating
hospitals were selected on the basis of long-term availability of electronic med-
ical records and geographical distribution throughout The Netherlands. Years
of inclusion of adenoma patients depended on the availability of electronic
medical records per hospital. Local hospital medical records, mainly endoscopy
and pathology reports, were reviewed until December 1, 2008 to collect infor-
mation on patient characteristics and adenoma characteristics at index
colonoscopy and surveillance endoscopies. Patients with any of the following
criteria were excluded: age at index colonoscopy younger than 40 years; (sus-
pected) hereditary CRC syndromes, such as Lynch syndrome (hereditary non-
polyposis colorectal carcinoma), familiar adenomatous polyposis, Peutz-Jeghers
syndrome, juvenile polyposis, or mutYH-polyposis; personal history of CRC or
CRC at index colonoscopy; inflammatory bowel disease; hyperplastic polyps
(nonadenomatous polyps) only; (partial) colonic bowel resections before or at
the time of index colonoscopy; acromegaly; uretero-sigmoidostomy; index en-
doscopy was a sigmoidoscopy; missing pathology or endoscopy report at index
colonoscopy; and no surveillance endoscopy.
The study was approved by the Institutional Review Board at the Erasmus MC
University Medical Center and confirmed by the local Institutional Review Board
of each participating hospital.
Measures and Deﬁnitions
Index colonoscopy was defined as the colonoscopy with first adenoma diagno-
sis. Repeat endoscopy examinations performed within 6 months were consid-
ered as one examination and histological findings were combined. In case of
combining results from endoscopies, date of last colonoscopy was used.
The adenoma characteristics collected at index and surveillance endoscopies
were number of adenomas, and per adenoma found: size (measured by endo-
scopist and pathologist), presence of HGD and villous histology, and location.
For the analysis, we coded the number of adenomas as 1 to 5+, and used en-
doscopic size of the largest adenoma categorized as <10mm or ≥10mm. Histo-
logical characteristics (HGD and villous histology) in any adenoma were coded
as present or absent. Adenoma location was considered proximal if at least 1
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adenoma was located proximal to the splenic flexure or if location was not spec-
ified when located at an endoscope insertion of ≥60cm. The colonoscopy-re-
lated characteristics collected at index colonoscopy were colonoscopy reach
(coded as full [to cecum], proximal colon, or distal colon), and index bowel
preparation (coded as good, moderate, or insufficient).
The 2 outcomes of interest were presence of at least 1 AA and presence of
non-advanced adenoma (NAA) only at surveillance endoscopy. We defined an
AA as an adenoma with at least1 of the following characteristics: size ≥10mm
(either on endoscopic description or pathology), villous histology (≥75% villous
architecture), or HGD (including intramucosal carcinoma or carcinoma in situ),
or CRC. In contrast, we defined NAA as size <10mm, with tubular or tubulovil-
lous histology, and with low-grade dysplasia. In cases where more than1 ade-
noma was found, patients were categorized according to most advanced
features. We present absolute numbers and percent with AA and NAA at sur-
veillance colonoscopy.
Statistical analysis
Missing values
We coded missing values as negative for presence of HGD, villous histology,
and a proximal location. We assumed “a good bowel preparation” and “a full
colonoscopy,” respectively, when bowel preparation and completeness of
colonoscopy were not explicitly documented (n = 2141 and n = 58, respectively).
For missing values concerning endoscopic adenoma size at index colonoscopy
(n = 584) and sex (n = 2) we used a statistical imputation technique.20 Imputa-
tions were based on correlations with patient characteristics at index
colonoscopy: age and gender; adenoma characteristics at index colonoscopy:
number of adenomas (1-5+), presence of HGD, (tubulo)villous histology (villous,
tubulovillous, tubular), proximal location, and adenoma size (pathology); year
of index colonoscopy; outcome (AA, NAA, or no adenoma during surveillance);
and surveillance interval, using the aregImpute function in R v2.11 software (R
foundation for statistical computing, Vienna, Austria). It is good methodological
practice to include the outcome variable in the imputation of predictor variables
to avoid biased imputations.21 The outcome is related to the predictor values;
by omitting the outcome in the imputation, the association between the pre-
dictor and outcome will falsely be weakened. Imputing missing outcomes was
not considered.21 For adenoma size at surveillance colonoscopy, we used either
endoscopic size or size at pathology (size ≥10mm) if available and otherwise we
assumed that the adenoma size was < 10mm.
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Strength of the association
Multinomial logistic regression analysis was used to assess odds ratios (OR) of pre-
dictors of AA and NAA during surveillance. We used a modulated renewal
method22 to make full use of the available follow-up data. For this purpose, we in-
cluded further surveillance data when available, in those patients with a (consec-
utive) negative surveillance endoscopy (no AA or NAA) until AA or NAA was
observed, or until the last negative surveillance endoscopy, with a maximum of
the fifth surveillance period. For these patients, multiple records were included in
the dataset, one for each included surveillance event. For each record, the time
of surveillance was calculated from the index date (date of colonoscopy with first
adenoma diagnosis) to the date of the surveillance endoscopy and the end point
was the finding at that particular surveillance endoscopy (AA/CRC, NAA, no ade-
noma). For example, if a patient had 2 negative surveillance endoscopies and at
the third surveillance examination a NAA detected, this patient was included 3
times in our database. This modulated renewal method leads to analysis of all first
NAAs and AA/CRCs that occur during follow-up. It enhances the efficiency of the
estimation with smaller standard errors of the estimated parameters.
Both univariable and multivariable analyses were performed, in the latter with
adjustment for age at index colonoscopy, sex, surveillance interval (coded in
years), and number of surveillance endoscopies (coded as 1 - 5) besides the ade-
noma and colonoscopy characteristics of the index colonoscopy (baseline ex-
amination). Analyses were performed using SPSS v17.0 (SPSS Inc, Chicago, IL).
Results
In total, 7086 patients were eligible for inclusion based on a colonoscopy with ade-
noma removal in one of the participating centers in the study period. Of these,
1674 patients were excluded for reasons of missing pathology (n = 25) or en-
doscopy reports (n = 1582), or both (n = 67). Another 2422 patients were excluded
because of absence of surveillance endoscopy in the study period. The remaining
2990 patients were included in further analysis (Figure 1). The excluded patients
were older compared with the included patients (67 vs. 61 years, Table 1), which
was in line with expectations, as age is a determinant for the indication of surveil-
lance. There were no differences with respect to sex (56% vs. 55%) and median
year of index colonoscopy (2000 for both, Table 1). Patients included in our analysis
had a higher proportion of AA at index colonoscopy as compared with those with-
out surveillance (38% vs 30%, based on nonimputed variables; P <.001).
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At surveillance (max 5th ): 
118 (9%) had advanced adenomas 
419 (32%) had non-advanced adenomas  
767 (59%) had no adenomas 
At surveillance (max 5th ): 
85 (5%) had advanced adenomas 
535 (32%) had non-advanced adenomas  
1066 (63%) had no adenomas 
7086 Eligible consecutive patients with a first adenoma diagnosed  
(between 1988 and 2002)  
2990 Adenoma patients in the cohort with follow-up data 
1674 Patients missing first pathology  
or endoscopy report 
2422 Adenoma patients without 
follow-up data 
 5412 Adenoma patients in the cohort 
1304 Had advanced adenomas 1686 Had non-advanced adenomas 
Figure 1 . The study cohort.
Percentages should be interpreted cautiously because they are not based on a formal
Kaplan-Meier analysis.
Male sex n, (%)
Age, y, mean
Median year of index endoscopy
1647 (55)
61.3
2000
2284 (56)
66.5 a
2000
Included patients
(N = 2990)
Excluded patients
(n = 4096)
Table 1. Characteristics of Included Patients (With Surveillance) and 
Excluded Patients (Without Surveillance Endoscopy or Missing Reports) 
a Significant P <.05.
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Mean number of adenomas at index colonoscopy was 1.6 (range, 1 - 15). Only
2.6% had ≥5 adenomas at index colonoscopy. One third of the patients had an
adenoma ≥10mm and a similar proportion had one with proximal location (Table
2). Correlations between the different adenoma characteristics at index
colonoscopy were modest. The strongest correlation was found between ade-
noma number and proximal location (Pearson r = .33).
Median interval until first surveillance endoscopy was 24 months (interquartile
range [IQR], 12 – 40 months). At first surveillance, 171 patients were diagnosed
with at least one AA (median interval, 27 months; IQR, 12 – 57 months), including
26 CRCs (median interval, 40 months; IQR, 20 – 79 months), 655 patients were
diagnosed with NAA only (median interval, 25 months; IQR, 13 – 40 months),
and 2164 patient had no adenoma or cancer (median interval, 23 months; IQR,
12 – 39 months). Of the 2164 patients with a negative first surveillance en-
doscopy, 1026 had more than 1 surveillance endoscopy (Figure 2). Median in-
terval between first and second surveillance was 36 months (IQR, 20 – 49
months) in these patients, 200 patients were diagnosed with NAA and 23 with
AA. In patients with NAA at first surveillance, the next surveillance was after a
median interval of 27 months (IQR, 14 – 39; n = 373), and in patients with AA
this was 15 months (IQR, 11 – 28; n = 83). In these last 2 groups at second sur-
veillance, 129 NAA and 8 AA and 31 NAA and 2 AA, respectively, were found
(Table 3). When including subsequent surveillance events after a (first) negative
surveillance colonoscopy (until a first event or last negative), the mean number
of surveillance endoscopies included for those with a negative first surveillance
was 1.7. Adding these surveillance examinations increased the number of pa-
tients with AA at surveillance to 203 (including 38 CRCs) and with NAA to 954,
after a median follow-up period of 35 months (IQR, 13 – 64 months) and 36
months (IQR, 15 – 64 months), respectively. Median follow-up for 1833 patients
without any adenoma or cancer was 48 months.
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Demographics 
Male sex, n (%)
Age groups, n (%)
40-49
50-59
60-69
70-79
80-89
Adenoma characteristics at index
No. of adenomas, n (%)
1
2
3
4
5+
Patients with any adenoma with: 
Size ≥10mm, n (%)c
Villous histology, n (%)
HGD, n (%)
Proximal location, n (%)
Any advanced adenoma, n (%)d
Colonoscopy characteristics at index
Reach colonoscopy, n (%)
Full, to cecume
Proximal colon
Distal colon
Bowel preparation, n (%)
Goodf
Moderate
Insufﬁcient 
1647 (55.1)
439 (14.7)
865 (28.9)
982 (32.8)
593 (19.8)
111 (3.7)
2043 (68.3)
559 (18.7)
241 (8.1)
68 (2.3)
79 (2.6)
1171 (39.2)
155 (5.2)
419 (14.0)
950 (31.8)
1304 (43.6)
2780 (93.0)
177 (5.9)
33 (1.1)
2718 (90.9)
227 (7.6)
45 (1.5)
940 (51.3)
285 (15.5)
528 (28.8)
582 (31.8)
368 (20.1)
70 (3.8)
1373 (74.9)
299 (16.3)
104 (5.7)
29 (1.6)
28 (1.5)
684 (37.3)
90 (4.9)
241 (13.1)
519 (28.3)
767 (41.8)
1705 (93.0)
109 (5.9)
19 (1.0)
1665 (90.8)
141 (7.7)
27 (1.5)
578 (60.6)
135 (14.2)
289 (30.3)
331 (34.7)
173 (18.1)
26 (2.7)
562 (58.9)
212 (22.2)
112 (11.7)
31 (3.2)
37 (3.9)
379 (39.7)
39 (4.1)
131 (13.7)
341 (35.7)
419 (43.9)
884 (92.7)
61 (6.4)
9 (0.9)
870 (91.2)
75 (7.9)
9 (0.9)
Characteristic at index colonoscopy All patients
(N = 2990)
No adenoma
(n = 1833)
Stratiﬁed by highest ﬁndings at surveillance endoscopy
NAAa
(n = 954)
106 (64.2)
18 (10.9)
38 (23.0)
58 (35.2)
38 (23.0)
13 (7.9)
83 (50.3)
39 (23.6)
21 (12.7)
8 (4.8)
14 (8.5)
88 (53.3)
20 (12.1)
34 (20.6)
77 (46.7)
94 (57.0)
156 (94.5)
5 (3.0)
4 (2.4)
152 (92.1)
5 (3.0)
8 (4.8)
AA(-CRC)b
(n = 165)
23 (60.5)
1 (2.6)
10 (26.3)
11 (28.9)
14 (36.8)
2 (5.3)
25 (65.8)
9 (23.7)
4 (10.5)
-
-
20 (52.6)
6 (15.8)
13 (34.2)
13 (34.2)
24 (63.2)
35 (92.1)
2 (5.3)
1 (2.6)
31 (81.6)
6 (15.8)
1 (2.6)
CRC
(n = 38)
Table 2. Characteristics of the Study Population at Index
Colonoscopy (N = 2990)
AA, advanced adenoma;  CRC, colorectal cancer; NAA, nonadvanced adenoma; HGD, high-
grade dysplasia.
a Includes adenomas <10mm, with tubular or tubulovillous histology and low-grade dysplasia.
b Includes adenomas with one or more of the following characteristics; villous histology, HGD,
and size ≥10mm.
c Based on the imputed size variable, 584 missing values were imputed.
d Advanced adenoma includes adenomas with one or more of the following characteristics;
 villous histology, HGD, and size ≥10mm. Size is based on the imputed size variable.
e These were missing in 58 cases and assumed to be full colonoscopies.
f These were missing in 2141 cases and assumed to have good bowel preparation.
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Figure 2. Flow chart of findings (and median interval) of first and 
subsequent (for patients without adenomas at previous examinations)
surveillance examinations.
AA includes adenomas with one or more of the following characteristics; villous histology,
HGD, and size ≥10mm, including CRC. NAA includes adenomas <10mm, with tubular or
tubulovillous histology and low-grade dysplasia. Red blocks add up to 203 patient records with
AA at surveillance (in 203 patients). Orange blocks add up to 954 patient records with NAA at
surveillance (in 954 patients). Green blocks add up to 3298 patient records with no adenoma at
surveillance (in 1833 patients). 
a Adds up to the number of patients with no adenoma detected at surveillance
FU, Follow-up examination/endoscopy
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Adenoma-related characteristics at index colonoscopy predictive for AA were
the number of adenomas (multivariable ORs ranging from 1.6; 95% confidence
interval [CI]:1.1 – 2.4 for 2 adenomas to 3.3; 95% CI:1.7 – 6.6 for patients with ≥5
adenomas); any adenoma with a large size (≥10mm; OR = 1.7; 95% CI:1.2 – 2.3),
a villous histology (OR = 2.0; 95% CI:1.2 – 3.2); and proximal location (OR  = 1.6;
95% CI: 1.2 – 2.3); Table 4). HGD was not predictive in the multivariable analysis.
Colonoscopy-related characteristics predictive for AA were insufficient bowel
preparation (OR = 3.4; 95% CI:1.6 – 7.4) and reach of the colonoscopy no further
than the distal colon (OR = 3.2; 95% CI:1.2 – 8.5). For NAA, the number of ade-
nomas at index colonoscopy was a predictor, in both univariable and multi -
variable analyses. In the multivariable analysis, ORs for multiplicity ranged from
1.5 (95% CI: 1.3 – 1.9) for patients with 2 adenomas, to 2.8 (95% CI:1.8 – 4.5) for
patients with ≥5 adenomas. Colonoscopy-related characteristics were not pre-
dictive.
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Advanced adenoma
Nonadvanced adenoma
AA
NAA
No
AA
NAA
No
50 (53)
173 (61)
473 (51)
33 (43)
200 (54)
553 (45)
2 (4)
6 (3)
17 (4)
0 (0)
2 (1)
6 (1)
Most advanced ﬁnding at index
colonoscopy
Most advanced
ﬁnding 
at ﬁrst 
surveillance
Individuals 
with
second
surveillance, 
n (%)
Most advanced  ﬁnding at second surveillance,
n (%)
Advanced 
adenoma 
17 (34)
54 (31)
87 (18)
14 (42)
75 (38)
113 (20)
Nonadvanced
adenoma 
31 (62)
113 (65)
369 (78)
19 (58)
123 (62)
434 (78)
No adenoma
14 / 15
13 / 27
13 / 30
20 / 19
19 / 27
17 / 37
Median time 
interval
between index to 
ﬁrst / ﬁrst to second
examination (mos)
Table 3. Adenoma Type at First vs Second Surveillance Endoscopies Accord-
ing to Index Findings in (n = 1482) With at Least 2 Surveillance Endoscopies.
NOTE. All values in table concern subjects with at least 2 surveillance colonoscopies.
AA, advanced adenoma; NAA, non-advanced adenoma; No, no adenoma.
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Adenoma characteristics
Adenoma number
1
2
3
4
5+
Any adenoma size ≥10mm
Any adenoma with HGD
Any villous adenoma
Any proximal adenoma
Colonoscopy characteristics
Bowel preparation
Good
Moderate
Insufﬁcient 
Reach colonoscopy
Full colonoscopy d
Proximal colon
Distal colon
1.0
1.6 (1.3 – 1.9)
2.3 (1.8 – 3.0)
2.6 (1.6 – 4.0)
2.7 (1.8 – 4.1)
1.0 (0.8 – 1.1)
0.9 (0.8 – 1.2)
0.7 (0.5 – 0.9)
1.5 (1.3 – 1.7)
1.0
1.0 (0.8 – 1.3)
0.7 (0.3 – 1.5)
1.0
1.1 (0.8 – 1.4)
0.9 (0.5 – 2.0)
1.0
1.8 (1.3 – 2.6)
2.7 (1.7 – 4.3)
3.4 (1.6 – 7.4)
5.3 (2.9 – 9.8)
1.7 (1.3 – 2.2)
1.8 (1.3 – 2.5)
2.3 (1.5 – 3.5)
2.1 (1.6– 2.8)
1.0
0.7 (0.4 – 1.3)
3.4 (1.6 – 7.0)
1.0
0.6 (0.3– 1.2)
2.4 (0.9 – 6.3)
1.0
1.5 (1.3 – 1.9)
2.3 (1.8 – 3.0)
2.5 (1.6 – 4.0)
2.8 (1.8 – 4.5)
1.1 (0.9 – 1.3)
0.9 (0.7 – 1.1)
0.7 (0.5 – 1.0)
1.2 (1.0 – 1.4)
1.0
1.1 (0.8 – 1.4)
0.7 (0.3 – 1.4)
1.0
1.1(0.8 – 1.5)
1.0 (0.5 – 2.2)
1.0
1.6 (1.1 – 2.4)
2.1 (1.3 – 3.4)
2.0 (0.9 – 4.6)
3.3 (1.7 – 6.6)
1.7 (1.2 – 2.3)
1.2 (0.8 – 1.8)
2.0 (1.2 – 3.2)
1.6 (1.2 – 2.3)
1.0
0.8 (0.4 – 1.5)
3.4 (1.6 – 7.4)
1.0
0.6 (0.3 – 1.3)
3.2 (1.2 – 8.5)
Index characteristics NAA b AA c
Univariable OR (95% CI) Multivariable OR a (95% CI)
NAA b AA c
Table 4. OR (95% CI) of Nonadvanced Adenoma and Advanced Adenoma at
Surveillance Endoscopy for Index Adenoma and Colonoscopy Characteristics. 
NOTE. The multinomial logistic regression analyses included 2990 patients with 954 NAA and
203 AA detected during follow-up (see Figure 2).
AA, advanced adenoma;  NAA, nonadvanced adenoma; HGD, high-grade dysplasia.
a Adjusted for the adenoma characteristics at colonoscopy mentioned in the table (adenoma
number, any adenoma size ≥10mm, any adenoma with HGD, any villous adenoma, and any
proximal adenoma, bowel preparation, reach of the index colonoscopy), and age at index
colonoscopy, sex, surveillance interval, and number of surveillance colonoscopies.
b Includes adenomas <10mm with tubular or tubulovillous histology and low-grade dysplasia.
c Includes adenomas with one or more of the following characteristics: villous histology, HGD,
and size ≥10mm, including CRC.
d Reach of the colonoscope to the cecum.
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Discussion
Our study shows that higher adenoma number, any adenoma with size ≥10mm,
any adenoma with a villous histology, and any adenoma with proximal location
at index colonoscopy together with insufficient bowel preparation and
colonoscopy reach no further than the distal colon are the most important pre-
dictors for detecting advanced colorectal neoplasia (AA or CRC) at surveillance
endoscopy. These factors were independent predictors for subsequent ad-
vanced colorectal neoplasia, meaning that having multiple of these factors at
the same time further increases a patient’s risk. HGD was not found to be an in-
dependent predictor of advanced colorectal neoplasia recurrence.
Examining predictors for both advanced and nonadvanced colorectal neo-
plasia simultaneously gave us the possibility to discriminate between predictors
for advanced and nonadvanced neoplasia. The ORs of adenoma number were
very similar for both AA and NAA. It makes sense that adenoma number would
be an important predictor for subsequent adenomas because individuals with
multiple adenomas have proven to be susceptible to developing adenomas
and can be expected to continue to do so in the future4, 23 24 Furthermore, mul-
tiple adenomas at baseline may be associated with a higher probability of miss-
ing lesions.25 In contrast, size ≥10mm and villous histology were only found to
be predictors for AA and not for NAA. Again, this can be explained from a sus-
ceptibility viewpoint: patients who have already been proven to have AAs de-
velop might be more susceptible to this type of adenoma and not so much for
adenomas in general. HGD forms the exception to this rule: this characteristic
was not found to be predictive for AA or NAA. This contrasts with some other
studies.24, 26-30 However, these studies were generally small and/or did not adjust
for other adenoma characteristics. The study by Toll et al, for example, could
not demonstrate the independent predictive effect of HGD, but only an effect
of HGD combined with size ≥10mm.29 Whether HGD is predictive in patients
with 1-2 small, nonvillous adenomas may warrant further investigation because
this group was quite small in our study. However, when considering statistical
interactions of HGD with adenoma number, villous histology or size, HGD was
still not a significant predictor. The one other large study of predictors for ade-
noma recurrence, a pooled analysis that included individual-level data from 8
clinical trials,9 corroborates our finding on HGD. Together, these findings sup-
port the notion that HGD may be dropped as a predictor in surveillance guide-
lines.
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We note that all estimated ORs for adenoma-related predictors were very
similar to the earlier pooled analysis of 8 clinical trials9, indicating that the ORs
for AA recurrence from clinical trials apparently also hold for average commu-
nity-based clinical practice. Clinical trial results might not be generalizable to
community-based practice because of higher-quality colonoscopies in trials,
which are associated with lower adenoma miss rates and higher rates of com-
plete adenoma removal. If removed incompletely, large, villous and HGD ade-
nomas may pose higher risks of adenoma recurrence than observed from clinical
trials. The absolute risk of developing advanced colorectal neoplasia were, how-
ever, lower in our study (7% during a median follow-up period of 48 months)
than in the pooled analysis of clinical trials by Martinez et al (12% during a me-
dian follow-up period of 47 months). In the latter, tubulovillous adenomas were
also included in the outcome definition of AA. Including tubulovillous histology
in our definition of AA would have increased the recurrence rate of AA to 10%
in our study. For any adenoma recurrence, recurrence rates were 39% vs 47%,
in our study vs the Martinez study, respectively. These recurrence rates should
be interpreted cautiously because they are not based on a formal Kaplan-Meier
analysis. However Pinsky et al reported that time to surveillance was not asso-
ciated with a higher AA recurrence rate.16
In addition to adenoma characteristics, our study also investigated the impact
of quality of the index examination on (advanced) adenoma recurrence rates.
Insufficient bowel preparation and visualization of the colon no further then the
distal part of the colon were both strong predictors for AA, but not for NAA.
Likely, the missed (advanced) lesions had time to progress and are found at sub-
sequent surveillance (and mainly in AA type). Our finding corroborates the find-
ings of a small population-based case-control study, showing that
colonoscopy-related factors (albeit different factors than the once studied here)
are more important predictors than adenoma characteristics for AA recur-
rence.31
The major strengths of this study are its large size and its community-based
design. The study size provided us with enough power to reliably estimate odds
ratios for adenoma recurrence. An observational study also has limitations. First,
there may be misclassification of adenoma characteristics. Pathology report pro-
tocols differed over time and between pathology centers. Histology reports
were generated by local pathologists with the inherent risk of inter-observer
variability in characterization of the histological types and degree of dysplasia.32,
33 This shows from the percentage of patients with HGD at index colonoscopy
in our study which varied from 5% to 39% between hospitals, and the range was
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2% - 17% for villous histology. We tried to diminish bias due to misclassification
of histological type by examining villous histology instead of (tubulo)villous his-
tology, which might be less prone to classification error.32 Measurement of ade-
noma size is also prone to error.34, 35 We used size measured by the endoscopist
as a predictor in our analysis, because this is most frequently reported in the lit-
erature and adenomas are known to shrink after excision.34 To avoid misclassi-
fication of size to some extent, the arbitrary cutoff value of 10 mm was used to
discriminate between small and large adenomas. The misclassification of ade-
noma histology, size, and location, might have resulted in diluting its predictive
effects.
Second, some polyps (potential adenomas) might not have been sent in for
pathology. As a result the actual number of adenomas might have been under-
estimated, which in turn might have led to an overestimation in the effect of
adenoma number. Third, the length of the surveillance interval was generally
shorter for patients with AA characteristics at index colonoscopy, which could
have let to bias. However, the risk ratios of the predictors were very consistent
when we compared results from different estimation techniques, including Cox
and logistic regression (data not shown). Especially the latter technique without
adjustment for surveillance interval would have led to lower risk ratios of the
predictors if the results were confounded by the length of surveillance interval.
However, this was not the case. Finally, we did not include shape of the ade-
noma and method of adenoma removal in our analysis, because these were not
well documented for the years under investigation. We tried to diminish bias
due to incomplete adenoma removal by combining endoscopy results within 6
months. 
Because risk of CRC relates to AA in particular, surveillance recommendations
should incorporate predictors of advanced colorectal neoplasia. Internationally,
surveillance guidelines are based on the presence of characteristics of the ad-
vanced adenoma (ie, size ≥10mm, HGD, and [tubulo]villous histology) and ade-
noma number.10-14 Historically, the international surveillance guidelines
distinguish only 2 patient categories: those with ≥3 and/or AAs and those with-
out. The UK, Scottish, and newer European guidelines distinguish three cate-
gories, recommending a 1-year surveillance interval for patients with ≥5
adenomas or very large (≥20 mm) adenomas.10, 11, 14 That people with ≥5 ade-
nomas are a higher risk-group is corroborated by our results; the OR of patients
with ≥5 adenomas was 3.3 compared with an OR of 2.0 for those with 3 or 4
adenomas. However, all these guidelines generally lack recommendations in
relation to adenoma location and for patients having multiple risk factors at the
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same time, despite their evidence as independent predictors for AA. These as-
pects should therefore be considered at the next iteration of the surveillance
guidelines. Our results imply that further risk stratification in surveillance guide-
lines is justified because 4 different adenoma characteristics were independently
found to be predictive for AA recurrence. For example, an individual with all 4
risk factors has a considerably higher risk and should therefore receive a shorter
surveillance interval than a person with just 1 risk factor. Adenoma patients
should be grouped based on the risk factors present and their associated risk
level, for example, by use of a scoring system or nomogram, such scoring sys-
tems are common practice in cardiovascular disease and for some cancers.36, 37
Then, formal cost-effectiveness analysis is needed to determine what the opti-
mal surveillance interval per risk group should be. Our results form an excellent
starting point for setting up such a score chart and determining the optimal sur-
veillance intervals in further research. Further research should also evaluate if
the presented adenoma-related predictors and their relative risks hold for an
(asymptomatic) adenoma patient population in a situation of mass screening
for CRC.
In conclusion, a higher adenoma number, larger adenoma size, villous histol-
ogy and proximal location are important independent adenoma-related pre-
dictors for AA during surveillance in community-based practice. These
adenoma-related predictors should be considered in combination with the qual-
ity of the index colonoscopy for better patient risk stratification for surveillance
aiming for a more personalized surveillance scheme.
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Abstract
Background and study aims: Current surveillance guidelines risk stratify patients
with adenoma by using only one or two factors: adenoma multiplicity or pres-
ence of an advanced adenoma characteristic. Combinations of adenoma char-
acteristics are not considered, which limits the predictive value of these
guidelines. The aim of the study was to develop a scoring system for more
 refined risk stratification of patients with adenoma.
Patients and methods: The Dutch Pathology Registry (PALGA) was used to iden-
tify newly diagnosed patients with adenoma in 10 Dutch hospitals between 1988
and 2002. Medical records were reviewed until 1 December 2008 for follow-up.
Logistic regression analysis was used to assess patient- and adenoma-related
predictors of metachronous advanced neoplasia. The prediction model was val-
idated by bootstrapping and cross-validation. A score chart was developed
based on identified adenoma-related predictors. The discriminative ability of
the prediction model was compared with currently used risk stratifications in
surveillance guidelines.
Results: A total of 2914 patients with adenoma were included (mean age 61
years; 55% male). The score chart consisted of characteristics that contributed
1 point (size ≥10 mm, villous histology, proximal location, having 2–4 adenomas)
or 2 points (having ≥5 adenomas). A patient’s adenoma risk score could range
from 0 to 5 points. A score of 5 for a 75-year-old man implied a 5-year risk of
advanced neoplasia of 46%. The discriminative ability of the model was mod-
erate (c-statistic 0.712) but better than risk stratifications in current international
guidelines, which had c-statistics of 0.642–0.674.
Conclusion: A score chart that combines adenoma-related predictors of ad-
vanced colorectal neoplasia optimized the risk stratification of patients with ade-
noma for appropriate surveillance colonoscopy intervals. 
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Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer-related death in
the Western world1–3. Detecting and removing (early stage) cancers and pre-
cursor lesions (adenomas) reduces CRC incidence and mortality4–7. Individuals
in whom adenomas are detected have an increased risk of developing CRC
compared with the average population, even after adenomas have been
 removed6,8–11. Patients with adenoma are therefore recommended to undergo
regular surveillance colonoscopy after polypectomy12–17.
Surveillance colonoscopy presents a considerable burden for individuals as well
as demand on endoscopy units. Surveillance colonoscopies are estimated to con-
stitute 13%–40% of all colonoscopies performed18–21. Improved risk stratification
of patients with adenoma can increase efficiency because it would target surveil-
lance colonoscopy more accurately to those patients who are most likely to benefit
from the procedure. Currently, risk stratification of patients in post-polypectomy
surveillance guidelines are predominately based on adenoma multiplicity and cat-
egorization of an adenoma as advanced or nonadvanced12–17. The definition of
an advanced adenoma is an adenoma with at least one of the following charac-
teristics: size ≥10 mm, high grade dysplasia (HGD), or villous histology. Generally,
guidelines do not incorporate a higher risk level for patients in whom multiple risk
factors (e.g. large adenoma size and villous histology) are present, despite studies
showing that each factor is an independent predictor of advanced adenoma re-
currence11,22. Furthermore, several additional predictors for recurrent advanced
colorectal neoplasia, such as older age, male sex, and proximal location of the
adenoma(s) are generally not considered at all11,22. Including predictors into a scor-
ing system could result in a more accurate risk stratification of patients with ade-
noma, and may improve efficiency of post-polypectomy surveillance. 
The aims of the current large community-based study were: 1) to develop a valid
scoring system for risk stratification of patients with adenomas, based on inde-
pendent predictors of advanced colorectal neoplasia (ACN); and 2) to compare
the score model to risk stratifications used in current post-polypectomy guidelines.
Patients and methods
Study population
In a nationwide histopathology registry (PALGA)23, patients aged 40 years and
above who had been newly diagnosed with at least one colorectal adenoma
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between 1988 and 2002 in one of 10 hospitals (3 academic and 7 nonacademic)
were identified. Local hospital medical records of these patients were reviewed
until December 1st 2008 to collect information on patient and adenoma char-
acteristics at index and surveillance colonoscopies. Patients were excluded if
they had: an increased risk of CRC (due to inflammatory bowel disease, hered-
itary CRC syndromes, or a personal history of CRC), (partial) bowel resection,
missing pathology or colonoscopy report, poor bowel preparation, and those
with a colonoscopy reach no further than intubation of the distal colon (splenic
flexure)22. 
The study was approved by the Institutional Review Board of the Erasmus MC
University Medical Centre. This approval was endorsed by the local Institutional
Review Board of each participating hospital.
Measures and deﬁnitions
The outcome of interest at follow-up colonoscopy was presence of ACN (CRC
or advanced adenoma). Advanced adenoma was defined as an adenoma with
at least one of the following characteristics: size ≥10 mm (either on endoscopic
description or pathology), villous histology (≥75% villous architecture), or HGD
(including intramucosal carcinoma or carcinoma in situ). 
The adenoma characteristics collected at index and follow-up colonoscopies
were number of adenomas, and per adenoma removed: size (measured by en-
doscopist and pathologist), presence of HGD, villous histology, and proximal
location. Adenoma location was considered proximal if located proximal to the
splenic flexure or if the colonic segment was not specified but colonoscope in-
sertion was ≥60 cm. 
Index colonoscopy was defined as the colonoscopy at which a patient’s first
adenoma diagnosis was made. In line with the literature, repeat colonoscopy
examinations performed within 6 months were considered as one examination
and findings were combined24,25. In these cases, the date of the last colonoscopy
(with polypectomy) was used. 
Statistical analysis
Missing values
Because endoscopists commonly only reported on bowel preparation and reach
if these factors were inadequate, it was assumed that bowel preparation was
“good” and that “a full colonoscopy” was conducted when these factors were
not explicitly documented (n = 2116 and n = 58, respectively). Similarly, it was
assumed that pathologists only reported the presence of villous histology or
Chapter 4
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HGD and not the absence of these features, and therefore missing values were
coded as negative for presence of HGD (n = 351), villous histology (n = 549),
and a proximal location (n = 41). For missing values relating to endoscopic ade-
noma size category at index colonoscopy (n = 568), and sex (n = 2), a statistical
multiple imputation technique was used, based on the correlation structure with
other covariates26,27. 
Regression analysis
Univariable and multivariable logistic regression analyses were performed to
estimate odds ratios (OR) of potential predictors of ACN during surveillance as
opposed to nonadvanced adenoma or no adenoma. In the analysis, a modu-
lated renewal method was used to make full use of the available follow-up data,
as described previously22. Data from follow-up colonoscopies were included,
when available, until an adenoma (nonadvanced adenoma or ACN) was de-
tected or until the last negative examination, to a maximum of the fifth follow-
up. As the focus of the study was on prediction of risk, a parametric model (i.e.
logistic regression) was considered to be more attractive than a model with a
nonparametric baseline hazard such as the Cox model, which might be pre-
ferred if the focus was on the effect of prognostic factors.
Age, sex, and adenoma characteristics at index colonoscopy were considered
as predictors for metachronous ACN. The number of adenomas was coded as
1 to 5+, and the endoscopic size categories of <10 mm or ≥10 mm were used.
Histological characteristics (HGD and villous histology) in any adenoma, and
proximal location were coded as present or absent. Besides patient character-
istics and adenoma characteristics at index colonoscopy, multivariable analyses
were adjusted for surveillance interval (coded in years), and number of negative
surveillance colonoscopies (coded as 1 to 5). 
In the univariable analysis, continuous variables (age, number of adenomas,
and the surveillance interval) were considered both continuously (as linear, with
polynomial transformations, and with a restricted cubic spline function including
2–4 knots) and categorically. The variant with best model fit in terms of Akaike’s
Information Criterion (AIC) was chosen to be included in the multivariable
model. A lower AIC indicates a better predictive performance.
Model validation
For internal validation, a bootstrapping procedure was performed28. First, dis-
criminative ability was assessed according to the concordance (c)-statistic, which
is equivalent to the area under the receiver operating characteristic curve. The
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c-statistic indicates how well the model discriminates between those patients
with and without ACN. A model was developed in the bootstrap sample (“boot-
strap model”), and then applied to both the bootstrap sample and the original
sample. The difference in model performance (difference in c-statistics) was av-
eraged over 1000 bootstraps to indicate optimism. The c-statistic of the original
prediction model was corrected with this optimism. A regular bootstrap scheme
was performed, which involved resampling each record rather than records re-
lated to one patient (selection of all patient records if a patient had multiple
records). Consequently, each record had the same chance to be selected in the
bootstrap analysis. This approach, although slightly less accurate than resam-
pling at the patient level, was chosen as it is less complicated and any differ-
ences in estimation of optimism are expected to be minor29.
Discrimination (c-statistic) and calibration characteristics (predicted and ob-
served ACN risk) were further evaluated in a cross-validation procedure where
patients from certain hospitals were omitted from the model-fitting procedure
one by one. First, the largest hospital was excluded, followed by the second-
largest hospital, then the three academic hospitals; finally, the remaining centers
were omitted. Each analysis omitted about 700 patients (validation sample) and
left about 2200 patients for model development (development sample). 
Score chart
A scoring system was developed (score chart), based on the adenoma charac-
teristics that were significant predictors of ACN in the multivariable analysis.
Points for each predictor were allocated on the basis of its estimated regression
coefficient. The coefficients were scaled by a factor and rounded to whole
points. The base category for each predictor was assigned 0 points in the scor-
ing system. Per patient, a total score can be calculated by adding up the points
of the adenoma characteristics present. The total score is referred to as the ade-
noma risk score. The odds ratio was also assessed for a 1-point increase in ade-
noma risk score in the multivariable score model. Patient-related predictors were
not included in the score chart as these impact life expectancy.
Discriminative ability of various risk stratification models
The optimism-corrected discriminative ability of various risk stratifications was
compared. First, the discriminative ability (c-statistic) of the null model was as-
sessed, including only surveillance interval and number of consecutive negative
(no adenoma detected and removed) surveillance colonoscopies. Then five dif-
ferent models were compared, each extending the null model: 1) a full model
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(including all predictors considered); 2) a simplified score model; 3) a model ac-
cording to the US surveillance recommendation: advanced adenoma or 3+ ade-
nomas vs. 1–2 nonadvanced adenomas; 4) a model according to the UK
guideline: 5 or more adenomas or 3 or more with at least one large vs. 3–4 ade-
nomas or at least one large vs. 1–2 small adenomas; and 5) a model according
to the Dutch 2002 surveillance guideline: 3 or more adenomas vs. 1–2 adeno-
mas. 
The c-statistics of models were compared, with percentage improvement in
c-statistic calculated as ([cnew – 0.5] – [cnull – 0.5]) / (cnull – 0.5), where the cnull
refers to the null model and cnew refers to a comparator model. The AIC, which
penalizes a better model fit for model complexity (degrees of freedom used),
was also considered. A lower AIC indicates a better predictive performance.
Absolute risk prediction
A table for 3- and 5-year ACN risk was designed as a guide for clinicians, similar
to the risk charts used for cardiovascular disease risk30. The multivariable logistic
regression score model was used to predict 3-year and 5-year absolute ACN
risk according to adenoma risk score, sex (male or female), and age (45–80 years
old). ACN risk is presented, stratified by age and sex, as both not only influence
ACN risk, but also life expectancy. Microsoft Excel 2010 was used for automated
coloring of the cells presenting absolute ACN risk in the table to visualize dif-
ferences in point estimates. Color differences do not indicate significant differ-
ences.
Regression analyses and cross validation were performed using SPSS v21.0
(IBM Corp., Armonk, New York, USA). R v2.11 software (R foundation for statis-
tical computing, Vienna, Austria) was used for imputation (which was done by
the aregImpute function), checks of nonlinearity in continuous predictors, boot-
strapping, and calculation of absolute ACN risk.
Results
Data were analyzed from 2914 patients with adenoma who had undergone a
colonoscopy with adenoma removal followed by at least one surveillance
colonoscopy. The mean age (±SD) was 61 ± 10 years, and 54.9% of patients
were male (Table 1). Only 2.7% of patients had five or more adenomas at index
colonoscopy. At surveillance colonoscopy, 189 patients had ACN. 
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Patient characteristics
Sex Female
Male
Age (per 20 year) 
40–59 years
60–79 years
80+ years
Adenoma characteristics 
No. of adenomas
1
2
3
4
5+
Any adenoma with: 
Size ≥10 mm
Villous histology4
HGD
Proximal location
Surveillance characteristics
Surveillance interval (per 2 year)
1 year
2–3 years
4–5 years
6+ years
A negative subsequent 
surveillance colonoscopy5
0
1
2
3+
1315 (45.1)
1601 (54.9)
1275 (43.8)
1530 (52.5)
109 (3.7)
1986 (68.2)
544 (18.7)
239 (8.2)
67 (2.3)
78 (2.7)
934 (32.1)
153 (5.3)
413 (14.2)
946 (32.5)
651 (22.3)
826 (28.3)
635 (21.8)
802 (27.5)
1914 (65.7)
675 (23.2)
244 (8.4)
81 (2.8)
1242 (45.6)
1483 (54.4)
1213 (44.5)
1417 (52.0)
95 (3.5)
1887 (69.2)
500 (18.3)
215 (7.9)
59 (2.2)
64 (2.3)
840 (30.8)
127 (4.7)
367 (13.5)
862 (31.6)
587 (21.5)
774 (28.4)
599 (22.0)
765 (28.1)
1755 (64.4)
653 (24.0)
237 (8.7)
80 (2.9)
71 (37.6)
118 (62.4)
62 (32.8)
113 (59.8)
14 (7.4)
99 (52.4)
44 (23.3)
24 (12.7)
8 (4.2)
14 (7.4)
94 (49.7)
26 (13.8)
46 (24.3)
84 (44.4)
64 (33.9)
52 (27.5)
36 (19.0)
37 (19.6)
159 (84.1)
22 (11.6)
7 (3.7)
1 (0.5)
1.0
1.4 (1.1–1.9)
2.1 (1.6–2.9)
1.0
1.7 (1.2–2.4)
2.2 (1.4–3.5)
2.9 (1.3–6.1)
4.3 (2.4–7.8)
1.8 (1.3–2.4)3
2.7 (1.7–4.1)
1.9 (1.3–2.7)
1.9 (1.4–2.5)
0.9 (0.8–1.1)
0.5 (0.4–0.7)
1.0
1.4 (1.0–1.9)
1.8 (1.3–2.4)
1.0
1.5 (1.0–2.1)
1.6 (1.0–2.7)
1.6 (0.7–3.6)
2.5 (1.3–4.9)
1.7 (1.2–2.3)3
2.3 (1.4–3.6)
1.3 (0.9–1.9)
1.5 (1.1–2.1)
1.3 (1.2–1.5)
0.4 (0.3–0.5)
Characteristic at index colonoscopy All patients
(n = 2914), 
n (%)
No/nonadvanced
adenoma1
(n = 2725)
Stratiﬁed by highest ﬁndings at
surveillance colonoscopy, n (%)
ACN, OR (95%CI), Logistic
regression
ACN
(n = 189)
Univariable Multivariable2
ACN, advanced adenoma (includes adenomas with one or more of the following characteris-
tics; villous histology, high grade dysplasia [HGD], and size ≥10 mm), and colorectal cancer.
1Includes adenomas <10 mm, with tubular or tubulovillous histology and low grade dysplasia.
2Multivariable model: adjusted for the all characteristics at index colonoscopy mentioned in the
table (adenoma number, any adenoma size ≥10mm, any adenoma with HGD, any villous ade-
noma, and any proximal adenoma, age at index colonoscopy [per 20 years], sex, surveillance
interval [in years]), and number of surveillance colonoscopies.
3OR based on the imputed size variable, 568 missing values were imputed.
4≥75% villous component.
5Negative means no adenoma detected and removed.
Table 1 Characteristics of the study population and odds ratios for advanced
colorectal neoplasia at surveillance colonoscopy (logistic regression analysis).
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Adenoma number was included as a categorical variable, whereas patient
age and surveillance interval were modeled as linear continuous variables. Ade-
noma-related characteristics at index colonoscopy predictive for detecting ACN
at surveillance in the multivariable analysis were: the number of adenomas (ORs
ranging from 1.5, 95% confidence interval [CI] 1.1–2.1 for 2 adenomas to 2.5,
95%CI 1.3–4.9 for patients with ≥5 adenomas); any adenoma with size ≥10 mm
(OR 1.7, 95%CI 1.2–2.3), villous histology (OR 2.3, 95%CI 1.4–3.6), and proximal
location (OR 1.5, 95%CI 1.1–2.1). HGD was not predictive in the multivariable
analysis. Patient-related characteristics predictive for ACN were age (per 20
years; OR 1.8, 95%CI 1.3–2.4) and male sex (OR 1.4, 95%CI 1.0–1.9) (Table 1).
Adjustment was made for the length of the surveillance interval and the number
of negative (no adenoma) follow-up endoscopies, which were associated and
inversely associated with a higher ACN risk, respectively. 
Performing analysis without imputation did not alter the results; only the point
estimate for adenoma size was slightly higher and the point estimate for villous
histology was slightly lower.
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Full model: sex, age, adenoma number, presence of adenomas ≥10 mm, presence of
 adenomas with a villous histology, presence of proximal adenomas, presence of adenomas with
high grade dysplasia, surveillance interval, and number of surveillance colonoscopies.
1 c-statistic in overall sample corrected for optimism by bootstrapping (1000 replications).
2 Cross-validation of prediction models developed without the validation sample, validation
sample being 3 academic centers (development sample n = 2112, validation sample n = 802);
the largest hospital (development sample n = 2215, validation sample n = 699); the 2nd-largest
hospital (development sample n = 2227, validation sample n = 687); and other centers
 (development sample n = 2188, validation sample n = 726).
Table 2 Validation of the full prediction model (n = 2914).
Overall1
Cross validation2
Academic centers
Largest hospital
2nd-largest hospital 
Other centers
2914
802
699
687
726
0.707 (0.669–0.744)
0.675 (0.608–0.743)
0.763 (0.680–0.846)
0.702 (0.612–0.793)
0.650 (0.574–0.726)
–
7.6
6.8
6.0
5.9
–
6.9 (5.0–8.7)
5.2 (3.5–6.8)
5.2 (3.5–7.0)
8.3 (6.4–10.7)
Validation sample Number of
patients, n
c-statistic (95%CI)
Discrimination Calibration characteristics
Predicted
ACN (%)
Observed ACN,
% (95%CI)
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Model performance – validation
The c-statistic of the full model on the original sample was 0.723 (95%CI 0.685–
0.761); following correction for model optimism the c-statistic was 0.707 (95%CI
0.669–0.744) (Table 2). Regarding cross validation on the basis of selecting cer-
tain hospitals for model development and validation by the other hospital(s),
the model c-statistic varied from 0.650 to 0.763. The discriminative ability of the
model was highest in the two largest participating hospitals. The predicted val-
ues for ACN risk were all within range of the 95%CIs of the observed values in
the validation samples, with the exception of the predicted value in “other cen-
ters,” which was lower than observed. 
Score chart: the adenoma risk score 
Regression coefficients of adenoma-related predictors were scaled by a factor of
1.7, such that the estimated regression coefficients of the individual predictors de-
scribed above resulted in adenoma size ≥10 mm, villous histology, proximal loca-
tion, and having 2–4 adenomas each contributing 1 point to the adenoma risk
score, whereas having ≥5 adenomas contributed 2 points (Table 3). Depending
on the number of risk factors present, patients could have an adenoma risk score
Chapter 4
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*Allocation of points is based on logistic regression
coefficients (see paragraph Results: ‘score chart: the
adenoma risk score’).
Table 3 Score chart based on adenoma characteristics.
No. of adenomas
1
2–4
≥5
Presence of at least one adenoma with:
Large size (≥10 mm)
No
Yes
Villous histology (≥75% villous component)
No
Yes
Proximal location
No
Yes
Total adenoma risk score (range)
0
1
2
0
1
0
1
0
1
(0–5)
Adenoma characteristics Points* 
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within the range of 0–5. One point increase in adenoma risk score corresponded
to an odds ratio of 1.69 (95%CI 1.46–1.92). More than 90% of patients had an ade-
noma risk score of 0–2. Less than 2.5% of patients had a score of 4 or 5.
Discriminative ability of risk stratiﬁcation used in current guidelines
The discriminative ability of the full model and the score model were both mod-
erate (c-statistic corrected for optimism: 0.707 and 0.712). For the other risk strat-
ifications used in current guidelines these were: c = 0.664 for the US 2012
guideline, c = 0.674 for the UK 2010 guideline, and c = 0.642 for the Dutch 2002
guideline (Table 4). The AIC for the full model and score model were lower than
those of the other guidelines, indicating a statistically better fit.
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1c-statistic corrected for optimism by bootstrapping (1000 replications).
2Percentage improvement in c-statistic calculated as ((cnew – 0.5) – (cnull – 0.5) / (cnull – 0.5),
where the cnull refers to the null model and  cnew refers to a comparator model.
3AIC: Akaike’s Information Criterion (-2LogLikelyhood +2*degrees of freedom); lower value
 indicates better fit of the model. For the score model the degrees of freedom from the full
model have been used, as it has been derived from that model.
4Null model: includes only surveillance interval and number of surveillance colonoscopies. 
5NL 2002 model: risk stratification according to the 2002 Dutch guidelines15: presence of ≥3
adenomas, surveillance interval, and number of surveillance colonoscopies.
6US model: risk stratification according to the 2012 US guidelines14: presence of ≥3 adenomas
or at least 1 advanced adenoma (size ≥10 mm, high grade dysplasia [HGD], 25% villous histol-
ogy) surveillance interval, and number of surveillance colonoscopies.
7UK model: risk stratification according to the 2010 UK guidelines13: adenoma risk category: 5 or
more adenomas or 3 or more with at least one large vs. 3-4 adenomas or at least one large
vs.1–2 small adenomas, surveillance interval, and number of surveillance colonoscopies.
8Full model: sex, age, adenoma number, presence of adenomas ≥10 mm, presence of adeno-
mas with a villous histology, presence of proximal adenomas, presence of adenomas with HGD,
surveillance interval, and number of surveillance colonoscopies.
9Score model: sex, age, adenoma risk score, surveillance interval, and number of surveillance
colonoscopies.
Table 4 Discriminative ability of different risk stratification models (n = 2914).
Null model4
NL 2002 model5
US model6
UK model7
Full model8
Score model9
0.614 (0.573–0.655)
0.642 (0.600–0.683)
0.664 (0.625–0.703)
0.674 (0.634–0.713)
0.707 (0.669–0.744)
0.712 (0.675–0.750)
+24
+44
+52
+81
+86
1526
1506
1495
1491
1456
1469
Model c-statistic
(95%CI)1
Relative improvement
in c-statistic, %2
AIC3
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Absolute ACN risk prediction 
Absolute ACN risk at surveillance colonoscopy according to adenoma risk score,
age, and sex after 3 years ranged from 1.4% in a 45-year-old woman with an
adenoma risk score of 0, to 43% in an 80-year-old man with an adenoma risk
score of 5 (Fig. 1). The 5-year risk in these patients ranged from 1.9% to 50%.
Female patients had an ACN risk at surveillance colonoscopy similar to that of
male patients who were 10 years younger with the same adenoma risk score.
To calculate ACN risk according to the full prediction model, we refer the reader
to the web-based calculator (http://shiny.mgz-intranet.nl/advancedadeno-
marisk/) or the formula given in Appendix e1 (available online).
Fig. 1 Absolute risk of advanced colorectal neoplasia (%) at 3 or 5 years after
index colonoscopy according to adenoma risk score (0–5), age (45–80 years),
and sex. Color differences visualize differences in point estimates, but do not
indicate significant differences.
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Discussion
The study shows that older age, male sex, adenoma number, size ≥10 mm, villous
histology, and proximal location at index colonoscopy are all independent predic-
tors for detecting ACN at surveillance endoscopy. A model incorporating all of
these independent predictors had moderate performance for predicting ACN (c-
statistic = 0.707). The discriminatory performance (c-statistic) of risk stratifications
used in current surveillance guidelines (US 2012, UK 2010, and the Dutch 2002 sur-
veillance guidelines) ranged from 0.642 to 0.674. The full model had a statistically
better model fit (AIC) than the risk stratifications in current surveillance guidelines.
A score chart was developed based on the adenoma-related predictors consisting
of six risk groups, referred to as the adenoma risk score. The score model, in which
the adenoma risk score replaced the separate adenoma-related predictors, had a
similar performance as the full model (c = 0.712). The score chart based on ade-
noma-related predictors can be used as a tool to stratify patients with adenoma
more accurately for the risk of detecting ACN at surveillance.
Better risk prediction by the adenoma risk score can be explained from the
following example patients: patient A with 3 small distal tubular adenomas (ade-
noma risk score 1), and patient B with 3 large proximal villous adenomas (ade-
noma risk score 4). Existing guidelines categorize both patients in the same risk
category (i.e. high risk)14,15. However, both the current data and previous studies
have shown that the risk for patient B is several times higher than that for patient
A, because of the presence of multiple risk factors at the same time. The ade-
noma risk score takes all these factors into account, resulting in better differen-
tiation between these patients.
The need for more detailed risk stratification of patients with adenoma as
suggested by the current findings is also supported by a pooled analysis of four
prospective US studies comparing 1-year risk of ACN according to risk stratifi-
cation on the basis of the UK and US guidelines31. The analysis also observed a
higher discriminative ability for the risk stratification from the UK compared with
the US guideline31. In addition, the US guideline appeared to be superior in dis-
criminating between low- and intermediate-risk patients, whereas the UK guide-
line was superior in discriminating between intermediate- and high-risk patients.
These findings suggest that combining both risk stratification schemes might
result in even better discrimination than either guideline alone. It has spurred
calls from gastroenterologists for a more detailed risk stratification method32.
The adenoma risk score proposed in the current study fulfills these calls. 
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The current study is the first study to develop and validate a score chart that
incorporates all independent adenoma-related predictors in order to determine
the risk for metachronous ACN in patients with adenoma. In addition to some
data limitations22, three limitations are noteworthy. First, the length of the sur-
veillance interval was generally shorter for patients with advanced adenoma at
index colonoscopy than for those with nonadvanced adenoma (26 vs. 33
months), which could have led to bias in the risk estimates. However, this bias
is expected to be small, as there was substantial overlap in the length of the
first surveillance interval between patients with advanced adenoma and those
with nonadvanced adenoma, and the analysis was adjusted for interval length.
Second, up to 20% of cases had missing information for some of the predictors.
Missing values were coded as negative for presence of HGD and villous histol-
ogy in the current study, because pathologists generally report the presence of
such features and not absence. This assumption on missing values is supported
by the larger proportion of patients with adenomas with HGD or tubulovillous
histology in the current study compared with the study of Martinez et al.11 Fi-
nally, the model was not validated externally; instead internal validation by cross
validation and bootstrapping was conducted. Although the c-statistics were cor-
rected for optimism, the discriminative ability of the full model and score model
might still have been overestimated. 
The study was performed in a clinical setting without an organized population
screening program. The score chart may therefore not necessarily apply to pa-
tients in whom adenomas are detected through CRC screening. In addition, the
predicted absolute risk for metachronous ACN in patients with adenoma may
not hold for other adenoma patient populations with other background ACN
risk. However, the odds ratios for predictors of metachronous ACN in the current
study are very consistent with those from other studies11,33, suggesting that the
need for further risk stratification also holds for patients in other settings. Un-
fortunately, endoscopist quality indicators (such as the adenoma detection rate
[ADR]), lifestyle factors or family history were not considered because these data
were not available. Future studies should focus on generalizability aspects, such
as external validation in distinct cohorts and settings, and consideration of ad-
ditional predictors. 
The ADR is currently an important point of discussion in surveillance of ade-
noma patients. The controversy arises because adenoma patients of an endo-
scopist with a high ADR will have more (advanced) adenomas detected, possibly
resulting in a higher adenoma risk score than patients of endoscopists with a
low ADR. Consequently, the former group of patients, while having a better
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clearing examination, would be recommended a shorter surveillance interval
than the latter patients, who potentially have more missed adenomas. This con-
tradiction emphasizes the importance of initiatives to improve ADR. Because
of the increased attention to colonoscopy quality indicators, such as ADR, and
because of improved endoscopy techniques, ADR has increased over time34.
This increase has led to a second controversy, namely that the number of pa-
tients detected with (advanced) adenomas increases and a migration of patients
from lower to higher adenoma risk scores occurs. Hence, absolute risk estimates
by adenoma risk score from the current study (adenoma patients up to 2002)
may not hold in contemporary adenoma patients. Although the absolute risk
of advanced adenoma recurrence in contemporary patients may be lower, pos-
sibly justifying longer surveillance intervals for these patients, this stage migra-
tion is not expected to impact on predictors and the adenoma risk score. Hence,
also in the (near) future, surveillance needs to be stratified based on adenoma
risk score to ensure efficient use of resources.
Risk stratification that is more closely tailored to individual patients is in line
with the current trend toward more personalized health care. By identifying pa-
tients at high likelihood of detecting ACN, the adenoma risk score may help to
target surveillance colonoscopy. Depending on which ACN risk value is ac-
cepted as the cutoff for surveillance colonoscopy, one can determine appropri-
ate surveillance intervals for each adenoma patient. For example, if a 10% yield
of ACN is considered high enough to warrant colonoscopy, a 60-year-old female
adenoma patient with an adenoma risk score of 3 should receive surveillance
after 3 years, whereas a woman of the same age with a lower score can wait for
more than 5 years for the next surveillance colonoscopy. The 10% yield chosen
here is arbitrary. From an equity perspective, the yield of colonoscopy in screen-
ing for the general population could be used as a threshold. In the Rotterdam
fecal immunochemical test trial, people are referred for colonoscopy if the con-
centration of blood in stool exceeds 10 μg per gram feces. At this concentration
in the 3rd screening round, 24% of colonoscopies yield advanced adenoma35.
Using this percentage as a cutoff, only 60-year-old female adenoma patients
with a risk score of 5 would receive surveillance after 3 years, whereas all other
60-year-old female adenoma patients would undergo surveillance after 5 years
or more. 
Although the above example is appealing as a rule-of-thumb, formal cost-ef-
fectiveness analysis is needed to determine the optimal surveillance interval.
This type of analysis can take life expectancy, as well as costs of surveillance
colonoscopy, complications, CRC treatment, and death into account to estimate
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costs and life–years gained for different surveillance strategies. This information
can then be used to determine optimal surveillance intervals for adenoma pa-
tients, based on adenoma risk score, age, and sex, and will provide clinicians
with the necessary information on how to efficiently target care to the individual
adenoma patients. The use of simulation models to inform post-polypectomy
guideline development has been recommended previously32.
Despite its obvious benefit, a drawback of more sophisticated risk stratifica-
tion may be its complexity. Current guidelines require a simple assessment –
presence or absence of a list of risk factors, with presence indicating a 3-year
surveillance interval, otherwise 5–10 years. However, simple guidelines do not
necessarily lead to better adherence, if simplicity interferes with clinical judge-
ment36. Improved risk stratification together with a better uptake can improve
surveillance effectiveness. The adenoma risk score is somewhat more compli-
cated, but this should be surmountable in the current technology era. Score
charts are successfully applied in several fields of medicine, such as the SCORE
chart used in the prevention of (fatal) cardiovascular risk30. The adenoma risk
score proposed in the current study has been incorporated into the latest Dutch
colonoscopy surveillance guideline in May 2013 (http://www.mdl.nl/uploads/
240/1308/Richtlijn_Coloscopie_Surveillance_definitief_2013.pdf). To facilitate
the use of the Dutch 2013 guideline, including the score chart, a wallet sized
card for clinicians, as well as an App for mobile devices (NLcolosurvRL), have
been developed. 
In conclusion, a score chart was developed that incorporates combinations
of various adenoma-related predictors of metachronous ACN, which improved
the risk stratification of patients compared with current guidelines. Clinicians
can use the score chart (adenoma risk score) together with age, sex, life ex-
pectancy, risk of complications, and patient preferences in their recommenda-
tions for the interval for surveillance colonoscopy.
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Appendix e1
Formulas of the multivariable logistic regression analyses
Formula logistic regression analysis, the full model
P(Advanced colorectal neoplasia) = 1 / (1+ exp(–L))
L = –4.238 + 0.571 * ((age – 60)/20) + 0.333 * (male sex) + 0.373 * (2 adenomas)
+ 0.490 * (3 adenomas) + 0.476 * (4 adenomas) + 0.925 * (5+ adenomas) + 0.270
* (HGD present) + 0.505 * (adenoma ≥10 mm) + 0.822 * (villous histology pres-
ent) + 0.421 * (adenoma with proximal location present) + 0.147 * (surveillance
interval in years) 
Fill in a 1 if the sex or adenoma characteristic is present and 0 otherwise. For
surveillance interval fill in the number of years.
Formula logistic regression analysis, the score model
P(Advanced colorectal neoplasia) = 1 / (1+ exp(–L))
L = –4.232 + 0.583 * ((age – 60)/20) + 0.318 * (male sex) + 0.523 * (adenoma risk
score) + 0.141 *(surveillance interval in years) 
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Abstract
Objective: To determine adherence to recommended surveillance intervals in
clinical practice.
Design: 2997 successive patients with a first adenoma diagnosis (57% male,
mean age 59 years) from 10 hospitals, who underwent colonoscopy between
1998 and 2002, were identified via Pathologisch Anatomisch Landelijk Geau-
tomatiseerd Archief: Dutch Pathology Registry. Their medical records were
 reviewed until 1 December 2008. Time to and findings at first surveillance
colonoscopy were assessed. A surveillance colonoscopy occurring within ±3
months of a 1-year recommended interval and ±6 months of a recommended
interval of 2 years or longer was considered appropriate. The analysis was strat-
ified by period per change in guideline (before 2002: 2-3 years for patients with
1 adenoma, annually otherwise; in 2002: 6 years for 1-2 adenomas, 3 years
 otherwise). We also assessed differences in adenoma and colorectal cancer
 recurrence rates by surveillance timing.
Results: Surveillance was inappropriate in 76% and 89% of patients diagnosed
before 2002 and in 2002, respectively. Patients eligible under the pre-2002
guideline mainly received surveillance too late or were absent (57% of cases).
For patients eligible under the 2002 guideline surveillance occurred mainly too
early (48%). The rate of advanced neoplasia at surveillance was higher in patients
with delayed surveillance compared with those with too early or appropriate
timed surveillance (8% vs 4-5%, p<0.01).
Conclusions: There is much room for improving surveillance practice. Less than
25% of patients with adenoma receive appropriate surveillance. Such practice
seriously hampers the effectiveness and efficiency of surveillance, as too early
surveillance poses a considerable burden on available resources while delayed
surveillance is associated with an increased rate of advanced adenoma and
 especially colorectal cancer.
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Signiﬁcance of this study
What is already known on this subject?
- A considerable proportion of colonoscopy use concerns procedures for sur-
veillance purposes. This proportion will further increase with the introduction
of mass screening for colorectal cancer (CRC).
- For optimal effectiveness of CRC prevention and limitation of resource deple-
tion, adherence to postpolypectomy surveillance guidelines is mandatory.
- Surveys show that gastroenterologists often advise shorter surveillance inter-
vals than recommended by guidelines.
- No large studies have assessed adherence to surveillance guidelines in clinical
practice.
What are the new ﬁndings?
- In clinical practice, only a minority of patients (11-24%) receives appropriate
surveillance according to guidelines. This is considerably lower than previously
estimated from surveys. 
- Over 45% of patients receive too intense surveillance compared with the 2002
guidelines.
- Compared with appropriate or too early surveillance, delayed surveillance was
associated with a higher rate of advanced and non-advanced neoplasia at sur-
veillance colonoscopy. 
- Poor penetration of the 2002 surveillance guidelines within 1 year following
implementation illustrates the importance of convincing evidence to support
endorsement of new guidelines by physicians.
How might it impact on clinical practice in the foreseeable future?
- Physicians should realise that current adherence to guidelines is inappropriate
and that that can seriously hamper effectiveness and efficiency of surveillance.
- Specific interventions should be compared for their effectiveness to improve
guideline adherence.
Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study
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Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer-related death in
the Western world.1, 2 Individuals with adenomas are at increased risk to develop
CRC compared with the average population, even after the adenoma has been
removed.3-6 Patients with adenoma are therefore recommended to undergo
regular colonoscopy surveillance.7-10. Currently in the USA about 15-25% of all
colonoscopy procedures are being performed for surveillance purposes,11, 12
while in the Netherlands estimates range from 13% to 40%.13, 14 Previous re-
search indicated that adherence to postpolypectomy surveillance guidelines is
insufficient.15-23 While too little surveillance threatens the effectiveness of CRC
prevention, too intensive surveillance may lead to unnecessary harms and makes
inefficient use of colonoscopy resources.
The introduction of mass screening for CRC combined with aging of the pop-
ulation in many Western countries will considerably increase the number of pa-
tients with adenoma in the coming years, and thus the number of surveillance
colonoscopies required. The number of colonoscopies in the Netherlands has
increased significantly from 117 000 in 2004 to 191 000 in 2009.24 An additional
66 000 to 99 000 colonoscopies each year are expected with full implementation
of CRC screening (after a positive faecal immunochemical blood test plus sub-
sequent surveillance).13, 25, 26 The associated increase in colonoscopy demand
together with the limited colonoscopy capacity in many countries27-30 emphasise
the importance of efficiency in surveillance practice and therefore adherence
to surveillance guidelines.
Previous studies regarding adherence to postpolypectomy surveillance
guidelines mainly consisted of surveys among gastroenterologists, in which the
follow-up decision of the gastroenterologist was compared with the guidelines’
recommendation.16, 18, 20, 31 However the gastroenterologists intention immedi-
ately after the index colonoscopy is only one factor on whether and when sur-
veillance colonoscopy will take place. Moreover these studies may be prone to
bias because of medically desirable answers. Few studies assessed actual ad-
herence to postpolypectomy surveillance guidelines.19, 23, 32 These were either
relatively small single-centre studies19, 32, 33 or based on a self-reported patient
survey.23 In addition, the proportion of patients not having surveillance at all
was not always assessed. 
We aimed to determine the extent of adherence to postpolypectomy surveil-
lance guidelines in community-based clinical practice, in which we were also in
the position to assess the influence of a change in guideline on adherence rates.
Chapter 6
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Methods
Patient selection
We used the nationwide registry of histopathology and cytopathology in the
Netherlands (Pathologisch Anatomisch Landelijk Geautomatiseerd Archief,
PALGA)34 to identify patients with a first adenoma diagnosis in the period from
1 June 1998 to 31 December 2002 in 10 hospitals (3 academic and 7 non-acad-
emic) throughout the Netherlands. This registry includes a résumé of findings of
all tissue materials (eg, polyps, biopsies) that have been submitted at any patho -
logy centre in the Netherlands since 1991. Years of inclusion of patients with ade-
noma per hospital depended on the availability of electronic medical records.
Patients with a first adenoma diagnosis aged 40 to 74 years were eligible for in-
clusion. Patients with any of the following criteria were excluded: (1) (suspected)
hereditary CRC syndromes, in particular Lynch syndrome (hereditary non-poly-
posis colorectal carcinoma), familial adenomatous polyposis, Peutz-Jeghers syn-
drome, juvenile polyposis, or polyposis associated with mutations in the
MUTYH-gene; (2) personal history of CRC or CRC at index colonoscopy; (3) (pre-
vious) bowel resections; (4) IBD; (5) acromegaly; (6) ureterosigmoidostomy; and
(7) recommended age of next surveillance exceeded the recommended age to
stop surveillance. Exclusion criteria 4 to 6  are associated with an increased CRC
risk, and we have therefore excluded patients with these conditions.
Data collection
After identification of patients with a first adenoma diagnosis via the PALGA data-
base, patients’ medical records, in particular endoscopy and pathology reports,
were reviewed in 10 hospitals to collect information on patient characteristics,
index and surveillance colonoscopy (colonoscopy or sigmoidoscopy) including
corresponding adenoma characteristics, until 1 December 2008, the end of the
study. Index colonoscopy was defined as colonoscopy or sigmoidoscopy with first
adenoma diagnosis. We considered repeat colonoscopy examinations performed
either within 6 months after index colonoscopy, or after surveillance colonoscopy
as one examination. In case of combining results from colonoscopies, the date
of last colonoscopy with the fullest reach including polypectomy was used. For
all patients, date of index colonoscopy, age and sex were collected. In patients
without a surveillance colonoscopy before 1 December 2008, we only collected
data on index colonoscopy characteristics and adenoma findings in a randomly
picked sample of 40% (433/1093) of patients. In all patients with surveillance after
adenoma detection we collected data on colonoscopy characteristics and ade-
Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study
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noma findings, at index and surveillance colonoscopy.
This study was approved by the Institutional Review Board of Erasmus MC
 University Medical Centre and all participating centres.
Outcomes
We evaluated the time interval to first surveillance colonoscopy as our main out-
come measure. Absence of surveillance was defined as not having received sur-
veillance within 90 months or before the end of the study period, whichever came
first. The definition of appropriate surveillance was based on the active guideline.
In the Netherlands, from June 1998 to October 2001, patients with one adenoma
were recommended a 2-3 year surveillance interval; patients with more than one
adenoma a 1-year interval.35, 36 In October 2001, a revised guideline was published
and implemented from January 2002 onwards. It was communicated at a national
conference and through a report including a wallet sized card with the summary
of the guideline by Dutch Institute for Healthcare Improvement.37 The revised
guideline recommended patients with three or more adenomas to have surveil-
lance after 3 years, and patients with fewer than three adenomas to return for sur-
veillance after 6 years. Surveillance colonoscopy could be ceased after age 65
years for patients with cumulative one adenoma at that age, and after age 75 years
for patients with cumulative two adenomas.10 The timing of surveillance
colonoscopy was arbitrarily considered appropriate if surveillance has been per-
formed within the range of ±3 months for the 1-year recommendation, and ±6
months for the 2-6 year recommendations. The corresponding appropriate sur-
veillance intervals are given in table 1. We also assessed the yield of advanced
adenoma (AA) and non-AA at surveillance colonoscopy and relate this to the num-
ber of adenomas at index colonoscopy and surveillance interval.
Chapter 6
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June 1998 - 2001
Since 2002
≥2 adenomas
1 adenoma
≥3 adenomas
1 or 2 adenomas
12 months (1 year)
24–36 months (2-3 year)
36 months (3 years)
72 months (6 years)
9 - 15 months
18 - 42 months
30 - 42 months 
66 - 78 months
Adenoma ﬁndings at
index colonoscopy 
Surveillance interval
recommendation
Interval considered
appropriate* 
Table 1. Recommended surveillance intervals and intervals considered
appropriate in the presented analysis
* Appropriate interval is ±3 months for a 1-year interval recommendation and ±6 months
for longer interval recommendations.
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Statistical analysis
We used Kaplan-Meier (KM) analysis to estimate the probability over time since
polypectomy that a patient would have surveillance colonoscopy. The analysis
was stratified by two different periods corresponding to the active guideline
(June 1998 to 2002, and from 2002 onwards), and by adenoma number at index
colonoscopy: one, two and three+ adenomas. Each patient in the study cohort
was followed from index colonoscopy until the first surveillance colonoscopy,
or until censored. Patients were censored (A) at reported time of death, (B) on
1 December 2008, or (C) 90 months after index colonoscopy, whichever came
first. We assumed no loss to follow-up. 
Differences in characteristics between groups were assessed by the Mann-
Whitney U test, Kruskal-Wallis test, or χ2 test. The log-rank test (Mantel-Cox)
was used to compare KM curves. All statistical analyses were conducted using
the Statistical Package for Social Sciences for Windows v. 17.0 (SPSS, Chicago,
Illinois, USA). Two-sided p values <0.05 were considered statistically significant.
Missing values
To perform the KM analysis stratified by active guideline and adenoma number
at index colonoscopy, we needed data on adenoma number for all subjects.
However, we only collected data on adenoma findings for a subgroup of pa-
tients without surveillance (n=433/1093). For missing values for adenoma num-
ber (n=660) and gender (n=1) we used a statistical imputation technique.38
Imputations were based on correlations with patient characteristics (age and
sex); hospital type (academic or non-academic); year of index colonoscopy,
reach and preparation of index colonoscopy; adenoma characteristics (number
of adenomas; presence of villous adenoma; presence of adenomas sized
≥10mm (as measured by the endoscopist or pathologist); adenomas with high-
grade dysplasia; and proximal adenomas); and presence of a surveillance
colonoscopy, using the aregImpute function in R V.2.11 software (R foundation
for statistical computing, Vienna, Austria).
Subanalyses
To assess the influence of having hospitals in the data set without observations
over the whole index period (June 1998 – 2002), we compared the KM-curves
of surveillance timing from five hospitals with data over the whole period to the
other hospitals.
Also, two sub analyses were performed regarding implementation issues. A
change in guideline usually involves a transitional phase in which anticipation
Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study
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(before) and implementation issues (after) influence actual practice. Regarding
the former issue, endoscopists possibly anticipated the lengthening of the sur-
veillance intervals in upcoming guidelines. Also, because of the change in the
guideline in 2002, clinicians may have prolonged surveillance intervals for pa-
tients with a first adenoma diagnosis in 2001 retroactively. We therefore consid-
ered the period from October 2000 (1 year before guideline publication) until
December 2001 as the transitional phase between the two guidelines. We com-
pared the median surveillance intervals and results of the KM-analysis between
the periods June 1998 – October 2000 and October 2000 – December 2001.
Second, because it might take time to familiarise and comply with a new
guideline, we also compared median surveillance intervals and the results of
the KM analysis for the first half of 2002 versus the second half of 2002.
Additionally, we compared KM curves of time to surveillance colonoscopy be-
tween academic and non-academic hospitals and between hospitals with or with-
out an active follow-up system. In general, gastroenterologists gave surveillance
recommendations to their patients and informed the patients’ general practitioner.
In hospitals with an active follow-up system patients were actively reminded to
have surveillance colonoscopy by the endoscopy centre. For all subanalyses we
looked at patients with one, two or three+ adenomas separately.
Results
A total of 2997 patients with a first adenoma diagnosis were included in our
study (figure 1). Their mean age was 58.6 (SD 9.0) years and 57.2% were male
(table 2). Of all index endoscopies, 2691 (89.8%) were intended colonoscopies
and 306 (10.2%) were sigmoidoscopies. In total, 2303 patients had a first ade-
noma diagnosis before 2002 and 694 patients in 2002. Most patients with ade-
noma (70%) were seen in non-academic hospitals. Of all patients with adenoma
11.6% had three or more adenomas. The contribution to this study the in num-
ber of  patients per hospital varied from 84 to 565.
The study follow-up period considered in our analysis for patients diagnosed
before 2002 ranged between 83 months to 90 months. For the patients diag-
nosed in 2002 it was between 71 months and 82 months. Of the patients with
surveillance colonoscopy, the median (25th-75th centile) intervals to first surveil-
lance colonoscopy were 25 (13-40) months for patients with their index
colonoscopy before 2002 and 35 (14-48) months for those with their index
colonoscopy in 2002 (p< 0.001). Before 2002, median surveillance intervals were
Chapter 6
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27 (13-45) months for those with one adenoma, 22 (12-37) months for those with
two adenomas, and 16 (12-35) months for patients with three+ adenomas 
(p< 0.001). In 2002, these intervals were 37 (20-50) months those with one ade-
noma, 35 (13-45) months those with two adenomas, and 24 (12-37) months for
patients with three+ adenomas (p< 0.001).
Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study
181
Figure 1. Identification of the study cohort and the subgroups.
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Characteristics of patients with adenoma
Male (n, %)
Age (mean, SD)
Active guideline (n, %)
June 1998 - 2001
2002
Hospital type  (n, %)
Non-academic
Academic 
Geographical area (n, %)
High density population area
Low density population area
Active follow-up system (n, %)
No
Yes 
Adenoma characteristics
No. of adenomas (mean, SD)*
No. patients with (n, %)
Multiple (≥3) adenomas*
Any adenoma with size ≥10mm ꝉ‡
Any adenoma with high-grade dysplasia ꝉ
Any villous adenoma ꝉ
Any proximal adenoma ꝉ
Index endoscopy characteristics
Intended sigmoidoscopy (n, %)
Reach endoscope (n, %) ꝉ
Complete colonoscopy §
Proximal colon
Distal colon
Bowel preparation (n, %) ꝉ
Good ¶ 
Moderate
Insufﬁcient 
1713 (57.2)
58.6 (9.0)
2303 (76.8)
694 (23.2)
2097 (70.0)
900 (30.0)
1641 (54.8)
1356 (45.2)
1975 (65.9)
1022 (34.1)
1.5 (0.9)
347 (11.6)
1127 (37.6)
368 (12.3)
150 (5.0)
900 (30.0)
306 (10.2)
2538 (84.7)
293 (9.8)
166 (5.5)
2723 (90.9)
221 (7.4)
52 (1.7)
All patients (n = 2997)
Table 2. Characteristics of the study population at index colonoscopy
(n = 2997)
* Variable truncated to 5+ adenomas, and imputed for missing values
ꝉ weighted average (data from 433 patients without surveillance weighted to the 
1093 patients without surveillance)
‡ Size ≥10 mm either as reported by endoscopist or pathologist
§ 58 missings assumed to have a complete colonoscopy (in 2337 (1904 + 433) patients
with data)
¶ 1598 missings assumed to have a good bowel preparation (in 2337 (1904 + 433) 
patients with data)
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Figure 2 (A). Kaplan-Meier probability curve for surveillance colonoscopy use
by month from index colonoscopy for patients with one adenoma, stratified
by active guideline. The shaded areas indicate appropriate intervals around 
2-3 years (<2002, n = 1676), and 6 years (2002, n = 417).
Figure 2 (B). Kaplan-Meier probability curve for surveillance colonoscopy use
by month from index colonoscopy for patients with two adenomas, stratified
by active guideline. The shaded areas indicate appropriate intervals around 
1 year (< 2002, n = 397) and 6 years (2002, n = 160).
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Figure 2 (C). Kaplan-Meier probability curve for surveillance colonoscopy use
by month from index colonoscopy for patients with three or more adenomas,
stratified by active guideline. The shaded areas indicate appropriate intervals
around 1 year (< 2002, n = 230) and 3 years (2002, n = 117).
June 1998 - 2001
1 adenoma (n = 1676)
2 adenomas (n = 397)
3+ adenomas (n = 230)
Overall (n = 2303)
In 2002
1 adenoma (n = 417)
2 adenomas (n = 160)
3+ adenomas (n = 117)
Overall (n = 694)
Overall, all patients (n = 2997)
2-3 
1 
1 
6 
6 
3 
24
4
6
19
47
57
39
48
25
24
23
30
24
9
11
18
11
21
53
73
63
57
44
33
43
41
53
35
32
22
33
40
33
33
37
34
Period of index
colonoscopy
Recommended 
interval (year)
Too early
(%)
Appropriate*
(%)
Delayed or no
surveillance (%)
No surveillance ꝉ
(%)
Table 3. Timing of surveillance colonoscopy relative to recommended
intervals according to guideline in effect (by period) and adenoma 
patient group, Kaplan-Meier analysis
Due to rounding row percentages may not add up to 100%.
* Appropriate interval, before 2002: 1-year plus or minus 3 months, 2-3 years plus 
or minus 6 months; and in 2002: 3- or 6-years plus or minus 6 months
ꝉ by the end of the study (1 December 2008) or within 90 months, whichever came first.
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Patients with an index colonoscopy in 2002 were seen after a longer interval
than those with an index colonoscopy before 2002 (figure 2A-C). Overall, 21%
of patients with adenoma received appropriate surveillance (table 3). The pre-
2002 surveillance guideline was better adhered to than the 2002 guideline (24%
vs 11% appropriateness). In both periods, a higher proportion of patients with
three+ adenomas received appropriate surveillance than patients with one and
two adenomas (before 2002: 30% vs 24% and 23%, and in 2002: 18% vs 9% and
11%, respectively).
The overall yield of AA at surveillance was 5% and 7% for patients in both
index periods respectively (table 4). The yield of non-AA was 22% for both pe-
riods (see appendix 1). The yield of AA at surveillance was, in particular in the
index period before 2002, higher in patients with delayed surveillance compared
to those with too early or appropriate timed surveillance (8% vs 3% and 4%, p<
0.01). This also pertained to the yield of CRC (1.8% vs 0.2% and 0.4%, p< 0.01).
Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study
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June 1998 - 2001
1 adenoma
2 adenomas
3+ adenomas
Overall
In 2002
1 adenoma
2 adenomas
3+ adenomas
Overall
Total
2-3 
1 
1 
6 
6 
3 
3% (12/389)
6% (1/16)
7% (1/14)
3% (14/419)
5% (9/193)
9% (8/86)
16% (7/44)
7% (24/323)
5% (38/742)
3% (13/384)
3% (3/90)
9% (6/68)
4% (22/542)
7% (2/28)
8% (1/12)
0% (0/20)
5% (3/60)
4% (25/602)
7% (21/298)*
6% (10/159)
17% (15/89)
8% (46/546)**
0% (0/3)
-
9% (1/11)
7% (1/14)
8% (47/560)**
4% (46/1071)
5% (14/265)
13% (22/171)
5% (82/1507)
5% (11/224)
9% (9/98)
11% (8/75)
7% (28/397)
6% (110/1904)
Period of index
colonoscopy
Recommended 
interval (year)
Too early Appropriate ꝉ Delayed Total
AA (n/ n total)
Table 4. Yield of advanced adenoma (AA) at surveillance endoscopy 
according to number of adenomas at index colonoscopy and timing of
surveillance according to the guidelines (n = 1904)
AA includes adenomas with size of 10 mm or larger at pathology or endoscopy,
villous histology or high-grade dysplasia, including CRC.
In total 14 CRCs were found at first surveillance colonoscopy (Before 2002: 
1 CRC in those with too early surveillance, 1 CRC in those with appropriate timed
surveillance and 10 CRCs in those with delayed surveillance. In 2002: 2 CRCs in
those with too early surveillance).
* Significant at level p< 0.05; ** Significant at level p< 0.01. 
ꝉ Appropriate interval, before 2002: 1-year ±3 months, 2-3 years ±6 months; and
in 2002: 3- or 6-years ±6 months
CRC, colorectal cancer
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Subanalyses
Results of all subanalyses are presented in appendix 2. No differences were ob-
served in surveillance pattern when comparing five hospitals with data over the
whole index period (1998 – 2002) with those without.
Patients with an index colonoscopy in the phase immediately preceding the
change in guideline (October 2000 – December 2001) had a significantly longer
median (25th-75th centile) surveillance interval than patients with an index
colonoscopy between June 1998 and October 2000: 29 (14-44) months versus
21 (12-39) months (p< 0.001). However, KM curves for these two periods were
only significantly different for patients with one adenoma (p< 0.001).
Median surveillance interval were similar between patients with an index
colonoscopy in the first half of 2002 versus those in the second half of 2002 for
patients with one, two or three+ adenomas (data not shown). Also, KM curves
did not differ significantly, indicating no significant implementation issues con-
cerning the new guideline, although the period might have been too short.
When comparing surveillance pattern from academic versus non-academic
hospitals, a difference was observed for patients with one or two adenomas with
their index colonoscopy before 2002, with longer intervals and less follow-up in
academic centres. For hospitals with an active versus passive follow-up system,
a different surveillance pattern was observed in patients with two or more ade-
nomas in 2002, with longer intervals and less follow-up in centres with an active
follow-up system. 
Discussion
This study shows high proportions of inappropriate adherence to the post-
polypectomy surveillance guidelines that are in effect in the Netherlands. This
finding holds for both guideline periods considered: before 2002, only 24% of
patients received appropriately timed adenoma-surveillance; in 2002 only 11%
did. Overall, a third of the patients did not receive surveillance at all by the end
of the study period. The absence of surveillance in such a large fraction of the
patients is alarming, because advanced neoplasia was found in 8% (of which a
fifth were CRCs) of those with delayed surveillance, and in particular up to 17%
in those with three or more adenomas at index colonoscopy.
Before 2002, inappropriate surveillance was predominantly too late or absent
(together, 57% of patients), while in 2002, when the recommended surveillance
Chapter 6
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intervals were lengthened, 48% of the patients received surveillance too early.
Appropriate adherence to surveillance guidelines was somewhat higher for pa-
tients with three or more adenomas than for patients with fewer than three ade-
nomas (overall, 26% vs 21%). 
The fact that surveillance was mostly delayed before 2002 can be expected
when the recommended intervals are relatively short (1 year and 2-3 years). This
finding coincides with the findings of two previous small single-centre studies
from the Netherlands and the UK.19, 39 The 2002 change in recommendations
to 3 years for patients with three+ adenomas and 6 years for patients with one
to two adenomas was associated with a change in average practice towards
longer surveillance intervals. However, the increase in interval in actual practice
was smaller than the increase in the guideline-recommended interval. As a re-
sult, the proportion of patients that received too early surveillance increased
from 19% before 2002 to 48% in 2002. This proportion was higher for patients
with one to two adenomas compared to those with three+ adenomas (50% vs
39% in 2002). The impact of too early surveillance on colonoscopy demand will
be largest in patients with one to two adenomas, since this group represents
more than 80% of the current patient population with adenoma. 
The poor penetration of the 2002 guideline within 1 year following the im-
plementation illustrates the importance of convincing evidence to support en-
dorsement of new guidelines by community practice. The 2002 guideline was
formulated when only limited data were available and showed differences with
other international guidelines. It has also been shown that gastroenterologist
experienced dilemmas with the guideline,18 which may explain non-compliance.
Patients assumed to be at higher risk for other reasons than adenoma number
may have received earlier surveillance colonoscopy than recommended by the
guideline. This latter can also be an explanation why the yield of AA was similar
for patients with too early surveillance compared with those having appropri-
ately timed surveillance (7% and 5%, respectively). Last year the Dutch guideline
has been updated and includes additional adenoma characteristics
(http://www.mdl.nl/uploads/240/1308/Richtlijn_Coloscopie_Surveillance_defin-
itief_2013.pdf). Although we combined index colonoscopies within 6 months,
some patients still did not have sufficient bowel preparation (165 of those with
surveillance), however it turned out not to be a reason for earlier surveillance.
Intervals were not different from patients with sufficient bowel preparation (data
not shown).
Our findings that surveillance was too frequent in patients whose recom-
mended surveillance intervals were longer (ie, 3 and 6 years) are in line with self-
Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study
187
hoofdst 6_Opmaak 1  25-11-18  20:32  Pagina 187
reported surveillance intervals in US and European surveys among gastroen-
terologists and/or surgeons,16-18, 20, 22 and also with the few smaller studies that
assessed the appropriate timing of postpolypectomy surveillance colonoscopy
in clinical practice.32, 40 In the latter, 46-54% of the patients with surveillance re-
ceived it too early.32, 40 In our study, the corresponding percentage was even
higher: 76% (ie, 48% of 63% of the patients with surveillance).
Schoen et al23 reported that surveillance colonoscopy was too early in 34% of
patients with a low-risk adenoma profile (patients with one or two non-AAs).The
larger proportion of overuse among the low-risk group in our study (48%) may
be explained by the discrepancy in risk stratification between the guidelines in
effect: whereas patients with one or two adenomas and high-grade dysplasia, a
(tubulo)villous aspect, or a size ≥10 mm are classified as high-risk patients ac-
cording to the US guideline and advised a 3-year surveillance interval,9 the Dutch
2002 guidelines classified these patients as ‘low-risk’ and recommended a 6-year
interval.10 Physicians in the Netherlands may have shortened the intervals for
these patients, considering them to be at higher risk.18 On the other hand, we
also found a considerably greater overuse of surveillance among patients with a
high-risk adenoma profile (39% in patients with ≥three adenomas) than Schoen
et al23 did (14-20% patients with ≥three non-AAs or ≥1 AA). In the USA, high-risk
patients have been recommended a 3-year interval since 1993. As a conse-
quence, US physicians may be more familiar with the 3-year recommendation
than the Dutch physicians were in 2002. Generally, the proportion of patients
with too early surveillance tends to be higher among low-risk patients than
among higher-risk patients,23, 32, 39, 41 which may again be inherent to the rela-
tively longer recommended surveillance interval itself or be related to a per-
ceived need for shorter surveillance by patients or their physicians.
An important finding in our study is that an estimated third of patients do not
receive surveillance colonoscopy after adenoma detection in community prac-
tice. Schoen et al23 reported that approximately half of patients had not (yet)
received surveillance colonoscopy after 5 years. These data were based on pa-
tient questionnaires and lacked actual assessment of hospital records. Cooper
et al42 found a similar proportion using Medicare claims data. However, this pop-
ulation only included subjects aged 70 years and above. Furthermore, as this
study was based on Medicare claims data, it implied that it used endoscopy
billing codes, in particular polypectomy, instead of histological evaluation. As
such, there was no verification of adenoma removal, and also lacked information
on advanced versus non-advanced histology. Appropriateness of adherence to
guidelines could thus not be assessed. Insight into the absence of surveillance
is important in the light of the 8% advanced neoplasia (1.8% CRC, 6.6% AA) re-
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currence rate and 25% non-AA recurrence rate in patients with delayed surveil-
lance. This shows that the observed delays are long enough for neoplasia to re-
occur and/or progress, and corroborates the expectation that there is a loss in
effectiveness when patients do not have timely or not at all have surveillance
colonoscopies.
Our study is one of the few studies to have assessed the actual use of post-
polypectomy surveillance colonoscopy in clinical practice in a multicentre set-
ting; and it is of considerable size. But two limitations are noteworthy. First, we
assumed no loss to follow-up. We feel this is a reasonable assumption, because
patient deaths were well-reported in hospital databases (the observed death
rate closely matched the expected rate based on age and gender of the pop-
ulation, data not shown) and we did not find correspondence in medical records
on colonoscopies performed elsewhere. Finally, the close link between patient,
referring family physician, and hospital in the Netherlands induce that the vast
majority of patients in the Netherlands regularly attend the same hospital for
surveillance and other purposes. Most importantly, we found our results to be
robust for this assumption: even if all patients without surveillance would have
died or had their surveillance colonoscopy in another hospital with a similar tim-
ing as observed for the other patients, still only 32% (21%/66%) would have re-
ceived appropriate surveillance.
Second, because of time constraints we collected information on index ade-
noma number in a random sample of 40% (433/1093) of the patients without
surveillance colonoscopy after adenoma detection. We assume that this sample
is representative. We statistically imputed adenoma number for 660 patients.
We expect any bias due to misclassification of patients according to number of
adenomas (one, two or three+ adenomas) as a result of imputation to be very
small, and that it will not have affected adherence rates. 
Our results show that postpolypectomy surveillance guidelines are not being
applied appropriately - a much larger proportion than one would expect devi-
ates from the recommendations. Some non-compliance, especially delayed or
absent surveillance, should be expected for good reasons, notably comorbidity
issues. As far as we know there is no literature on comorbidity rates in patients
with adenoma, but it is unlikely that the presence of comorbidity fully explains
the observed lack of surveillance in our study. Patients who receive adenoma-
surveillance too early represent unnecessary endoscopic procedures, harms and
costs. As the implementation of mass screening for CRC is expected to (further)
increase the demand for colonoscopies considerably, it will become even more
Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study
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important to avoid unnecessary use of resources, especially for low-risk patients.
On the other side of the spectrum of non-adherence, delayed or absent sur-
veillance represents loss of health benefits. 
Which interventions could improve adherence to surveillance guidelines? Sev-
eral interventions have been previously suggested. One was to update the
Dutch 2002 postpolypectomy surveillance guideline towards less discrepancy
with the endoscopist’s judgment, and thereby improving physicians’ compli-
ance. Other suggestions include an active approach policy directed towards
patients and general practitioners to invite patients for a surveillance
colonoscopy,19, 43 to disseminate summarised guidelines among professionals
through the distribution of wallet-sized cards (which nowadays can also be ap-
plications for mobile devices), to place guideline charts near workstations, to
reinforce guidelines in regular continuous quality-improvement meetings44 and
to supervise application of guidelines by a nurse coordinator.45, 46 It is also nec-
essary to increase patients’ awareness in terms of their adenoma findings and
the need for surveillance, including recommended surveillance interval.47Imple-
mentation studies are required to determine which of the interventions work
best. Monitoring postpolypectomy surveillance intervals combined with efforts
to encourage timely adherence should be a mainstay in continuous quality im-
provement.
In conclusion, the vast majority of patients with adenoma in community-based
clinical practice (76-89%) did not receive surveillance timed according to Dutch
postpolypectomy surveillance guidelines. The poor penetration of the 2002
guideline within 1 year following the implementation, illustrates the importance
of convincing evidence to support endorsement of new guidelines by commu-
nity practice. Our results suggest that there is considerable room for improving
the effectiveness and the efficiency of surveillance practice, because too early
surveillance poses a considerable burden on available resources while delayed
surveillance is associated with an increased rate of AA and especially CRC. Since
adherence to guidelines is mandatory for the effectiveness and cost-effective-
ness of CRC prevention (including CRC screening programs), measures should
be taken to improve adherence. Implementation studies are needed to deter-
mine which of the potential interventions work best.
Chapter 6
190
hoofdst 6_Opmaak 1  25-11-18  20:32  Pagina 190
Acknowledgements
The authors thank the staff of the gastroenterology and pathology departments
at the following hospitals for their participation in this study: Academic Medical
Centre, Amsterdam; Albert Schweitzer Hospital, Dordrecht; Deventer Hospital,
Deventer; Erasmus MC, University Medical Centre, Rotterdam; Isala Clinics,
Zwolle; Medical Centre Leeuwarden, Leeuwarden; Orbis Medical Centre, Sit-
tard; Reinier de Graaf Hospital, Delft; St. Antonius Hospital, Nieuwegein; and
University Medical Centre Groningen, Groningen. The authors thank Mariel Cas-
parie from the Pathologisch Anatomisch Landelijk Geautomatiseerd Archief
(PALGA) institute for identifying the patients with adenoma for the participating
hospital-pathology laboratories; Katharina Biermann for her help regarding
pathological issues (PALGA query and during data collection); Anke Enneman,
Janine de Zeeuw, Isabel Siemelink, Irene van Sloten, Simone van Kessel, Emma
Steenbergen, and Judith van den Broek for their assistance in data collection;
and Frank Santegoets for his cooperation in database development and data
management.
Conﬂicts of interest 
Clemens J.M. Bolwerk is a member of an MSD medical advisory board
Funding
This study was funded by ZonMw (the Netherlands Organisation for Health Re-
search and Development), project number 170882801.
Ethics approval 
This study was approved by the Institutional Review Board of Erasmus MC Uni-
versity Medical Centre and all participating centres.
Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study
191
hoofdst 6_Opmaak 1  25-11-18  20:32  Pagina 191
References
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns
in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.
2. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
3. Cottet V, Jooste V, Fournel I, et al. Long-term risk of colorectal cancer after adenoma removal:
a population-based cohort study. Gut 2012;61:1180-6.
4. Leung K, Pinsky P, Laiyemo AO, et al. Ongoing colorectal cancer risk despite surveillance
colonoscopy: the Polyp Prevention Trial Continued Follow-up Study. Gastrointest En-
dosc2010;71:111-7.
5. Martinez ME, Baron JA, Lieberman DA, et al. A pooled analysis of advanced colorectal neo-
plasia diagnoses after colonoscopic polypectomy. Gastroenterology 2009;136:832-41.
6. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic
polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-81.
7. Atkin WS, Valori, R, Kuipers, EJ, Colonoscopic surveillance following adenoma removal. In:
Segnan N, Patnick J, von Karsa L. eds. European guidelines for quality assurance in colorectal
cancer screening and diagnosis. Luxembourg: European Commission. Publication Office of
the European Union, 2010:273-98.
8. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and sur-
veillance in moderate and high risk groups (update from 2002). Gut 2010;59:666-89.
9. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after
screening and polypectomy: a consensus update by the US Multi-Society Task Force on Col-
orectal Cancer. Gastroenterology 2012;143:844-57.
10. Nagengast FM, Kaandorp CJ. [Revised CBO guideline 'Follow-up after polypectomy']. Ned
Tijdschr Geneeskd 2001;145:2022-5.
11. Lieberman DA, De Garmo PL, Fleischer DE, et al. Patterns of endoscopy use in the United
States. Gastroenterology 2000;118:619-24.
12. Lieberman DA, Holub J, Eisen G, et al. Utilization of colonoscopy in the United States: results
from a national consortium. Gastrointest Endosc 2005;62:875-83.
13. Gezondheidsraad (The Health Council of the Netherlands). Bevolkingsonderzoek naar
darmkanker. Den Haag: Gezondheidsraad 2009: publicationnumber 13.
14. Terhaar Sive Droste JS, Craanen ME, van der Hulst RW, et al. Colonoscopic yield of colorectal
neoplasia in daily clinical practice. World J Gastroenterol 2009;15:1085-92.
15. Goodwin JS, Singh A, Reddy N, et al. Overuse of Screening Colonoscopy in the Medicare
Population. Arch Intern Med 2011; 171;1335-43.
16. Huppertz J, Coriat R, Leblanc S, et al. Application of ANAES guidelines for colonoscopy in
France: a practical survey. Gastroenterol clin et biol 2010;34:541-8.
17. Krist AH, Jones RM, Woolf SH, et al. Timing of repeat colonoscopy: disparity between guide-
lines and endoscopists' recommendation. AmJ Prev Med 2007;33:471-8.
18. Mulder SA, Ouwendijk RJ, van Leerdam ME, et al. A nationwide survey evaluating adherence
to guidelines for follow-up after polypectomy or treatment for colorectal cancer. J Clin Gas-
troenterol 2008;42:487-92.
19. Mulder SA, Van Leerdam ME, Ouwendijk RJ, et al. Attendance at surveillance endoscopy of
patients with adenoma or colorectal cancer. Scand J Gastroenterol 2007;42:66-71.
Chapter 6
192
hoofdst 6_Opmaak 1  25-11-18  20:32  Pagina 192
20. Mysliwiec PA, Brown ML, Klabunde CN, et al. Are physicians doing too much colonoscopy? A
national survey of colorectal surveillance after polypectomy. Ann Intern Med 2004;141:264-71.
21. O'Connor A, Keane RA, Egan B, et al. Adherence to colorectal polyp surveillance guidelines:
is there a 'scope' to increase the opportunities for screening? Eur J Cancer Prev 2011;20:40-5.
22. Saini SD, Nayak RS, Kuhn L, et al. Why don't gastroenterologists follow colon polyp surveil-
lance guidelines?: results of a national survey. J Clin Gastroenterol 2009;43:554-8.
23. Schoen RE, Pinsky PF, Weissfeld JL, et al. Utilization of surveillance colonoscopy in community
practice. Gastroenterology 2010;138:73-81.
24. van Turenhout ST, Terhaar Sive Droste JS, Meijer GA, et al. Anticipating implementation of
colorectal cancer screening in The Netherlands: a nationwide survey on endoscopic supply
and demand. BMC cancer 2012;12:46.
25. National Institute for Public Health and the Environment (RIVM). [Bevolkingsonderzoek
darmkanker vanaf 2013, stand van zaken invoering, maart 2012]. Bilthoven, Ministry of Health,
Welfare and Sport: RIVM 2012.
26. van Hees F, Lansdorp-Vogelaar I, van Ballegooijen M. [De benodigde extra capaciteit in de
zorg, de kosten en de voorkomen sterfte aan dikkedarmkanker na introductie van een bevolk-
ingsonderzoek naar dikkedarmkanker in Nederland]. Rotterdam, Erasmus MC University Med-
ical Centre 2011.
27. Chivers K, Basnyat P, Taffinder N. The impact of national guidelines on the waiting list for
colonoscopy: a quantitative clinical audit. Colorectal Dis 2010;12:632-9.
28. Leddin D, Bridges RJ, Morgan DG, et al. Survey of access to gastroenterology in Canada: the
SAGE wait times program. Can J Gastroenterol 2010;24:20-5.
29. Price J, Campbell C, Sells J, et al. Impact of UK Colorectal Cancer Screening Pilot on hospital
diagnostic services. J Public Health (Oxf) 2005;27:246-53.
30. Yeoman A, Parry S. A survey of colonoscopy capacity in New Zealand's public hospitals. NZ
Med J 2007;120(1258):U2632.
31. van Kooten H, de Jonge V, Schreuders E, et al. Awareness of postpolypectomy surveillance
guidelines: a nationwide survey of colonoscopists in Canada. Can J Gastroenterol 2012;26:79-
84.
32 Schreuders E, Sint Nicolaas J, de Jonge V, et al. The appropriateness of surveillance
colonoscopy intervals after polypectomy. Can J Gastroenterol 2013;27:33-8.
33. Arguello L, Pertejo V, Ponce M, et al. The appropriateness of colonoscopies at a teaching hos-
pital: magnitude, associated factors, and comparison of EPAGE and EPAGE-II criteria. Gas-
trointest Endosc2012;75:138-45.
34. Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in The
Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data
network and archive. Cell Oncol 2007;29:19-24.
35. Nagengast FM, Snel P. [Herziening Consensus Follow-up na poliepectomie (namens de Werk-
groep Herziening Consensus Follow-up na poliepectomie)]. Ned Tijdschr Geneeskd
1998;142:1353.
36. Snel P, de Wolf AN. [Consensus follow-up study after polypectomy]. Ned Tijdschr Geneeskd
1988;132:489-91.
37. Dutch Institute for Healthcare Improvement. [Herziene richtlijn: Follow-up na poliepectomie].
Utrecht: Kwaliteitsinstituut voor de Gezondheidszorg CBO, 2002.
Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study
193
hoofdst 6_Opmaak 1  25-11-18  20:32  Pagina 193
38. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure co-
variates in survival analysis. Stat Med 1999;18:681-94.
39. Pickard M, Dewar EP, Kapadia RC, et al. Follow up of patients with colorectal polyps: are the
BSG guidelines being adhered to? Colorectal Dis 2007;9:203-6.
40. Radaelli F, Paggi S, Bortoli A, et al. Overutilization of post-polypectomy surveillance
colonoscopy in clinical practice: A prospective, multicentre study. Dig Liver Dis 2012;44:748-
53.
41. Ransohoff DF, Yankaskas B, Gizlice Z, et al. Recommendations for post-polypectomy surveil-
lance in community practice. Dig Dis Sci2011;56:2623-30.
42. Cooper GS, Kou TD, Barnholtz Sloan JS, et al. Use of colonoscopy for polyp surveillance in
Medicare beneficiaries. Cancer 2013;119:1800-7.
43. Leffler DA, Neeman N, Rabb JM, et al. An alerting system improves adherence to follow-up
recommendations from colonoscopy examinations. Gastroenterology 2011;140:1166-1173.
44. Sanaka MR, Super DM, Feldman ES, et al. Improving compliance with postpolypectomy sur-
veillance guidelines: an interventional study using a continuous quality improvement initiative.
Gastrointest Endosc 2006;63:97-103.
45. Bampton PA, Sandford JJ, Young GP. Applying evidence-based guidelines improves use of
colonoscopy resources in patients with a moderate risk of colorectal neoplasia. Med J Aust
2002;176:155-7.
46. Bampton PA, Sandford JJ, Young GP. Achieving long-term compliance with colonoscopic sur-
veillance guidelines for patients at increased risk of colorectal cancer in Australia. Intern J Clin
Pract 2007;61:510-3.
47. Sint Nicolaas J, de Jonge V, Cahen DL, et al. Awareness of surveillance recommendations
among patients with colorectal adenomas. Clin Gastroenterol Hepatol 2012;10:405-11.
Chapter 6
194
hoofdst 6_Opmaak 1  25-11-18  20:32  Pagina 194
Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study
195
Appendix 1
Yield of non-advanced adenoma (NAA) at surveillance endoscopy according
to number of adenomas at index colonoscopy and  timing of surveillance
 according to the guidelines (n = 1904)
June 1998 - 2001
1 adenoma
2 adenomas
3+ adenomas
Overall
In 2002
1 adenoma
2 adenomas
3+ adenomas
Overall
Total
2-3 year
1 year
1 year
6 year
6 year
3 year
17% (68/389)
25% (4/16)
29% (4/14)
18% (76/419)
16% (31/193)
27% (23/86)
27% (12/44)
20% (66/323)
19% (142/742)
21% (81/384)
23% (21/90)
31% (21/68)
23% (123/542)
18% (5/28)
17% (2/12)
45% (9/20)
27% (16/60)
23% (139/602)
21% (63/298)
28% (45/159)
28% (25/89)
24% (133/546)
0% (0/3)
-
36% (5/11)
36% (5/14)
25% (138/560)*
20% (212/1071)
26% (70/265)
29% (50/171)
22% (332/1507)
16% (36/224)
26% (25/98)
35% (26/75)
22% (87/397)
22% (419/1904)
Period of index
colonoscopy
Recommended 
interval (year) Too early Appropriatea Delayed Total
NAA, % (n/ n total)
NAA includes adenomas with size smaller than 10 mm at pathology or endoscopy, tubular or
tubulovillous histology and low-grade dysplasia
a Appropriate interval, before 2002: 1-year plus or minus 3 months, 2-3 years plus or minus 
6 months; and in 2002: 3- or 6-years plus or minus 6 months* 
* Significant at level P < 0.05
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Appendix 2
Subanalyses: comparison (P values) of Kaplan-Meier probability curves for
 surveillance colonoscopy use by month from index colonoscopy between
 various subgroups
June 1998 - 2001
1 adenoma
2 adenomas
3+ adenomas
Overall
In 2002
1 adenoma
2 adenomas
3+ adenomas
Overall
P = 0.86
P = 0.52
P = 0.10
P = 0.55
P = 0.95
P = 0.68
P = 1.00
P = 0.67
P < 0.01
P = 0.17
P = 0.63
P < 0.01
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
P = 0.34
P = 0.41
P = 0.62
P = 0.41
P < 0.01
P = 0.03
P = 0.63
P < 0.01
P = 0.85
P = 0.54
P = 0.33
P = 0.92
P = 0.77
P = 0.52
P = 0.03
P = 0.34
P = 0.46
P = 0.05
P = 0.04
P < 0.01
Period of index
colonoscopy
Five hospitals 
with data over 
complete period 
versus the other 
hospitals
June 1998 - 
Oct 2000
vs. transitional 
phase
(Oct 2000 – Dec 2001) 
1st half vs.
2nd half of 2002
Academic vs.
non-academic
hospital
Active vs.
passive
follow-up
system
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Chapter 7
Interpretation and compliance to the 
updated risk-stratified guideline for
colonoscopy surveillance after poly -
pectomy - a nationwide survey.
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General discussion
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Answers to research questions
In this thesis, we have estimated pooled perforation and mortality rates of
colonoscopy (Chapter 2), determined colonoscopy-, adenoma-, and patient-re-
lated predictors of advanced colorectal neoplasia recurrence (Chapter 3, 4), de-
veloped a score chart to optimize risk-stratification for surveillance of adenoma
patients (Chapter 4), proposed intervals for surveillance colonoscopy according
to this risk-stratification (Chapter 5), assessed actual adherence rates to previous
surveillance guidelines for adenoma patients in clinical practice (Chapter 6), and
investigated whether adherence may be better with the updated guideline for
surveillance colonoscopy (Chapter 7). 
In this chapter, we will answer the specific research questions as formulated
in Chapter 1, discuss the interpretation of our findings (including the main
methodological issues and practical implications), suggest directions for future
research, and give our main conclusions and recommendations. 
1. What are perforation and mortality rates of colonoscopy according to 
literature over the past 30 years? (Chapter 2)
In many countries the number of (surveillance) colonoscopies is increasing rap-
idly, mainly due to national screening programmes for colorectal cancer. When
exposing relatively healthy people (people without symptoms) to (surveillance)
colonoscopy it is important that colonoscopy is a safe, high-quality procedure.
Therefore thresholds for quality assurance have been set, incorporating a max-
imum rate for colonoscopy complications. To better inform screening partici-
pants and patients under surveillance, accurate estimates for complication rates
in usual clinical practice are necessary.
Current quality thresholds included a maximum rate of 20 perforations in
10,000 colonoscopies and 10 perforations in 10,000 colonoscopies for screening
colonoscopies. 1 In our systematic review of literature, we found a pooled mor-
tality rate of 0.13 (95%CI 0.1 – 0.3) per 10,000 colonoscopies and a pooled per-
foration rate of 5.7 (95%CI 4.7 – 6.8) per 10,000 colonoscopies with a declining
trend over the past decades. When we stratified for type of colonoscopy, per-
foration rates were 9.7 per 10,000 (95%CI 6.8 – 16.8) for therapeutic colono-
scopies and 3.4 per 10,000 (95%CI 2.4 – 4.9) for diagnostic colonoscopies. And
the pooled perforation rate for primary screening colonoscopies was 1.8 per
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10,000 (95%CI 0.9 – 3.4). The pooled perforation rates are therefore below the
set maximum quality thresholds.
2. What are adenoma and colonoscopy-related predictors of (advanced) 
colorectal neoplasia recurrence at surveillance examinations? (Chapter 3)
The sole factor included for risk stratification in the 2002 Dutch surveillance guide-
line was the number of adenomas. This may have been a reason for gastroenterol-
ogists to deviate from the guideline because there was evidence for more
predictors of (advanced) colorectal neoplasia recurrence. However, evidence was
limited and mainly based on small studies assessing adenoma predictors one at
a time or based on meta-analyses including mostly high-quality examinations in
healthy individuals in academic institutions that may not be representative for cur-
rent practice. Therefore, we determined independent predictors of (advanced)
colorectal neoplasia recurrence in community surveillance practice. 
In our study, called Surveillance After Polypectomy (SAP), we collected data from
community-based surveillance practices in the Netherlands and showed that higher
adenoma number, large adenoma size (≥10 mm), villous histology, and proximal
location of adenoma at index colonoscopy together with insufficient bowel prepa-
ration and limited colonoscopy reach are important predictors for detecting ad-
vanced colorectal neoplasia (AA or CRC) at surveillance endoscopy. These factors
were independent predictors, implying that having multiple of these factors at the
same time further increases a patient’s risk. High-grade dysplasia was not found to
be an independent predictor of future advanced adenoma detection.
3. How can we improve risk stratification of adenoma patients? (Chapter 4)
Current surveillance guidelines risk-stratify adenoma patients by one or two factors
only, and combinations of adenoma characteristics are not considered. Given that
several adenoma characteristics, as presented in Chapter 3, are independent pre-
dictors of advanced colorectal neoplasia (ACN), how can these factors be consid-
ered simultaneously for better risk stratification in surveillance guidelines?
A score chart that combines adenoma-related predictors of ACN can be used
to improve risk stratification of adenoma patients for surveillance colonoscopy.
General discussion: answersto research questions
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We developed a score chart that consisted of characteristics that contributed 
1 point (size ≥10 mm, villous histology, proximal location, 2-4 adenomas) or 2
points (having ≥ 5 adenomas). A patient total risk score could range from 0-5
points.  In addition to the adenoma-related predictors, independent patient-
related predictors were older age, male gender. Based on the risk of the ade-
noma patient population in our community-based study, the 5-year absolute
risk of ACN ranged from 2,5% for 55 year old women with risk score 0 to 46%
for 75-year old men with risk score 5. The score chart we developed is included
in the current Dutch 2013 guidelines for surveillance colonoscopy. 2
4. What are cost-effective strategies for surveillance of adenoma patients
with different risk profiles? (Chapter 5)
To propose intervals for surveillance guidelines formal cost-effectiveness analy-
sis is needed. We aimed to determine the optimal interval for surveillance given
a patient’s adenoma risk score (i.e., risk according to the developed and vali-
dated score chart), sex and age.  
The appropriate interval for colonoscopy surveillance depended heavily on ade-
noma risk score and to a lesser extent on sex and age. Patients with risk score 0
would receive surveillance colonoscopy after 10 years, patients with risk scores 4
and 5 after only 2 or 3 years. Surveillance would no longer be recommended in
patients with risk score 0 aged 70 years or older, patients with risk score 1 and
males with risk score 2 aged 75 years or older and higher-risk patients aged 80
years or older. Results were robust to variations in the overall level of health care
costs in a country. However, applying less stringent cost-effectiveness thresholds
resulted in substantially more intensive surveillance recommendations, particularly
in those with a low adenoma risk score. The surveillance intervals recommended
in the Dutch 2013 guidelines were based on results of this study. 2
5. What are actual adherence rates to recommended surveillance intervals in
clinical practice? What is the influence of a recent change in the guideline?
(Chapter 6)
Most previous studies about adherence to guidelines for surveillance of ade-
noma patients were surveys among gastroenterologists and showed that shorter
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intervals than recommended by guidelines were often recommended. However,
the gastroenterologist’s recommendation is only one factor in whether and
when surveillance colonoscopy will take place. Therefore, we assessed actual
guideline adherence rates in clinical practice. 
Actual adherence to the Dutch guidelines for surveillance of adenoma pa-
tients was inappropriate in 76 – 89% of cases. This finding holds for both guide-
line periods considered: before 2002, only 24% of patients received
appropriately timed adenoma-surveillance; in 2002 only 11% did. Appropriate
adherence to surveillance guidelines was somewhat higher for patients with
three or more adenomas than for patients with one or two adenomas (26% vs.
21%). Overall, a third of the patients did not receive surveillance at all by the
end of the study period. The absence of surveillance in such a large fraction of
the patients is alarming, because advanced neoplasia was found in 8% (of which
a fifth were CRCs) of those with delayed surveillance, and in particular up to
17% in those with three or more adenomas at index colonoscopy. Before 2002,
inappropriate surveillance was predominantly too late or absent (together, 57%
of patients), while in 2002, when the recommended surveillance intervals were
lengthened, 48% of the patients received surveillance too early. This proportion
was higher for patients with one or two adenomas compared with those with
three or more adenomas (50% vs. 39%). 
6. Is the new risk-stratified surveillance guideline feasible for gastroentero -
logists? What difficulties do gastroenterologists have regarding guideline
 interpretation or compliance? (Chapter 7)
Compliance to the 2002 Dutch surveillance guideline was low, only 11% - 59%
of adenoma patients received appropriately timed surveillance (3, Chapter 6).
A new surveillance guideline was released in 2013 and risk-stratified patients at
a more detailed level than the previous one. 2 Through a score chart polyp char-
acteristics are combined into a risk score (0 - 5) to optimize-risk stratification of
patients for designation of a surveillance interval. Since this new guideline is
more complex, it may also lead to low compliance. Therefore, we evaluated
gastroenterologists' interpretation and compliance to this new risk-stratified
guideline using a nationwide survey including 15 questions with  example cases
of patients with adenoma or polyp findings. 
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Respondents that finished all 15 example cases indicated the correct surveil-
lance interval in a median of 10 cases. The number of correct recommendations
did not differ by the respondents’ gender, age, type of hospital and their par-
ticipation in the national screening program, but consulting the guideline during
the questionnaire was associated with an increase in compliance. The median
compliance to the guideline for the example cases was 76%. Compliance
ranged from 14% to 95% per case. Cases involving serrated polyps, elderly pa-
tients, or adenomas with tubulovillous histology were most often answered in-
correctly. Deviations were mainly due to misinterpretation of the guideline (48%)
or misreading of the questions (30%). For example, 92-95% of incorrect answers
to cases on serrated polyps were based on the fact that these polyps were
scored the same as conventional adenomas, taking into account location and
number of lesions.
Interpretation of our ﬁndings
Predictors of (advanced) neoplasia recurrence and more efﬁcient
 surveillance of adenoma patients 
Methodological issues
Chapters 3 and 4 are based on the SAP-study. The major strengths of this study
are its large size and its community-based design. The study size provided us
with enough power to reliably estimate odds ratios for (advanced) adenoma re-
currence. However, an observational study also has limitations. First, the study
was initiated prior to time of structured reporting systems for endoscopy and
pathology, which may have resulted in lack of (high) quality of such reports, lead-
ing to missing values in some cases or misclassification. There may have been
inter- and intra-observer variability between pathologists in characterization of
the histological types and degree of dysplasia. 4 5 In the SAP-study, the percent-
age of patients with HGD at index colonoscopy varied from 5% to 39% between
hospitals, and the range was 2% -17% for villous histology. The misclassification
of adenoma characteristics may have resulted in diluting their predictive effects.
Also, some polyps (potential adenomas) might not have been sent in for pathol-
ogy. As a result, the actual number of adenomas might have been underesti-
mated, which in turn may have led to an overestimation in the effect of adenoma
number as predictor of ACN. Second, since serrated polyps were not accurately
captured and reported at time of our study, we did not have sufficient informa-
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tion on these lesions. Serrated polyps may have been classified as adenoma,
not send in for pathology or not reported at all. Therefore, the presence and
risk of ACN that these lesions harbor may have interfered with results for ade-
nomas. Third, since our study is based on a clinical patient population, our re-
sults may not necessary apply to patients in whom adenomas have been
detected through screening. However, our results are consistent to those found
in a meta-analysis of 8 North American studies. 6 Therefore, we believe that the
score chart is a reliable instrument to risk-stratify adenoma patients, also in other
settings. 
In Chapter 5 we provided surveillance recommendations based on a formal
cost-utility analysis. Recommendations that are tailored to the individual ade-
noma patient, ensures that surveillance colonoscopies are targeted at those pa-
tients most likely to benefit. A restriction of our analysis is that it focused on the
appropriate interval for a first surveillance colonoscopy as we modelled strate-
gies with a fixed surveillance interval to a certain stop age. 
In the cost-effectiveness analysis we included complication rates of 1 per
every 30,000 colonoscopies with polypectomy for mortality and age-specific
rates for other complications requiring a hospital admission or emergency de-
partment visit, ranging from 20 per 10,000 colonoscopies with polypectomy in
40 year olds to 380 per 10,000 colonoscopies with polypectomy in 85 year olds.
These rates are higher than the results of our meta-analysis in which we solely
assessed perforations (Chapter 2). Our results on pooled complications rates in
Chapter 2 could have been underestimated, as underreporting or under regis-
tration of post-colonoscopy complications is a known issue. 7 However, this un-
derestimation may be mitigated since we include complications over a longer
period of time, with higher rates in earlier years. 
Practical  implications 
We showed that independent predictors of ACN are insufficient bowel prepara-
tion, poor colonoscopy reach, age, sex, number of adenomas, large adenoma size
(≥10 mm), villous histology, and proximal location (Chapter 3, 4). We have incor-
porated these adenoma-related predictors into a score chart that may help to bet-
ter target surveillance colonoscopy (Chapter 4). Based on formal cost-effectiveness
analysis - that takes into account age, sex, life-expectancy, costs of surveillance
colonoscopy, complications, and CRC treatment – we proposed optimal intervals
for surveillance colonoscopy according to combination of age, sex and adenoma
risk score (Chapter 5). We realize that it might not be feasible to stratify adenoma
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patients to the level we have done in our analysis. Since the appropriate surveil-
lance intervals and stop ages are primarily affected by adenoma risk score and to
a lesser extent by sex and age, one way to simplify surveillance recommendations
would be to base on adenoma risk score only. This approach was chosen by the
Dutch Association of Gastroenterologists when they revisited the guideline for
colonoscopy surveillance. 2 The guideline incorporates the score chart and rec-
ommends a 3-year interval for patients with risk score 3-5, 5-year for those with
risk score 1-2 and no surveillance or returning to the national screening program
after 10 years for those with risk score 0 (if their age is within the screening range
of 55-75 years) (Figure 1). Clinicians can use the score chart together with the pro-
posed intervals of surveillance colonoscopy, but should also consider patients’
preferences, co-morbidity status, lifestyle, and family history of CRC. 
The pooled perforation and mortality rates estimated in Chapter 2 can be
used to inform subgroups of individuals (those with colonoscopy for primary
screening, as follow-up after a positive screen test, or for symptoms) on poten-
tial harms of colonoscopy. These complication rates can also be used to inform
decision analysis and can serve as a benchmark. In addition, our results imply
that set quality thresholds for perforation rates can be more stringent, since our
pooled rates are remarkably lower.
Adherence to and acceptance of guidelines for surveillance of 
adenoma patients 
Methodological issues
In Chapter 6we assessed the actual use of surveillance colonoscopy in adenoma
patients in clinical practice. Since we were only in the position to assess adher-
ence in the first year after implementation of the 2002 guideline, this could have
resulted in higher rates of inappropriate adherence due to the adaptation phase
of new guidelines. But the large proportion of inappropriate adherence will not
be fully explained by this issue and will therefore not change our conclusions.
Guideline adherence may have improved somewhat in the years after, but it is
unlikely that it reached more than 59% as reported in 2008 by a survey per-
formed in the Netherlands. 3
The strength of our study in Chapter 7 is that the survey was based on a pilot
which consisted of interviews with 10 gastroenterologists that also provided us
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Figure 1: Score chart and recommended intervals of the Dutch guideline for colonoscopy sur-
veillance after polypectomy. The surveillance interval is based on the risk score. Serrated polyps
are incorporated in the guideline only if at least one serrated polyp measures ≥10mm. Other
characteristics (total number, localisation) of the serrated polyps are not taken into account.
High-grade dysplasia (HGD) in adenomas is not incorporated as a risk factor in the guideline as
it is not confirmed to be an independent risk factor, probably because HGD is highly associated
with other factors such as size. The length of the surveillance interval is based on the total
score. The total score indicates a recommended surveillance interval of 3 or 5 years, or no sur-
veillance at all. 
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with insight into situations that may led to deviation of the guideline and its rea-
soning. A limitation of this survey is the low response rate (17%), which may have
led to bias. Gastroenterologists with a strong opinion (either positive or nega-
tive) might have been more prone to participate. Gastroenterologists that are
dealing with these patients in their daily practice may also be more likely to par-
ticipate than those with other clinical focus. We did not see any differences in
age and gender between respondents and the complete group and there was
a good spread in types of hospitals among respondents. Since our findings are
based on a survey, compliance in daily practice may be different for various rea-
sons.
Practical  implications
In Chapter 6, we showed poor adherence with the Dutch 2002 guidelines. Over
45% of patients receive too intense surveillance. Poor penetration of the 2002
surveillance guidelines within 1 year following implementation illustrates the
importance of convincing evidence to support endorsement of new guidelines.
The 2002 guideline was formulated when only limited data were available and
differed from other international guidelines, probably causing gastroenterolo-
gist to deviate from the guideline. In this guideline only adenoma number was
considered to be a risk factor of future CRC risk. Patients with other risk factors
than adenoma number may have received earlier surveillance colonoscopy than
recommended by this guideline. Given that the yield of AA was similar for pa-
tients with too early surveillance compared with those having appropriately
timed surveillance (7% and 5%, respectively), it indeed seem to be the higher
risk adenoma population that received too early surveillance. In 2013, the Dutch
surveillance guideline has been updated including additional adenoma char-
acteristics for risk stratification (Figure 1). 
Our survey (Chapter 7) suggests that this guideline update will improve ad-
herence to the recommended intervals, especially for surveillance in patients
with conventional adenomas. We cannot directly compare the estimates for
compliance to the guideline from Chapter 7 with Chapter 6, because of the dif-
ference in study design. However, a previous study with a similar design as
Chapter 7 showed that 59% of gastroenterologists complied to the appropriate
surveillance interval with the simple 2002 guideline. When we compare this to
our estimate of compliance of 76% with the 2013 guideline, there is a clear in-
crease. This comparison indicates that more complex guidelines do not neces-
sarily lead to confusion and lower compliance, but that they might actually
increase compliance, as long as important risk factors are considered. 
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According to our survey, adherence to the 2013 guidelines for colonoscopy
surveillance can be improved by: 1) informing gastroenterologists on serrated
polyps and its perceived risk for CRC and how to use the guideline in case of
serrated lesions, 2) provision of more reasoning why high-grade dysplasia is not
included in the score chart, and 3) improved reporting and classification of vil-
lous or tubulovillous histology, and emphasizing that only villous histology is a
predictor of ACN.
Together, these studies demonstrate that it is important that guidelines for
surveillance of adenoma patients are up to date and evidence-based. When
guidelines include known independent risk factors of ACN recurrence and risk
stratify adenoma patients in a way that better aligns with physician’s clinical ex-
perience and knowledge, physicians are more likely to adhere. Regular review
of surveillance guidelines is recommended. With regard to quality assurance,
physicians should realize that inappropriate adherence to guidelines seriously
hampers the effectiveness and efficiency of surveillance, as too early surveillance
poses a considerable burden on available resources, and delayed surveillance
is associated with an increased rate of advanced neoplasia with the conse-
quence that cancers will be missed, which in turn may lead to less cases of CRC
deaths prevented.
The European Society of Gastrointestinal Endoscopy (ESGE) recommends
that 95% of post-polypectomy surveillance recommendations should adhere to
guidelines. 8 Monitoring surveillance intervals combined with efforts to encour-
age timely adherence should be a mainstay in continuous quality improvement,
especially too early surveillance should be prevented. Extra attention may be
needed for endoscopists with lower ADR (< 20%), since these physicians also
show lower adherence to surveillance guidelines. 9
Future research and directions
Safety of colonoscopy 
We observed a decreasing trend in perforation rate over the past 30 years, sug-
gesting that the colonoscopy procedure has become safer over time. This is
likely due to increased colonoscopy quality, better trained and experienced en-
doscopists, and potentially the shift in comorbidity status of the population un-
dergoing colonoscopy (from a patient population with symptoms with a
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presumed higher comorbidity status towards a more healthy population under-
going colonoscopy for (primary) colorectal cancer screening and post-polypec-
tomy surveillance). Conversely, perforation rates may rise when the population
undergoing colonoscopy shifts towards a population with follow-up
colonoscopy after a positive screen test (higher prevalence of (advanced) lesions
requiring polypectomy). Especially the increased removal of large polyps or
early cancers during colonoscopy instead of during surgery may cause
colonoscopy complications rates to rise in the near future when more advanced
techniques of polypectomy will be increasingly performed, like endoscopic mu-
cosal resection (EMR) and endoscopic submucosal dissection (ESD). It is impor-
tant that complication rates (especially mortality rates) do not exceed the
complication rates of surgery and vice versa. This should be investigated in
order to decide the best treatment option.
Monitoring complications of colonoscopy in clinical practice should be a
mainstay of quality control. To accurately monitor the safety of colonoscopy, use
of complication registries and uniform registration is essential as well as reliable
recording of all complications. Methods to collect information on complications
are through review of medical reports, patients’ self-reported complications in
questionnaires or via telephone consultation, and analysis of administrative data
claims. 8 Standard registry of complications should include date of complication,
type and severity of late or early (immediate) complication (with uniform defini-
tions), date and location of colonoscopy and with preferably a link to
colonoscopy data (colonoscopy indication, type of procedure (therapeutic / di-
agnostic), type of bowel preparation, method of polypectomy). 8 Complication
registries may include more complications than those related to the endoscopic
procedure itself and it may not always be clear if the complication is a conse-
quence of the endoscopic procedure. Therefore, it would be good to register
the likelihood of the complication to be related to the procedure. 
Besides these registries, studies that include control populations to correct
for risk of certain complications are desired, especially in case of mortality. How-
ever, this requires studies with enormous sample sizes. Complication registries
with the possibility of linkage of data with other registries on the individual level
may be useful for future research, like linkages with a registry with causes of
death and registries of colonoscopy reports. Scandinavian countries may have
such possibilities. 10
Linkage with endoscopy databases would facilitate research on characteristics
of colonoscopy and polypectomy related to complications, in order to better
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inform patients on potential harms of colonoscopy procedures and it can make
endoscopists and health professionals more aware of factors associated with a
higher risk of complications. Feedback to gastroenterologists on quality- as well
as safety-indicators is essential, especially in screening programmes. In the
Netherlands, as part of the Dutch Institute for Clinical Auditing (DICA), a national
registry for complications; Dutch Registration of Complications in Endoscopy
(DRCE) was launched in 2016 and recently an initiative started for a national
database for endoscopies; the Dutch Gastrointestinal Endoscopy Audit (DGEA).
Evaluation of risk stratiﬁcation
The score chart suggested in Chapter 4 is based on predictors of ACN in an
adenoma patient population before the introduction of the national CRC
screening programme, a more symptomatic population. Although we do not
expect differences in predictors of ACN in an adenoma population following
screening, this should be evaluated. Definitions used for low- and high risk
groups in various guidelines are not uniform and warrant further investigation. 
Future studies should focus on the effectiveness of surveillance colonoscopy
according to various risk classifications in terms of yield of ACN at surveillance
examinations and post-colonoscopy interval cancers. Studies should also inves-
tigate the longest interval that is still effective in various subgroups. Ideally, in-
stead of ACN as surrogate marker, long-term risk of CRC and CRC mortality
reduction are measured to assess effectiveness of a surveillance programme.
Using ACN as an surrogate marker is (somewhat) arbitrary, aspects like villous-
ness may be related to development of subsequent villous adenomas (thus
ACN), but may not necessarily be related to CRC development. 
Currently, several European trials (European Polyp Surveillance – EpoS – stud-
ies) have started that aim to determine whether recommended surveillance in-
tervals can be extended by randomly assigning participants to different
surveillance intervals based on colonoscopy findings (for low-risk adenoma pa-
tients at a 5- and 10 year interval, for high-risk patients at 3- and 5 years) and as-
sessing the yield of CRC at surveillance colonoscopy. However, data collection
of this study is scheduled to end no earlier than 2028. 11
Besides yield of CRC at surveillance, studies investigating characteristics of
interval cancers and predictors of interval cancers following colonoscopy are of
interest. They can inform us on lesions that are more likely to be missed at
colonoscopy or lesions that may harbor increased cancer risk and on patient
and procedure related predictors. It has been suggested that interval cancers
are more likely to arise from missed sessile (serrated) lesions. 12
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The risk of CRC (or ACN) and need for surveillance in patients with serrated
polyps is unclear, and should be studied. Some surveillance guidelines give rec-
ommendations for this subgroup of patients, but evidence is low. This may lead
to uncertainty in usefulness of surveillance and non-adherence to guidelines.
Serrated polyps that are large in size (≥ 10 mm), dysplastic or at proximal loca-
tion have been associated with a higher risk of ACN at follow-up. 13-15 Guidelines
recommend a 3-5 years surveillance interval in these patients. 16 17 In the EPoS-
study patients with only serrated polyps will also be followed-up with
colonoscopy after 5- and 10 years to assess CRC risk. 11
Risk attenuation after first surveillance colonoscopy needs to be investigated
as findings at surveillance colonoscopy may alter subsequent ACN risk. Evi-
dence on appropriate intervals for subsequent surveillance colonoscopies is
lacking. So far, only few, small studies have been conducted in this area with a
maximum of two surveillance colonoscopy rounds. These studies suggested
that findings at both the baseline and the most recent colonoscopy impact sub-
sequent advanced adenoma risk, especially presence of high-risk lesions at any
examination. 18-20
To further optimize and personalize risk stratification for surveillance, future
research may include molecular markers/biomarkers (detected in polyps, stool,
or blood), ethnic and lifestyle factors.  Nowadays, with the technological devel-
opments, the possibility of data collection/gathering and data accessibility has
improved. Unique patient identifiers create the option of linkages of (individual)
data with other databases, like pathology or cancer registries and demographic
databases. This supports performance of large sized studies with improved
quality (precision) of research outcomes. An Australian initiative describes an
example of whole population data linkage to develop risk stratification models
for CRC surveillance with the possibility to include colonoscopy history and ade-
noma burden over time. 21
Impact of improved colonoscopy quality on surveillance practice
Justification of lengthening of surveillance intervals is expected in the near fu-
ture in the light of improved quality of (index) colonoscopy examinations with
first adenoma diagnosis. The introduction of CRC screening in the Netherlands
has improved colonoscopy quality as well as the method of uniform registration
in colonoscopy and pathology reports. With the increase in quality, more (small)
polyps will be detected and removed at colonoscopy examinations, which will
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result in a shift in risk classification of patients towards higher risk groups. As
they were earlier assumed to be at low-risk (when lesions were missed), now
they will be classified as higher risk since (more lesions detected and removed
and less lesions missed). According to current risk stratifications, this leads to-
ward more stringent surveillance intervals in these patients, while in contrary
their ACN risk has lowered due to the higher quality of the examination and
therefore in fact justifying longer surveillance intervals. The impact of improved
colonoscopy quality on ACN yield at surveillance examinations needs to be
studied as well as the understanding of clinical importance of smaller lesions
(<10 mm). 
Burden of surveillance colonoscopy 
As the burden of surveillance colonoscopy is expected to increase, it is impor-
tant to keep control of endoscopic resources and monitor utilization of surveil-
lance procedures. And how it relates to other colonoscopy indications. One
may expect that with the introduction of screening many people will enter a
colonoscopy surveillance program, which leads to a larger proportion of colono-
scopies being indicated for surveillance purposes. When considering improved
colonoscopy quality and colonoscopy overuse in low-risk adenoma patients 9,
the burden on endoscopy units will further increase, leading to unnecessary ex-
aminations, costs and risks. 
(Cost)-effectiveness of surveillance colonoscopy and future surveillance
practice 
Ideally, surveillance colonoscopy is targeted to a small group of patients that is
truly at high risk of developing cancer with an interval as long as possible but
still effective. 22 Studies have suggested that surveillance in patients at low-risk
for ACN may not be necessary, especially in case of the possibility of referral to
a national screening programme. 2 23 Atkin et al. suggests that surveillance may
even not be necessary in some intermediate risk patients (patients with adeno-
mas without HGD that are smaller than 20 mm and of distal location) as CRC in-
cidence in this group may be similar compared to the general population. 24
Alternative surveillance strategies as referral to FIT screening (< 10 years) war-
rant investigation in these groups. 
The (cost-) effectiveness of colonoscopy surveillance of adenoma patients in
a setting of a national screening program is not clear. A recent cost-effectiveness
study evaluated the additional benefit and colonoscopy demand associated
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with colonoscopy surveillance according to the Dutch 2013 guideline in a
screening setting, and assessed how extending the surveillance intervals to 5
or 10 years would affect these. 25 They concluded that surveillance colonoscopy
would not be cost-effective compared to FIT screening in 10 years for low-risk
patients (risk score 0) and FIT screening in 2 years for medium to high-risk pa-
tients (risk score >=1). FIT screening every two years irrespective of colonoscopy
findings, thus also for the low-risk group seemed to be the best strategy. 25 How-
ever, to support these findings, evidence on the performance of FIT in a sur-
veillance population and in a population with serrated polyps is needed.
According to our study in Chapter 5 we did not found biennial FIT screening to
be a cost-effective surveillance strategy.
Greuter et al. estimated that surveillance colonoscopy can reduce the CRC
mortality by 2% in addition to FIT screening and that extending surveillance in-
tervals to 5 years in high-risk patients would decrease colonoscopy demand
without substantial loss of effectiveness. 25 However, since the high-risk group
comprises only a small proportion of the total (screening) population the reduc-
tion of use of resources may not be substantial. More effective in terms of re-
duction of use of endoscopic resources would be if the interval of low- and
intermediate-risk patients could be extended or if these patients can be referred
to FIT, as these lower risk groups present the main burden of all surveillance
colonoscopies. It would be of interest to further explore the use of FIT in sur-
veillance at various intervals and cut-off levels as compared to the FIT cut-off
level and frequency used in the national screening programme. 
Conclusions and recommendations
Conclusions
- The post-colonoscopy mortality rate within 30-days is estimated to be 0.1 per
10,000 colonoscopies and the pooled perforation rate is estimated to be 10
per 10,000 for therapeutic colonoscopies and 3 per 10,000 for diagnostic
colonoscopies. (Chapter 2)
- Independent predictors of ACN recurrence are the adenoma characteristics:
number of adenoma, large adenoma size (≥10 mm), villous histology, and
proximal adenoma locations; and colonoscopy characteristics: insufficient
bowel preparation and poor colonoscopy reach (Chapter 3). Independent pa-
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tient-related predictors were increasing age and male gender. (Chapter 4)
- Adenoma-related predictors of ACN recurrence can be combined into an
adenoma risk score to risk stratify adenoma patients taking into account mul-
tiple factors simultaneously, resulting in 6 risk groups. (Chapter 4)
- Personalizing surveillance using the adenoma risk score targets colono-
scopies to those patients most likely to benefit. The appropriate interval for
a first surveillance depends mainly on a patients’ adenoma risk score, and to
a lesser extent on age and sex. (Chapter 5)
- Surveillance colonoscopy should be offered after 2-3 years in patients with
high adenoma risk scores (4 or 5), after 4-7 years for intermediate scores (1-3)
and after 10 years in patients with a low adenoma risk score (0), with shorter
intervals for men and those at older age. (Chapter 5)
- Surveillance colonoscopy should no longer be recommended in patients of
70 years and older with adenoma risk score 0, in patients of 75 years and older
with risk score 1 and males with risk score 2 and in patients of 80 years and
older with higher risk scores. (Chapter 5)
- Adherence to the Dutch guidelines for surveillance of adenoma patients in
community practice was poor. Prior to 2002, colonoscopy surveillance in ade-
noma patients was either late or absent. After 2002, almost half of patients
received too intense colonoscopy surveillance. There was poor penetration
of the 2002 surveillance guidelines in the first year after guideline implemen-
tation. (Chapter 6)
- Advanced neoplasia was found in 8% (of which a fifth were CRCs) of those
with delayed surveillance, and in up to 17% in those with three or more ade-
nomas at index colonoscopy. (Chapter 6)
- The new Dutch surveillance guideline that incorporates important predictors
of ACN recurrence simultaneously was associated with higher compliance
than the previous guideline. (Chapter 7)
General discussion: answersto research questions
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Recommendations
- The observed colonoscopy mortality and perforation rates can be used to in-
form individuals about the risks of colonoscopy and these rates can serve as
benchmark for endoscopy units. (Chapter 2)
- The (inter-)national quality thresholds for perforation rates should be more
stringent and should relate to procedure and patient characteristics. (Chapter
2)
- Independent adenoma related predictors of advanced colorectal neoplasia
recurrence should be considered jointly in risk stratification of adenoma pa-
tients for surveillance. We recommend the use of a score chart based on ade-
noma number, size, villousness and location to tailor surveillance
recommendations. (Chapter 3, 4)
- Surveillance colonoscopy intervals can be lengthened to 10 years for patients
at low risk of advanced colorectal neoplasia recurrence. (Chapter 5)
- To support endorsement of (new) guidelines for surveillance of adenoma pa-
tients convincing evidence is needed, as well as a clear instruction to avoid
misinterpretation. (Chapter 6, 7)
- To improve adherence to the current guideline for surveillance of adenoma
patients, clarification is needed on the use of the score chart in case of ser-
rated polyps (especially with respect to location and number of these lesions)
and adenomas with tubulovillous histology. (Chapter 7)
- The use of a pocket-sized score chart, app or other source of the guideline
when making surveillance recommendations should be encouraged to im-
prove compliance to the guideline. (Chapter 7)
Chapter 8
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Summary
Surveillance of adenoma patients – towards more efﬁcient guidelines
Colorectal cancer (CRC) is the third most common malignancy in the world. In
the Netherlands, about 14,000 people are annually diagnosed with CRC and al-
most 5,000 people die from this disease. Most colorectal cancers develop from
benign precursor lesions to cancer, the majority of these precursors (65-95%)
are adenomatous polyps (adenomas). Adenomas can vary in shape and size,
arise throughout the colon, and may have various microscopic features. An ade-
noma large in size (≥10 mm), with (tubulo)villous histology, or high-grade dys-
plasia is assumed to have elevated risk to develop into CRC. An adenoma with
at least one of these characteristics is therefore called an advanced adenoma.
Individuals in whom adenomas have been detected and removed may have an
increased risk for recurrent adenomas and subsequent CRC. These patients are
therefore recommended to undergo regular surveillance colonoscopy. The main
focus of this thesis is on colonoscopy surveillance of adenoma patients.
This thesis is divided into 3 parts. In part I, we examined literature to estimate
the frequency of complications (perforation and mortality) after colonoscopy. In
part II we investigated factors that were predictive for advanced neoplasia (ad-
vanced adenoma and cancer) at surveillance. We further assessed how these
predictors could be used to improve surveillance of adenoma patients. Finally,
in part III, we evaluated to what extent guidelines for surveillance of adenoma
patients are adhered to.
Part I: Complications of colonoscopy
In Chapter 2, we systematically reviewed medical literature on perforation and
mortality after colonoscopy. Through a meta-analysis we estimated a mortality
rate of 0.1 per 10,000 colonoscopies and a perforation rate of 5.7 per 10,000
colonoscopies. The perforation rate showed a declining trend over the past
decades and depended on the type of colonoscopy. The perforation rate for
primary screening colonoscopies was 1.8 per 10,000, for follow-up colono-
scopies after a positive non-invasive primary screen test it was 8 per 10,000
colonoscopies, and for therapeutic and diagnostic colonoscopies it was 10 and
3 per 10,000, respectively. The perforation rates of colonoscopy and of primary
screening colonoscopy are well below the set maximum quality thresholds by
the American and European societies for Gastroenterology (20 and 10 per
10,000 colonoscopies, respectively). 
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Part II: Predictors of (advanced) neoplasia recurrence and more 
efﬁcient surveillance of adenoma patients
In Chapter 3, we determined which characteristics were associated with the
presence of advanced neoplasia at surveillance colonoscopy. In our study, called
“Surveillance After Polypectomy” (SAP), we collected data of almost 3,000 ade-
noma patients with surveillance colonoscopy from 10 hospitals in the Nether-
lands. We showed that higher adenoma number, large adenoma size (≥10 mm),
villous histology, and proximal location of adenoma at index colonoscopy to-
gether with insufficient bowel preparation and limited colonoscopy reach were
important and independent predictors of advanced neoplasia. Having multiple
of these risk factors at the same time further increases a patient’s risk. High-
grade dysplasia was not found to be an independent predictor.
Based on the four adenoma related predictors for advanced neoplasia at sur-
veillance colonoscopy we developed an adenoma score chart in Chapter 4. The
score chart consists of characteristics that contribute 1 point (size ≥10 mm, vil-
lous histology, proximal location, 2-4 adenomas) or 2 points (having ≥ 5 adeno-
mas). A patient total risk score can range from 0-5 points, resulting in 6 risk
groups. The score chart can be used to improve risk stratification of adenoma
patients for surveillance colonoscopy. In addition to the adenoma-related pre-
dictors, independent patient-related predictors were ‘older age’ and ‘male sex’.
According to our prediction model based on the adenoma patient population
in the SAP-study, the 5-year absolute risk of advanced neoplasia ranged from
2,5% for 55 year old women with risk score 0 to 46% for 75-year old men with risk
score 5. 
In Chapter 5 we performed a cost-effectiveness analysis to assess optimal
strategies for surveillance by sex, age and adenoma risk score as developed in
Chapter 4. Our analysis showed that the appropriate interval for colonoscopy
surveillance depended mainly on adenoma risk score and to a lesser extent on
age and sex. Patients with risk score 0 should receive surveillance colonoscopy
after 10 years, patients with risk scores 1 to 3 after 4 to 7 years, and patients with
risk scores 4 and 5 after 2 or 3 years. Surveillance would no longer be recom-
mended in patients with risk score 0 aged 70 years or older, patients with risk
score 1 and males with risk score 2 aged 75 years or older and higher-risk pa-
tients aged 80 years or older. 
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Part III: Adherence to and acceptance of guidelines for surveillance of
adenoma patients
In this part we evaluated the adherence and acceptance of guidelines for sur-
veillance of adenoma patients in the Netherlands. Based on the SAP study,
Chapter 6 showed that historically adherence to the Dutch guidelines for sur-
veillance colonoscopy was inappropriate in 76 – 89% of cases. Before 2002, only
24% of patients received appropriately timed surveillance colonoscopy. This
proportion dropped to a mere 11% after a guideline change in 2002. Appropri-
ate adherence to surveillance guidelines was somewhat higher for patients with
three or more adenomas than for patients with one or two adenomas (26% vs.
21%). A third of adenoma patients did not receive surveillance at all by the end
of the study period. The absence of surveillance in such a large fraction of the
patients is alarming, because advanced neoplasia was found in 8% (of which a
fifth were CRCs) of patients with delayed surveillance, and in particular in up to
17% in patients with three or more adenomas. Before 2002, when the guidelines
recommended shorter intervals, inappropriate surveillance was predominantly
too late or absent (together, 57% of patients). In 2002, when the recommended
surveillance intervals were lengthened, 48% of the patients received surveillance
too early. The proportion of too early surveillance was higher for patients with
one or two adenomas compared with those with three or more adenomas (50%
vs. 39%). 
In Chapter 7, we performed an online survey presenting gastroenterologists
15 cases of patients with polyps to evaluate the acceptance and interpretation
of the new guideline for colonoscopy surveillance that was launched in 2013.
The median compliance to the guideline (i.e. the proportion of physicians that
correctly answered the cases) was 76% for the cases. Compliance ranged from
14% to 95% per case. Cases involving serrated polyps, elderly patients, or ade-
nomas with tubulovillous histology were most often answered incorrectly. Gas-
troenterologists who consulted the guideline during the questionnaire answered
more cases correctly than those who did not. Deviations from the guideline were
mainly due to misinterpretation of the guideline (48%) or misreading of the cases
(30%). For example, 92-95% of incorrect answers to cases on serrated polyps
were based on the fact that these polyps were incorrectly scored the same as
adenomas, taking into account location and number of lesions.
An important strength of this thesis is that the main results (Chapters 3-6) are
based on the SAP-study, a large community-based observational study. How-
ever, an observational study also has its limitations. First, the study was initiated
Chapter 9
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before serrated polyps were widely recognized as an alternative pathway to col-
orectal cancer. Therefore, serrated polyps were not evaluated in this thesis. Sec-
ond, adenoma characteristics may have been misclassified, because there were
no uniform structured reporting systems for endoscopy and pathology. Third,
variation in surveillance intervals between patients could have confounded our
results. Finally, we lacked (sufficient) documentation on other potentially impor-
tant risk factors for advanced neoplasia recurrence such as shape of the ade-
noma or method of adenoma removal. Notwithstanding these limitations, this
study led to some important results. 
Based on this thesis we have the following recommendations:
- The observed colonoscopy mortality and perforation rates can be used to in-
form individuals about the risks of colonoscopy and these rates can serve as
benchmark for endoscopy units. (Chapter 2)
- The (inter-)national quality thresholds for perforation rates should be more
stringent and should relate to procedure and patient characteristics. (Chapter
2)
- Independent adenoma related predictors of advanced colorectal neoplasia
recurrence should be considered jointly in risk stratification of adenoma pa-
tients for surveillance. We recommend the use of a score chart based on ade-
noma number, size, villousness and location to tailor surveillance
recommendations. (Chapter 3, 4)
- Surveillance colonoscopy intervals can be lengthened to 10 years for patients
at low risk of advanced colorectal neoplasia recurrence. (Chapter 5)
- To support endorsement of (new) guidelines for surveillance of adenoma pa-
tients convincing evidence is needed, as well as a clear instruction to avoid
misinterpretation. (Chapter 6, 7)
- To improve adherence to the current guideline for surveillance of adenoma
patients, clarification is needed on the use of the score chart in case of ser-
rated polyps (especially with respect to location and number of these lesions)
and adenomas with tubulovillous histology. (Chapter 7)
- The use of a pocket-sized score chart, app or other source of the guideline
when making surveillance recommendations should be encouraged to im-
prove compliance to the guideline. (Chapter 7)
Based on the results of this thesis, the guideline for surveillance of adenoma pa-
tients was updated in 2013, including the score chart as suggested in Chapter 4
and with recommended surveillance intervals based on the results from Chapter 5.
Summary
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Samenvatting
Surveillance van adenoompatiënten – op weg naar efﬁciëntere richtlĳnen
Darmkanker (DK) is de derde meest voorkomende kankersoort wereldwijd. In
Nederland worden jaarlijks ongeveer 14.000 mensen met DK gediagnosticeerd
en overlijden er bijna 5.000 mensen aan. De meeste darmkankers ontwikkelen
zich vanuit goedaardige voorstadia (poliepen) tot kanker, in de meeste gevallen
(65-95%) zijn deze voorstadia ‘adenomen’. Adenomen kunnen variëren in vorm
en grootte, komen verspreid over de dikke darm voor en kunnen er onder de
microscoop verschillend uit zien. Van adenomen met een grootte van ≥10mm,
hooggradige dysplasie en/of een villeus aspect wordt aangenomen dat zij een
hoger risico hebben op het ontwikkelen van kanker. Deze worden daarom ad-
vanced adenomen genoemd. Patiënten bij wie een adenoom is gediagnos-
ticeerd en verwijderd hebben mogelijk een verhoogd risico op het ontwikkelen
van adenomen en DK. Hen wordt daarom geadviseerd periodiek terug te
komen voor een controle coloscopie. In dit proefschrift staat met name deze
periodieke controle oftewel surveillance van adenoompatiënten centraal.
Dit proefschrift bestaat uit drie delen. In deel I onderzochten we de literatuur
om de kans op complicaties na coloscopie (darmperforatie en overlijden) te
schatten. In deel II onderzochten we voorspellende factoren voor het detecteren
van advanced neoplasie (advanced adenomen en kanker) bij surveillance colo-
scopie. Verder bepaalden we hoe deze factoren gebruikt kunnen worden om
de surveillance van adenoompatiënten te verbeteren. Tot slot evalueerden we
in deel III in hoeverre de richtlijnen voor surveillance van adenoompatiënten
worden opgevolgd. 
Deel I: Complicaties na coloscopie
In hoofdstuk 2 hebben we de medische literatuur systematisch onderzocht op
grote studies die perforaties en overlijden na coloscopie hebben gerappor-
teerd. Met behulp van meta-analyse hebben we de kans op overlijden na een
coloscopie geschat op 0,1 per 10.000 coloscopieën en de kans op een perfo-
ratie op 5,7 per 10.000 coloscopieën. De kans op een perforatie is in de loop
van de jaren afgenomen en was afhankelijk van het type coloscopie. Bij primaire
screening coloscopieën was de perforatiekans 1.8 per 10.000, bij follow-up colo-
scopie na een positieve niet-invasieve screentest is de kans 8 per 10.000 colo-
scopieën en bij therapeutische en diagnostische coloscopieën respectievelijk
10 en 3 per 10.000. Hiermee is de kans op een perforatie bij coloscopie en bij
primaire screening coloscopie beduidend lager dan de maximaal toegestane
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drempelwaarde in kwaliteitsrichtlijnen van de Amerikaanse en Europese maag-
darm-lever verenigingen (respectievelijk, 20 en 10 per 10.000 coloscopieën). 
Deel II: Voorspellers voor ontwikkeling van (advanced) neoplasie en
efﬁciëntere surveillance van adenoompatiënten
In hoofdstuk 3 hebben we bekeken welke kenmerken van invloed zijn op het
detecteren van advanced neoplasie bij surveillance-coloscopie. Dit hebben we
onderzocht in onze studie ‘Surveillance After Polypectomy’ (SAP), waarin we
gegevens van bijna 3.000 adenoompatiënten met surveillance coloscopie(ën)
verzamelden in 10 ziekenhuizen in Nederland. We hebben laten zien dat het
aantal adenomen, adenoom grootte (≥10 mm), villeus aspect, en proximale
 locatie van het adenoom bij index coloscopie belangrijke onafhankelijke voor-
spellers waren voor advanced neoplasie, naast onvoldoende darmvoorbereid-
ing en onvolledig bereik van de coloscoop in de darm. Het hebben van
meerdere van deze kenmerken tegelijkertijd doet het risico van de patiënt
verder toenemen. Hooggradige dysplasie was geen onafhankelijke voorspeller. 
Op basis van de vier adenoomkenmerken, die voorspellend waren voor ad-
vanced neoplasie bij surveillance-coloscopie, hebben we een adenoomrisico-
scorekaart ontwikkeld in hoofdstuk 4. In de scorekaart wordt 1 punt toegekend
aan de aanwezigheid van een groot adenoom (≥10mm), een proximaal ade-
noom, een villeus adenoom en het hebben van 2-4 adenomen, en 2 punten in-
dien er 5 of meer adenomen aanwezig zijn. Middels deze scorekaart kunnen
patiënten in 6 risicogroepen worden ingedeeld, met een score variërend van
0-5. De scorekaart kan worden gebruikt ter verbetering van de risicostratificatie
van adenoompatiënten voor surveillance. Naast de adenoomkenmerken waren
ook hogere leeftijd en mannelijk geslacht voorspellers voor advanced neo-
plasie. Volgens ons predictie model gebaseerd op  de onderzochte groep ade-
noompatiënten in de SAP-studie varieerde het 5-jaars risico op een advanced
neoplasie van 2,5% voor 55-jarige vrouwen met adenoomscore 0 tot 46% voor
75-jarige mannen met adenoomscore 5. 
In hoofdstuk 5 hebben we een kosteneffectiviteitsanalyse uitgevoerd om op-
timale strategieën te bepalen voor surveillance naar geslacht, leeftijd en ade-
noom-risicoscore zoals bepaald in hoofdstuk 4. Deze analyse laat zien dat het
optimale surveillance-interval voornamelijk afhankelijk is van de adenoom-risi-
coscore, en in mindere mate van leeftijd en geslacht. Surveillance-coloscopie
kan worden aangeboden na 2-3 jaar voor patiënten met hoge adenoom-risi-
coscores (4-5), na 4-7 jaar voor de tussenscores (1-3), en na 10 jaar voor patiënten
met een lage risicoscore (0). Surveillance-coloscopie wordt niet meer aanbe-
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volen voor patiënten van 70 jaar en ouder met een adenoom-risicoscore 0, voor
patiënten van 75 jaar of ouder met risicoscore 1 en mannen met risicoscore 2,
en voor hoog-risico patiënten van 80 jaar of ouder. 
Deel III: Opvolging en acceptatie van richtlĳnen voor surveillance van
adenoompatiënten
In dit deel hebben we de navolging van de richtlijnen voor surveillance van ade-
noompatiënten in Nederland onderzocht. Op basis van de SAP-studie, laat
hoofdstuk 6 zien dat opvolging van de Nederlandse richtlijnen voor surveillance-
coloscopie in het verleden ontoereikend was in 76-89% van de gevallen. Voor
2002 ontving maar 24% van de patiënten het correcte surveillance-interval. Na
verandering van de richtlijn in 2002 was dit zelfs nog maar 11%. Het percentage
correcte surveillance-intervallen was iets hoger voor patiënten met 3 of meer
adenomen dan voor patiënten met 1-2 adenomen (26% vs. 21%). Aan het eind
van de door ons onderzochte periode ontving een derde van de adenoom-
patiënten in het geheel geen surveillance-coloscopie. De afwezigheid van sur-
veillance in zo’n groot deel van de patiënten is verontrustend aangezien we in
8% van de patiënten met verlate surveillance-coloscopie advanced neoplasie
vonden (waarvan 1 op de 5 een kanker was), en zelfs in 17% in de groep patiën-
ten met 3 of meer adenomen. Voor 2002, toen de richtlijn een korter interval
adviseerde, was surveillance-coloscopie vooral te laat of afwezig (totaal 57%).
In 2002, toen de richtlijn langere intervallen adviseerde, was surveillance-colo-
scopie bij 48% van de adenoompatiënten te vroeg. Het aandeel te vroege sur-
veillance was groter bij patiënten met 1-2 adenomen vergeleken met patiënten
met 3 of meer adenomen (50% vs. 39%).
In hoofdstuk 7 hebben we MDL-artsen een online vragenlijst met 15 casussen
van patiënten met poliepen voorgelegd om acceptatie en interpretatie van de
in 2013 nieuw voorgestelde richtlijn voor surveillance-coloscopie te evalueren.
De mediane opvolging van de richtlijn (d.w.z. het percentage artsen dat de
casus goed beantwoordde) voor de casussen was 76%. Per casus varieerde de
opvolging van 14-95%. Casussen over geserreerde poliepen, oudere patiënten,
en adenomen met een tubulovilleus aspect werden het vaakst incorrect beant-
woord. Artsen die de richtlijn raadpleegden gedurende de vragenlijst beant-
woordden gemiddeld een hoger aantal casussen goed dan zij die dat niet
deden. Het incorrect antwoorden op de casussen kwam met name door misin-
terpretatie van de richtlijn (48%) of onvoldoende lezen van de casus (30%). In
het voorbeeld van geserreerde poliepen, zouden 92-95% van de incorrect
beantwoordde casussen goed zijn geweest als geserreerde poliepen op
Chapter 9
252
hoofdst 9_Opmaak 1  26-11-18  23:17  Pagina 252
dezelfde manier werden gescoord als adenomen, met inachtneming van locatie
en aantal laesies. 
Een sterk punt van dit proefschrift is dat de resultaten grotendeels (hoofd-
stukken 3-6) gebaseerd zijn op de SAP-studie, een grote observationele studie.
Echter, een observationele studie heeft ook zijn beperkingen. In de eerste
plaats, is de studie uitgevoerd voordat erkend werd dat geserreerde poliepen
ook tot kanker kunnen ontwikkelen. Geserreerde poliepen zijn daarom in dit
proefschrift niet onderzocht. Ten tweede kan er sprake zijn van misclassificatie
van adenoomkenmerken, aangezien er geen uniforme gestructureerde regis-
tratiesystemen waren voor endoscopische en pathologische verslaglegging.
Ten derde kan de variatie in surveillance-intervallen tussen patiënten hebben
geleid tot verstoring van de resultaten. Tot slot, ontbrak (toereikende) informatie
over andere mogelijke risicofactoren voor advanced neoplasie, zoals de vorm
van het adenoom en de wijze waarop deze verwijderd was. Ondanks deze
beperkingen, heeft deze studie een aantal belangrijke antwoorden opgeleverd. 
Op basis van dit proefschrift doen wij de volgende aanbevelingen:
- De geobserveerde mortaliteits- en perforatieschattingen zouden gebruikt
kunnen worden om personen te informeren over de risico’s van de coloscopie
en kunnen dienen als benchmark voor endoscopieafdelingen (Hoofdstuk 2).
- De gehanteerde drempelwaarden in (inter-)nationale kwaliteitsrichtlijnen ten
aanzien van de kans op perforaties na coloscopie kunnen stingenter en
zouden onderscheid moeten maken naar procedure- en patiëntkenmerken.
(Hoofdstuk 2).
- Onafhankelijke adenoom-gerelateerde voorspellers voor toekomstige detec-
tie van advanced neoplasie zouden gezamenlijk moeten worden mee -
genomen bij de risico-stratificatie van adenoompatiënten voor surveillance.
Wij raden aan om een scorekaart te gebruiken gebaseerd op aantal, grootte,
villeus aspect en locatie van de adenomen voor het personaliseren van aan-
bevelingen voor surveillance (Hoofdstuk 3, 4).
- Intervallen voor surveillance-coloscopie voor patiënten met laag risico op het
ontwikkelen van advanced neoplasie kunnen worden verlengd naar 10 jaar
(Hoofdstuk 5).
- Om de opvolging te bevorderen, is het belangrijk dat (nieuwe) richtlijnen zijn
gebaseerd op overtuigend bewijs, en dat er een duidelijke instructie van de
richtlijn is ter voorkoming van misinterpretatie (Hoofdstuk 6, 7).
- Om de opvolging van de huidige richtlijn voor surveillance van adenoom-
patiënten te bevorderen moet het scoren van geserreerde poliepen (met
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name met betrekking tot de locatie en het aantal van deze laesies) en
tubulovilleuze adenomen beter toegelicht worden (Hoofdstuk 7).
- Het raadplegen van de richtlijn door middel van een zakkaartje, App of een
andere bron bij het bepalen van het surveillance-interval moet aange-
moedigd worden, om zo naleving van de richtlijn te vergroten (Hoofdstuk 7).
Op basis van de resultaten in dit proefschrift, is in 2013 de Nederlandse richtlijn
voor surveillance van adenoompatiënten aangepast, inclusief de scorekaart voor
adenoomkenmerken zoals ontwikkeld in hoofdstuk 4 en met aanbevolen sur-
veillance-intervallen mede gebaseerd op uitkomsten van hoofdstuk 5. 
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Dankwoord
Wat een rijkdom heb ik mogen ervaren aan begeleiding en support tijdens mijn
promotietraject, echt fantastisch!! Ik kan terugkijken op een mooie tijd! En dat
heb ik aan velen te danken. Dit proefschrift is mede tot stand gekomen door
de inzet en steun van velen. Het is mij dan ook een groot genoegen een aantal
personen hiervoor te bedanken. 
In de eerste plaats wil ik mijn twee promotoren (prof. dr. H. J. de Koning en prof.
dr. E.J. Kuipers) en co-promotor (dr. I. Lansdorp- Vogelaar) bedanken voor het
vertrouwen, de ruimte die mij gegeven werd en de prettige samenwerking. 
Beste Harry, ook al zagen wij elkaar wat minder frequent en was je wat betreft
de inhoudelijke kant van de papers misschien iets minder direct betrokken dan
de overige leden, ik heb de begeleidingsgesprekken en samenwerking altijd als
zinvol en prettig ervaren. Ik vind je een fijn en relaxed persoon. Veel dank voor
jouw kritische blik op een aantal essentiële onderdelen van dit proefschrift. Beste
Ernst, veel dank voor jouw altijd snelle, enthousiaste en positieve commentaar.
Daaraan heb ik veel gehad en dat werkte motiverend. Je positieve benadering,
support, open houding en toegankelijkheid heb ik enorm gewaardeerd. Daarnaast
straal je rust uit en ben je down to earth. Ik denk dat je voor velen een voorbeeld
bent, zeker voor mij! Ik ben daarom ook blij dat jij mijn 2e promotor bent! En ik
vind het super dat je daar nu nog tijd voor vrij maakt. Dank!! Beste Iris, de meeste
begeleiding heb ik aan jou te danken, heel veel dank! Ik kon altijd bij je terecht
en heb veel van je kunnen leren. Na jouw review stegen mijn papers gelijk in
‘waarde’! Ik heb veel respect voor je, ik vind het knap hoe je alle ballen in de lucht
weet te houden, scherp blijft en altijd ontspannen overkomt.
Ook wil ik prof.dr.ir. J.D.F. Habbema bedanken voor het vertrouwen en de
support met name in de beginfase van mijn promotietraject. Daarnaast hebben
prof.dr. E.W. Steyerberg en dr. M. van Ballegooijen een enorm waardevolle
 bijdrage geleverd aan zowel de inhoud van dit boekje als aan persoonlijke
begeleiding! Beste Ewout, heel veel dank voor jouw altijd snelle en enthousi-
aste commentaar en de tijd die hebt gestoken in de begeleiding. Ik vond onze
discussies altijd heel interessant en leerzaam en ik kon altijd direct weer verder,
super fijn! De samenwerking heeft geleid tot een aantal belangrijke papers,
welke een relevante bijdrage hebben geleverd aan de vernieuwde Nederlandse
richtlijn voor surveillance coloscopie. Beste Marjolein, je was mijn officiële leid-
inggevende, bedankt voor het vertrouwen, de persoonlijke begeleiding en je
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kritische blik op mijn papers. Discussies leidden vaak tot stof om over na te
denken. Dank daarvoor. 
Leden van de kleine commissie, prof.dr. J.A. Hazelzet, prof.dr. A.A.M. Masclee
en prof.dr. I.D. Nagtegaal, ik wil jullie bedanken voor de bereidwilligheid dit
proefschrift te beoordelen. 
Leden van de grote commissie bedankt voor jullie tijd en bereidwilligheid
om jullie te verdiepen in hetgeen ik heb onderzocht. Ik kijk ernaar uit om met
jullie van gedachten te wisselen tijdens mijn verdediging.
Dank aan alle co–auteurs voor de zeer waardevolle input waardoor de
kwaliteit van de papers enorm is verbeterd!
Een groot deel van de papers in dit proefschrift zijn gebaseerd op de SAP-
studie, een studie die niet kon worden uitgevoerd zonder de inzet van vele par-
tijen. Mariel Caspari van de Stichting PALGA, hartelijk dank voor het selecteren
van nieuw gediagnostiseerde adenoompatiënten in de aan de SAP-studie deel-
nemende centra. Heel veel dank aan het personeel van de MDL- en pathologie
afdelingen van deelnemende centra (Reinier de Graaf Group; Isala Klinieken;
Albert Schweitzer Ziekenhuis; Deventer Ziekenhuis; AMC; Medisch Centrum
Leeuwarden; UMCG; Orbis Medisch en Zorgconcern; St. Antonius ziekenhuis
en het Erasmus MC), met name aan de MDL-artsen Clemens Bolwerk, Frank ter
Borg, Evelien Dekker, Leopold Engels, Jan Kleibeuker, Jan Jacob Koornstra,
Wilco Lesterhuis, Pieter Spoelstra, Robin Timmer en Juda Vecht, zonder het
beschikbaar stellen van de data, zou er niks te analyseren zijn… Daarnaast
hartelijk dank voor de gastvrijheid, het beschikbaar stellen van werkplekken en
de verdere support!  Echt top! Mede door jullie inzet liep alles op rolletjes.
Omdat gegevens destijds nog niet gestructureerd werden vastgelegd was
er veel werk aan het overnemen van de gegevens van de adenoompatiënten
in onze SAP-database, vele handen hebben daaraan bijgedragen: Anke Enne-
man, Janine de Zeeuw, Isabel Siemelink, Irene van Sloten, Simone van Kessel,
Emma Steenbergen en Judith van den Broek, heel veel dank! Na ca. 1,5 jaar
data verzamelen bereikten we de inclusie van de beoogde 3.000 adenoom-
patiënten met follow-up gegevens. Frank Santegoeds, dank voor alle energie
die je gestoken hebt in het ontwikkelen van de SAP-database en je hulp bij data
management. Katharina Biermann, hartelijk dank voor het beantwoorden van
de vragen op gebied van pathologie wanneer we tijdens de dataverzameling
onduidelijkheden tegenkwamen in de verslaglegging. Ook Monique van Leer-
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Dankwoord
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dam dank voor de prettige samenwerking en support! Super dat de onderzoek-
sassistenten met coloscopieën mee mochten kijken en erg leuk om met jou de
presentatie coloscopie surveillance te houden tijdens de NVGE. 
Het promotietraject heb ik uitgevoerd vanuit de afdeling Maatschappelijke
Gezondheidszorg. Ik wil dan ook graag iedereen van de afdeling (het zijn er te
veel om op te noemen) bedanken voor de fijne, leuke en leerzame tijd! In het
bijzonder de collega’s van de screeningssectie, met name Noortje en Nicolien,
jullie maakten mij snel wegwijs en brachten mij ook een hoop gezelligheid.
Daarom, Nicolien, heb ik jou ook gevraagd mijn paranimf te willen zijn. Bedankt
dat je naast me wilt staan! Natuurlijk gaat ook mijn dank uit naar de directe col-
lega’s van de colon-groep: Janneke, Luuk, Frank, Miriam, Sonja, Alex en Reinier.
Inmiddels zijn daar veel nieuwe collega’s bij gekomen, waaronder Maaike,
Elleke, Dayna, Esther en Arthur. Allen bedankt voor de support! Janneke, onze
reis naar New Orleans zal ik nooit vergeten!! Ook mijn kamergenoten: Wilma,
Nicole, Frank, Liz, Tiago en later nog even Suzette, Kevin en Leah en de buurt-
jes: Natasja, Erica en Eveline wil ik bedanken voor de fijne gesprekken en de
gezelligheid tijdens mijn periode op MGZ. Caspar, Gerard, David en Daan dank
voor jullie advies en hulp rondom statistische en methodologische
vraagstukken. Arry, Anja, Yvonne en Sanne dank voor jullie hulp en onderste-
uning. Naast inspanning was er ook tijd voor ontspanning, ik heb genoten van
de lunchwandelingen, uitjes, etentjes, borrels, spelletjesavonden, kraambe-
zoeken, enz. Iedereen die daar onderdeel van was, hartelijk dank!! Ik wens jullie
het allerbeste toe en hoop jullie nog af en toe te zien. 
De collega’s van de MDL-afdeling van het Erasmus MC, Aafke, Margot, Ce-
line, Vincent, Jerome, Renate, Paul, Paul, Arjun, Lieke, Vera, Lauran, Aria, Esther,
Florine, Eline, Femme, Edmee, Nicoline, Veerle, Jorie, Marius, Lisanne, Judith,
Vivian, Caroline, Leonie en Atija wil ik bedanken voor de gastvrijheid en gezel-
ligheid op de afdeling, tijdens lunches, de NVGE congressen in Veldhoven en
tijdens de DDW in New Orleans en Chicago! Ik heb ervan genoten! In het bij-
zonder bedank ik Aafke en Margot voor de introductie op de afdeling. Wendy
Holleman wil ik graag bedanken voor de hulp en ondersteuning. 
Graag wil ik ook mijn (oud)collega’s van FSB, de SO’s en externen, bedanken
voor de steun en interesse! En zeker voor het begrip tijdens de laatste fase van
dit promotietraject.
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Al met al heb je dan na veel inspanning en steun van collega’s de inhoud van
het boekje voor elkaar gekregen, maar dan ben je er nog niet... Bert
Hoogeveen, ik ben jou heel dankbaar dat jij, onder enige tijdsdruk, het ontwerp
van de omslag en de opmaak van dit proefschrift hebt willen verzorgen! Ik ben
heel blij met het resultaat!!
Lieve vriend(inn)en, jullie hebben voor de nodige afleiding gezorgd de
afgelopen jaren. Etentjes, dagjes uit, borrels, kroeggesprekken, feestjes en fes-
tivals, toneelstukken, sportlesjes, wandelingen, weekendjes weg en vakanties.
Ik had het allemaal voor geen goud willen missen! En laten we er ook vooral
lekker mee doorgaan! Daarnaast zijn jullie ook in moeilijke tijden een enorme
steun geweest. Ik ben jullie hiervoor erg dankbaar. You rock! This also holds for
my dear international friends. You are great and in my heart! 
Lieve familie en kennissen, dank voor jullie interesse en support de afgelopen
jaren. Jullie zijn super en betekenen veel voor mij. Ik ben daarom dan ook heel
blij met jullie! Een paar familieleden wil ik in het bijzonder noemen…
Maaike en Myrthe, jullie zijn niet alleen lieve nichtjes, ook vriendinnen en
eigenlijk ook wel een beetje zusjes voor mij, wat ben ik blij met jullie. En Myrthe,
ik vind het geweldig dat jij aan mijn zij wil staan als paranimf, dank je wel!  
Lieve opa Jan, helaas ben je er niet meer. Jouw interesse, zelfs op momenten
dat het heel slecht met je ging, jouw levenslust, je doorzettingsvermogen en je
altijd positieve kijk op het leven hebben mij geïnspireerd. Wat was je een
ontzettend lieve man! Ik ben zo trots dat jij mijn opa bent. Ik mis je.
Tot slot, mijn ouders, Anja en Theo jullie hebben mij altijd de ruimte gegeven
mijn eigen keuzes te maken en hebben altijd volledig achter mij gestaan. Ook
tijdens moeilijke tijden, kon ik altijd op jullie terugvallen. Bedankt voor jullie on-
voorwaardelijke vertrouwen en steun. Dat geldt natuurlijk ook voor mijn super
lieve broertje, Erik-Jan!! Ik hou van jullie!!!
Feeling blessed and thankfull. Let’s move on to the next chapter...
Else-Mariëtte
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Curriculum vitae
Else-Mariëtte Beatrice van Heijningen werd geboren op 24 september 1982 te
Leiden. In 2001 behaalde zij haar VWO diploma aan het Adelbert College te
Wassenaar. Na het behalen van haar HBO-opleiding ‘Voeding en Diëtetiek’ aan
de Haagse Hogeschool, studeerde zij ‘Nutrition and Health’ aan de Wagenin-
gen Universiteit, met als specialisatie ‘Public Health and Nutritional Epidemio -
logy’. Haar stages op gebied van Voeding en Diëtetiek liep zij in het Rijnlands
Revalidatie Centrum te Leiden en in het Academisch Medisch Centrum te Am-
sterdam. Haar afstudeerproject, een wetenschappelijke pilotstudie naar de ab-
sorptiecapaciteit van de darm: ‘Fecaal energie- en vetverlies bij volwassen
IC-patiënten met dunne ontlasting: Is er een probleem?’, voerde ze uit in het
VUmc te Amsterdam, waarvoor zij in 2006 de Novartis Diëtetiek prijs ontving.
Wetenschappelijke stages werden verricht aan de Medical Research Council -
Human Nutrition Research, Departement of Public Health Nutrition, Cambridge,
Verenigd Koninkrijk en aan Queensland Institute for Medical Research, Brisbane,
Australië. Tijdens deze stages verrichtte zij onderzoek naar de invloed van voed-
ingsmiddelen en dranken die toegevoegde, niet van melk afkomstige, suikers
bevatten op energie- en nutriënt inname en adipositas bij Britse volwassenen
en naar vitamine D inname en huidkanker bij een Australische gemeenschap.
Haar afstudeerscriptie aan de Wageningen Universiteit ging over visconsumptie
en serum meervoudig onverzadigde vetzuren en het risico op colorectale ade-
nomen.
In juli 2008 startte zij als epidemioloog haar promotieonderzoek op het ge-
bied van doelmatigheid betreffende surveillance van adenoompatiënten
(ZonMw-project ‘Surveillance after polypectomy – towards efficient guidelines’,
No. 170882801), onder leiding van Marjolein van Ballegooijen en promotoren
Prof. dr. H.J. Koning en Prof. dr. E.J. Kuipers, en co-promotor Iris Lansdorp-
 Vogelaar. Voor deze studie werd data verzameld in 10 Nederlandse zieken-
huizen: Albert Schweitzer Ziekenhuis, AMC, Deventer Ziekenhuis, Erasmus MC,
Isala Klinieken, Medisch Centrum Leeuwarden, Orbis Medisch en Zorgconcern,
Reinier de Graaf Groep, St. Antonius Ziekenhuis en het UMCG. In november
2011 haalde zij subsidie binnen voor een vervolgstudie (ZonMw-project ‘Sur-
veillance after polypectomy - towards successful implementation of guidelines
(SAP-Adh)’, No. 171203009).
Sinds voorjaar 2014 is zij werkzaam als data-analist bij Facilitaire Samenwerk-
ing Bevolkingsonderzoeken te Utrecht.
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List of Publications
1. Van Heijningen EMB, Kooyker A, Massl R, Nieboer D, Meester R, de Koning
HJ, Kuipers EJ, Lansdorp-Vogelaar I. Perforation and mortality rates of
colonoscopy – systematic review and meta-analysis. Submitted.
2. Van der Meulen MP, Ida J. Korfage, van Heijningen EMB, de Koning HJ, van
Leerdam ME, Dekker E, Lansdorp-Vogelaar I, on behalf of the working group
on the guideline for colonoscopy surveillance. Interpretation and compli-
ance to the updated risk-stratified guideline for colonoscopy surveillance
after polypectomy - a nationwide survey. Submitted.
3. Van Heijningen EMB*, van Hees F*, Steyerberg EW,  Kuipers EJ, de Koning
HJ, van Ballegooijen M, Lansdorp-Vogelaar I. Personalizing colonoscopy sur-
veillance in adenoma patients - A cost-effectiveness analysis. Submitted.
4. Van Heijningen EM, Lansdorp-Vogelaar I, van Hees F, Kuipers EJ, Biermann
K, de Koning HJ, van Ballegooijen M, Steyerberg EW; SAP Study Group. De-
veloping a score chart to improve risk stratification of patients with colorectal
adenoma. Endoscopy. 2016 Jun;48(6):563-570.
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van Ballegooijen M. Nonbleeding adenomas: Evidence of systematic false-
negative fecal immunochemical test results and their implications for screen-
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Name PhD student: Else-Mariëtte B. van Heijningen 
Erasmus MC Department: Public Health  
Research School: Netherlands institute for Health Sciences (NIHES), 
Erasmus University, Rotterdam 
PhD period: 2008 – 2018
Promotors: Prof. dr. H.J. de Koning & Prof. dr. E.J. Kuipers
Supervisors: Dr. I. Lansdorp-Vogelaar
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1. PhD training
General academic skills 
Biomedical English Writing and Communication, Erasmus MC, 
Rotterdam
Schrijfgroep Maatschappelijke Gezondheidszorg (MGZ), Erasmus
MC, Rotterdam
CPO Minicursus Methodologie van Patiëntgebonden Onderzoek en
Voorbereiding van Subsidieaanvragen, Erasmus MC, Rotterdam
In-depth courses 
Absolute risk prediction, NKI, Amsterdam 
Health Economics (ESP25)
Clinical Decision Analysis (ESP04)
Large-scale and multicenter studies (ESP58)
Cohort studies (ESP39)
Survival Analysis (ESP28)
Topics in Meta-analysis (ESP15)
Planning and Evaluation of Screening (HS05)
Advanced Analysis of Prognosis Studies (EWP13)
Prognosis Research (EWP16)
Oral presentations
Coloscopie surveillance (NVGE)
Metachronous colorectal neoplasia after adenoma removal. 
A multivariate analysis of risk factors for non-advanced and advanced
neoplasia (NVGE) 
Risk factors for metachronous advanced colorectal neoplasia in a 
cohort of adenoma patients: advanced morphology and multiplicity
(DDW, NVGE)
Post-polypectomy surveillance practice of adenoma patients – 
considerable room for improvement (DDW, NVGE, MGZ)
SAP studie opzet (MGZ)
Poster presentations
Updating/Personalized post-polypectomy surveillance guidelines in-
corporating patient and adenoma-related predictors of advanced
colorectal neoplasia: A cost-effectiveness analysis (UEGW, DDW)
Metachronous colorectal neoplasia after adenoma removal. A multi-
variate analysis of risk factors for non-advanced and advanced neo-
plasia (DDW)
Perforation and mortality of colonoscopy – a systematic review
(DDW)
Year 
2010
2010, 2011
2010
2012
2010
2010
2009
2009
2009
2009
2009
2009
2009
2013
2012
2011
2010
2008
2012, 2013
2011
2010
Workload
Hrs/ECTS
4 ECTS
80 hrs
8 hrs
8 hrs 
0.7 ECTS
0.7 ECTS
0.3 ECTS
0.9 ECTS
1.4 ECTS
0.9 ECTS
1.4 ECTS
0.9 ECTS
0.9 ECTS
20 hrs
20 hrs
30 hrs
50 hrs
20 hrs
30 hrs
20 hrs
20 hrs
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1. PhD training
(International) conferences
World Endoscopy Organisation (WEO) - Colorectal Cancer 
Screening Committee, Vienna, Austria
Voorjaarscongressen - Nederlandse Vereniging voor 
Gastroenterologie (NVGE), Veldhoven
CvB congres Bevolkingsonderzoeken naar kanker, Utrecht
CvB-café, Amersfoort
Nationaal Congres Bevolkingsonderzoek Darmkanker ‘De wind in de
zeilen: op naar de start!’, Utrecht.
Nationaal Symposium ‘De invoering van colonscreening; 
wat betekent dit voor ons in de praktijk? – een scherpe blik vooruit’,
Zeist
Nationaal symposium ‘Colorectaal carcinoom en de toegevoegde
waarde van colonscreening’, Oegstgeest
20th United European Gastroenterology Week (UEGW), Amsterdam
Symposium ‘Successen van preventie’, Rotterdam
Digestive Disease Week (DDW), New Orleans, LA & Chicago, IL, USA
NvVO 68ste Oncologiedag ‘Colorectale Kanker’, Utrecht 
CISNET Mid-Year meeting, Rotterdam
Patient Oriented research (CPO) Symposium: Cost-Effective 
Interventions in Health Care: From Evaluation to Application, 
Erasmus MC, Rotterdam
7e & 8e Erasmus MC Endoscopy Day, Rotterdam
Seminars and workshops
MGZ seminars and journal clubs, Erasmus MC, Rotterdam
Basiscursus MS Access database, Erasmus MC, Rotterdam
Other
Reviewer for international scientific journals
Cursus Loopbaanoriëntatie voor wetenschappers, Erasmus MC, 
Rotterdam
Honoured grand application ‘Surveillance after polypectomy - 
towards successful implementation of guidelines (SAP-Adh)’, 
No. 171203009 (ZonMw)
Projectidee ‘Efficient surveillance after polypectomy – Incorporating
biomarkers (SAP-bm)’, Preventieprogramma, Deelprogramma 3
'Screening en preventieve interventies' (ZonMw)
ZonMw eindverslag en voortgangsverslagen SAP-project
PhD days, Erasmus MC, Rotterdam
2016, 2018
2011 - 2013 
2017 
2014 
2013
2012
2011
2012
2011
2010, 2011
2010
2009
2009
2008 - 2009
2008 - 2013
2008
2014, 2015
2012
2010 - 2011
2010
2009 - 2012
2011 - 2013
Year 
18 hrs
48 hrs
8 hrs
8 hrs
8 hrs
8 hrs
8 hrs
32 hrs
4 hrs
56 hrs
8 hrs
8 hrs
4 hrs
16 hrs
2 ECTS
8 hrs
40 hrs
1 ECTS
120 hrs
48 hrs
72 hrs
18 hrs
Workload
Hrs/ECTS
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2. Teaching activities
Supervising practicals and excursions
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Uitnodiging
Voor het bijwonen van de 
openbare verdediging van
mijn proefschrift 
Surveillance of
adenoma patients
towards more 
efficient guidelines
Woensdag 19 december 2018
9:30 uur
Prof. Andries Querido zaal
Onderwijscentrum Erasmus MC
Dr. Molewaterplein 40
Rotterdam
Aansluitend bent u van harte
welkom op de receptie
Else-Mariëtte van Heijningen
Leliestraat 15a
2313 BC Leiden
06-15187476
em2409@hotmail.com 
Paranimfen
Myrthe van der Hoeven
Mnvdhoeven@gmail.com
Nicolien van Ravesteyn
n.vanravesteyn@erasmusmc.nl
boekenlegger_Opmaak 1  21-11-18  17:00  Pagina 1
